

JONATHAN G. BRAUN, M.D., Ph.D.

Curriculum Vitae

Academic History

- 1969-1972 Birmingham High School, Van Nuys, California, with honors, diploma
- 1967-1971 Los Angeles Hebrew High School (Valedictorian), diploma
- 1971-1972 University of California, Los Angeles, UCLA High School Honors Program (no degree)
- 1972-1975 B.S., Stanford University, Stanford, CA (University Distinction)
- 1975-1981 M.D., Harvard Medical School, Boston, Massachusetts, cum laude
- 1977-1980 Ph.D., Harvard University, Graduate School of Arts and Sciences (Immunology).
Thesis: *Transmembrane Signaling Generated by Surface Immunoglobulin*, in the laboratory of Emil Unanue, M.D.

Residencies and Fellowships

- 1976-1981 Medical Scientist Training Program Fellow, Harvard Medical School
- 1981-1985 Resident in Pathology, Brigham and Women's Hospital, Boston, Massachusetts
- 1981-1983 Clinical Fellow, Department of Pathology, Harvard Medical School
- 1984-1985 Research Fellow, Department of Pathology, Harvard Medical School
- 1984-1985 Visiting Scientist (1984) and Research Associate (1984-5), The Whitehead Institute and Massachusetts Institute of Technology, Cambridge, Massachusetts, in the laboratory of David Baltimore, Ph.D.

Medical Licensure

- 1981- Diplomat, National Board of Medical Examiners
- 1982-2018 Massachusetts
- 1985- California

Academic Appointments

- 2019-2024 Professor and Enterprise Operations Director, IBDI, Cedars Sinai Medical Center
- 2019-present Emeritus Professor, University of California, Los Angeles
- 1994-2018 Chair of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles
- 1995-2018 Professor, Pathology and Laboratory Medicine and Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles
- 2006-2009 Co-Director to Director (Assistant Vice Chancellor), Clinical and Translational Sciences Institute, University of California at Los Angeles

1991-2018 Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center
 2011-2018 Associate Director, Tumor Immunology, Jonsson Comprehensive Cancer Center
 1991-1995 Associate Professor of Pathology and Laboratory Medicine, School of Medicine, University of California at Los Angeles
 1985-1995 Assistant Professor of Pathology, School of Medicine, University of California at Los Angeles
 1989-2018 Deputy Coroner, County of Los Angeles, State of California
 1985-2018 Member, Molecular Biology Institute, UCLA

Professional Memberships

1984-2024 American Association of Immunologists
 1986-2024 American Society of Investigative Pathology (formerly, AAP)
 1987-present American Association for the Advancement of Science
 - AAAS Fellow, 2001
 1988-2024 Clinical Immunology Society
 1990-2020 Los Angeles Society of Pathologists
 1991-1993 New York Academy of Sciences
 1994-2019 Association for Pathology Chairs
 1995-2019 California Medical Association
 1995-1999 American Medical Association
 1997-2024 Society for Mucosal Immunology
 1997-2024 American Gastroenterological Association
 1998-2019 College of American Pathologists
 2000-2024 American Society of Microbiology
 2000-2020 Association for Pathology Informatics
 2005-present Academy of American Poets

Advisory Committees and Study Sections

American Association for the Advancement of Science
 Member, Immunotherapeutics study section, May 2016, July 2016

American Cancer Society
 Immunology-Immunotherapy Advisory Board (1989, 1991, 1992)

American Gastroenterological Association
 Abstract Committee, Microbial-Induced Mucosal Inflammation and Immunity Section (2004-2019);
 Chair (2009-2012)
 Chair, Abstract Committee, Microbiome in Inflammatory Bowel Diseases (2013, 2014)
 Chair, Abstract Committee, Microbiome Structure and Function (2015)
 Abstract Committee, Epithelial Innate Immune Function (2015)
 Research Grants Committee (2017-2024)
 Chair, Undergraduate grant program (2022-2023)

American Society of Investigative Pathology
 1997-1999 Awards Committee
 1999-2004 Member, Membership Committee
 2000-2001 Member, Program Committee
 2001-2006 Member, Nominating Committee

Association of Pathology Chairs
 1998 Co-Chair, National Meeting, Boulder Colorado

1999 Chair, Western Regional Meeting, Pasadena, California
 2002 Vice Chair, Research Committee
 2004-2006 Chair, Research Committee

California Medical Association

1997-1999 Vice Chair, Scientific Advisory Panel on Pathology
 2001-2003 Council of Scientific Affairs - Pathology Scientific Committee
 2003-2012 Council of Scientific Affairs – Pathology Scientific Subcommittee

Canadian Crohn's and Colitis

2022 GIA and INN Study Sections

City of Los Angeles

2015 Health Commission, Member (3rd Council District Representative)

Clinical Immunology Society

1999 Appointed Councilor
 2000-2004 Finance committee
 2001-2004 Secretary/Treasurer
 2004 Elected Councilor
 2008-2009 President

Concern Foundation

1997-2000 Scientific Advisory Board

Crohn's and Colitis Foundation of America

2002-present National Scientific Advisory Committee
 2003-2005 Chair, Research Training Committee
 2005-2008 Chair, National Scientific Advisory Committee
 2008-2012 Member, Board of Trustees
 2013-2017 Chair, Translational Research and Biobanking Subcommittee, IBD Exchange
 2015- 2018 Member, Senior Research Advisory Council

Fondation Recherche Medicale (France)

2021 Extramural review

Federation of Clinical Immunology Societies

2002 I.M.I.D. Advisory Board
 2002-2007 Secretary/Treasurer
 2007-2009 Vice President (Chair elect)
 2009-2011 President
 2011-2013 Board of Directors

Harvard Medical School

2004-present Ad Hoc Professor Review Committees (5)
 2006-present External Advisory Board, Harvard Digestive Diseases Center

Helmsley Charitable Trust

2014-2019 Scientific Advisory Board, IBD program

Jonsson Comprehensive Cancer Center

1985-present Member
 1989-2012 Member, Seed Grant Review Committee

1991-2011 Director, Tumor Immunology Program Area
 2012-2018 Co-director, Tumor Immunology Program Area

International Congress of Mucosal Immunology (ICMI)

2008-2009 Scientific Advisory Council
 2012-2013 Scientific Advisory Council

Israel IBD Research Nucleus

2015-present Chair, EAB

Leukemia and Lymphoma Society (formerly, Leukemia Society of America)

1992-1998 Scientific Advisory Board
 1998-2002 Medical-Scientific Council

Milieu Interieur Consortium – Institut Pasteur, Paris

2014-2018 Scientific Advisory Board

National Institutes of Health

1987 ALY Study Section, ad hoc member
 1988 Comprehensive Cancer Center Site Visit
 1992 ALY Study Section, ad hoc member
 2001-2004 Cooperative Prostate Cancer Tissue Resource (CPCTR), Chair of REP
 2003 IMB Study Section, ad hoc member
 2004-2005 III Study Section
 2004-2006 Gastrointestinal Mucosal Pathobiology (GMPB) Study Section
 2005 Center for HIV/AIDS Vaccine Immunology (ZAI1 CL-A M1)
 2006 ZRG1 DIG-C (04 M) Study section
 2007 ZDK1 GRB-9 (M2 S) Study section
 2008-2013 DDK-C Digestive Diseases and Nutrition C Subcommittee
 2009 ZDK1 GRB8 Study Section
 2009 NIAID Loan Repayment Program (ZAI1-ELB-M-S1)
 2009 NIDDK Challenge Grant (RC1) ZRG1 DKUS-A (58)R
 2010 RC4 Director's Opportunity (Immunology) ZRG1 IMM-E (55) R
 2009-2013 ACE/ITN/TrialNet Data Safety Monitoring Board
 2013-2016 ACE/ITN/TrialNet External Advisory Board
 2011 Chair, Immune Defense Mechanisms at the Mucosa NIH CSG, ZAI1-WFD-I-M2
 2012 Special Emphasis Panel, ZDK1 GRB8 (M1), NIH Director's New Innovator Award
 2014 Member, NIH GMPB (Gastrointestinal Mucosal Pathobiology) Study Section
 2014 Member, NIH Microbiome study section, ZRG1 DKUS L 55
 2014 Chair, NIDDK Microbiome Ancillary Study Section NI2014/10 ZDK1 GRB-C (O2)
 2014 Development, Differentiation, Modulation Immune Responses (ZRG1 IMM-F 02M)
 2015, 2016 Member, CMIB (Cellular and Molecular Immunology B) Study Section
 2016 Chair, Exploratory Studies for Delineating Microbiome (ZDK1 GRB-6 M2)
 2017 Member, SEP/SRG 2017/01 ZCA1 SRB-J (J4) R meeting
 2019 Board of Scientific Counselors, NIAID Division of Intramural Research, June 2019
 2019-2023 NIAID TrialNet External Evaluation Panel, member
 2020 NIH ZEY1 VSN(01) NEI Clinical Trial and Clinical Applications
 2024 NIH ZRG1 KUDS-R10 NIDDK SBIR study section

NEOPICS (International Early Onset Paediatric IBD Cohort Study, www.neopics.org)
2012-2018 Scientific Advisory Board

Raine Medical Research Foundation (Western Australia)
2022 Study Section

Ruzic Research Foundation
2000-2004 Board of Scientific Advisors

Sinai Helmsley Alliance for Research Excellence
2011-2016 External Advisory Committee

Society for Mucosal Immunology
2003-2007 Membership Committee
2008-2009 ICMI Program Committee
2010-2011 International Scientific Advisory Committee, 15th International Congress of Mucosal Immunology (ICMI 2011), July 5-9 in Paris
2015-2016 Planning Committee of et Mucosal Immunology Course & Symposium (MICS): *Microbiota and Mucosal Immunity: Rules of Engagement in Health and Disease*, June 26-29

Stanford Oncology Lymphoma Program Project
1999-2006 Advisory Committee

UCLA Asthma, Allergy, Immunological Disease Comprehensive Research Center
1992-2004 Advisory Panel

UCLA-Boston University Lung Cancer Biomarker Development Lab
2009-2018 Internal Advisory Board

Ad Hoc Grant Reviewer
1988-present NSF
1988-2002 March of Dimes
1989-2018 American Cancer Society
1992-2008 Lymphoma Research Foundation of America
2002-2012 Medical Research Council (U.K.)
2004-2012 Medical Research Council (Canada)
2019 Austrian Institute for Human Sciences (Austria)
2019, 2020 Medical Research Council (U.K.)
2019, 2020 Swiss National Science Foundation

Editorial Boards

2000-2004 Deputy Editor, *Cellular Immunology*
2001-2010 Section Editor, *Clinical Immunology*
2006-2016 Section Editor, *Inflamm. Bowel Dis.*
2008-2016 Editorial Board (Associate Editor) *Gastroenterology*
2011 Guest Editor, *Int J Inflamm*
2011-2014 Member, Editorial Board, *Clinical Immunology*
2019 *F1000 Prime*, Gastrointestinal Pharmacology Section

Commercial Activities

1989-1992 Diagnostic Products Corporation (Scientific Advisory Board)
 1992-1993 Medclone Corporation (Consultant)
 1994-1999 Reprogen Corporation (Scientific Advisory Board)
 2005-2007 Genentech Corporation (Consultant)
 2008-2010 Kirin Holdings Company, Ltd. (Central Laboratories for Frontier Technology)
 2014-2019 IBD Scientific Advisory Board, Janssen Research and Development
 2016-2020 Scientific Advisory Board, Prolacta Biopharma

Company formation

Prometheus Laboratories, Inc. (founded 1995)

Roles: Scientific founder, Board member (1995-2000)

History: Acquired by Nestlé Health Science S.A., 2011

Santarus, Inc. (founded 1996)

Role: Scientific founder

History: NASDQ SNTS; acquired by Salix Pharmaceuticals, 2014

Paganini Biopharma, Inc. (founded 2008)

Roles: Scientific founder, Board member (2008-2017)

History: acquired by OncoResponse, 2017

Non-departmental Committee Memberships, UCLA

1986-1988 Chair, Immunology Forum Seminar Series
 1986-1993 Executive Committee, M.S.T. program
 1988-1993 Jonsson Cancer Center Seed Grant Committee
 1989-1994 Coordinator, Advanced Immunology Curriculum
 1990-1994 EPCC; renamed MEC (Curriculum and Promotions, Medical School)
 1990-1991 Search Committee, Jerry Lewis Neuromuscular Institute Directorship
 1991 Small Instrument Grant Review Committee (School of Medicine)
 1991-1992 Search Committee, Chair of Pathology and Lab Medicine
 1991-1992 Search Committee, Howard Hughes Medical Institute
 1992-1994 Member, Task Force on Grading, School of Medicine
 1992 Member, University Committee on Research Computing
 1992-1993 Chair, Immunology Forum Seminar Series
 1995-1996 Department of Surgery Chair Search Committee
 1995-2016 Jonsson Cancer Center Seed Grant Committee
 1995-2018 Board of the Medical Group
 1995-2018 Medical Staff Executive Committee
 1995-1997 Clinical Advisory Council
 1995-1997 School of Medicine Chairs Committee
 1996-2000 Frontier in Science Review Committee
 1995-1999 CRCC Review Committee
 1995-2005 CMA Scientific Advisory Committee
 1996-1998 Clinical Program Planning Committee, UCLA
 1997-2001 Technology and Systems Committee
 1997-2018 School of Medicine Departmental Clinical Chairs Committee
 1998-2006 Chair, Immunology Forum Seminar Series
 1998 Ronald S. Hirshberg Chair Pancreatic Cancer Research (Committee Chair)
 1998-1999 Department of Pediatrics, Chair Review Committee
 1999-2001 East of Westwood Steering Committee

1999-2001 Non-intellectual Property Policy Committee
 1999 Board of UCLA Healthcare
 2000 Search Committee, Drew University Department of Pathology Chair
 2000-2001 Member, Neurobiology Advisory Blue Ribbon Committee
 2001 Search Committee Chair, Microbiology, Immunology and Molecular Genetics Chair
 2002 Member, Faculty Search Committee, Medicine/Rheumatology
 2002 Pancreatic Cancer SPORE Advisory Board
 2002 Search Committee, Dept. of Neurology, Muscle Disorders Program
 2002-2021 GU Cancer SPORE Internal Advisory Board
 2002-2018 GU CANCER SPORE Career Development Program Selection Committee
 2002-2018 UCLA AIDS Institute Executive Steering Committee
 2004 Member, HHMI Review Committee
 2003 Chair, 5-year Review Committee, Executive Chair Pediatrics
 2003-2018 UCLA CURE Advisory Committee
 2004-2018 UCLA Faculty Practice Group Executive Committee
 2004 Search Committee, Chief Operating Officer, UCLA Healthcare
 2004 Resource Allocation Committee, UCLA Healthcare
 2006-2007 ARC Sub-Committee on Pain Categorization and Morbidity
 2006-2007 Peter Bing Chair of Urologic Research search committee
 2006-2010 UCLA AIDS Institute Executive Steering Committee
 2006-2012 Co-Director, UCLA Institute for Molecular Medicine
 2006-2007 Co-PI, UCLA Center for Translational Science Institute
 2006-2007 Chair, Five-year review committee, Molecular and Medical Pharmacology Chair
 2008-2010 PI/Program Director, Clinical and Translational Science Institute at UCLA
 2009-2018 External Advisory Board, UCLA Flow Cytometry Core Facility
 2009 Search Committee, Vice Chancellor-Medical Sciences & Dean School of Medicine
 2009 Search Committee, Vice Chancellor-Research
 2010-2011 Steering Committee, 2010 School of Medicine Strategic Plan
 2010-2011 Clinical Strategy Design Team, 2010 School of Medicine Strategic Plan
 2010 Search Committee, UCLA Chair of Department of Pediatrics
 2011 Search Committee, Faculty Practice Group President
 2011 Search Committee, UCLA Health System COO
 2011 Search Committee, Chief of Pediatric Allergy and Immunology
 2011 Inquiry Committee, Dean of Academic Affairs, School of Medicine
 2011-2012 Chair, Administrative Review Committee, Chair of Obstetrics and Gynecology
 2011-2012 Unincorporated IT advisory Committee, UCLA Health System
 2013-2018 Internal Advisory Board, Jonsson Comprehensive Cancer Center
 2013-2018 External Advisory Committee, UCLA Department of Urology T32 Application
 2013-2018 Leadership committee, IIIT Research Theme
 2014-2018 Oversight Advisory Committee, MBI-IDP
 2015 Health Care Symposium Advisory Committee
 2015-2018 UCLA Health Sciences Data Strategy and Governance Committee

Departmental Committee Memberships

1990-1991 Member, Hematopathology Search Committee
 1992-1994 Member, Academic Promotions Committee
 1992-1993 Administrative Head, Anatomic Division

Cedars-Sinai Institutional Committees

2019 Malaniak Award Committee
 2020 Department of Pathology Chair Search Committee

2021 Academic Promotions and Appointments Council

Awards

1975 (Stanford University)
Phi Beta Kappa
Graduation with University Distinction
Departmental Honors in Biological SciencesNone

1981 (Harvard Medical School)
Aesculapian Society
Graduation cum laude in a special field (Immunology)

1984 Leukemia Society Special Fellowship

1986 Leukemia Society Scholar Award
Life and Health Insurance Medical Research Fund Award

1987 Basil O'Connor Research Starter Award

1988 RJR-Nabisco Research Scholar Award

1991 Outstanding Professor Award, UCLA School of Medicine, Class of 1993

1992 Outstanding Professor Award, UCLA School of Medicine, Class of 1994

1994 Margaret E. Early Trust Research Award

1996 G& L Pfeiffer Research Award

2001 Fellow, American Association for the Advancement of Science

2007 Honorary Professor, Jiaotong University, Xi'an, PRC

2011 Fellow, American Gastroenterological Association

2015 Modell Award, Crohn's and Colitis Foundation of America

2016 Georgia Health Sciences University Presidential Lecture

2018 James Kangos Lecture, UPMC

2018 Ramzi Cotran Lecture, Brigham and Women's Hospital

2018 Charles M. Mansbach, II, MD, Memorial Lecture. American Gastroenterological Association

2019 Sidney Truelove Lecture, International Organization for the Study of IBD (IOIBD)

2019 Robert B. Nussenblatt Lecture, American Uveitis Society

2020 International Organization for the study of Inflammatory Bowel Diseases, elected member

Research Funding (1985-present)

1985-88 Polyclonal B cell Activation, Life and Health Insurance Medical Research Fund, \$27,272 annual direct cost.

1985-88 Immunoglobulin expression in B-Ly1 Cells, NIH, AI22678(1-3), \$98,000 annual direct cost.

1986-91 Variable region somatic mutation in human B lymphocytes, NIH, CA12800 (16-19), \$57,000 annual direct cost.

1986-91 Leukemia Society Scholar Award, Leukemia Society of America, \$40,000 annual direct cost (salary).

1986-89 Ig variable region somatic mutation in a murine B-cell line, March of Dimes Basil O'Connor Grant 5-557, \$30,000 annual direct cost

1989-94 Immunoglobulin expression in B-Ly1 Cells, NIH, CA49308(1-5), \$105,344 annual direct cost.

1988-91 RJR-Nabisco Research Scholars Award WP880818, \$68,182 annual direct cost.

Aug 2026

1989-90	Skewing of B cell clonal diversity in AIDS, Universitywide Taskforce on AIDS #542493, \$20,900 annual direct cost.
1992	Marker B lymphocytes in inflammatory bowel disease, Crohn's and Colitis Foundation, \$64,287 annual direct cost.
1992	VH3 Ig gene products, a second natural gp120 receptor, UCLA AIDS Institute, \$14,000 annual direct cost.
1993-95	VH3 Ig, a second natural receptor for HIV gp120. Universitywide AIDS Research Program. \$50,200 annual direct cost.
1993-96	A novel octamer-binding protein expressed in lymphoma-prone B lymphocytes. Margaret E. Early Trust Award, \$41,667 annual direct cost.
1994-99	Identification of genes affecting host-tumor interaction in B cell lymphoma. NIH, CA12800 (19-22), \$98,000 annual direct cost.
1995-99	Role of the gp120 VH3 superantigen in HIV-1 pathogenesis. NIH/NIAID, RO1-A138505, \$127,000 annual direct cost
1995-2000	Marker B lymphocytes in ulcerative colitis and Crohn's disease, NIH/DDK, PO1-DK46763 (04-09), \$95,000 annual direct cost.
1998-99	Molecular basis of host-tumor interaction in AIDS lymphoma. Lloyd Foundation. \$21,000 annual direct cost.
1998-99	Genes in malignant progression of B cell lymphoma. PAD/Tumor Immunology, Jonsson Comprehensive Cancer Center Foundation Grant. \$14,625 annual direct cost
1998-99	Role of EMP-2 in host-tumor interaction of B lymphoma. Jonsson Comprehensive Cancer Center Interdisciplinary Seed Grant. \$29,850 annual direct cost
1999-2000	Genomic analysis of Mantle Cell Lymphoma. Lymphoma Research Foundation. \$80,000 annual direct cost.
2000-2001	CURE Seed Grant. "Bacterial and immune pathogenesis in colorectal carcinoma". \$20,000 annual direct costs.
2000-2005	Immune mechanisms of pathogenesis and protection for Crohn's disease candidate microbial antigens, NIH/DDK, DK46763 (10-15), \$125,000 annual direct cost
2000-2002	Crohn's and Colitis Foundation of America. \$30,000 annual direct cost. \$90,000 total cost. 7/1/00-6/30/03. Microbial and immunologic characterization of I2-expressing bacteria expressing the Crohn's disease-associated I2 protein.
2000-2001	UCLA Human Gene Medicine. \$30,000 annual direct cost. Defining the role of <i>fizzy-related</i> in MHC1 tumor antigen presentation.
2000-2002	CURE Seed Grant. \$16,500 annual direct cost. Modeling bacterial and immune factors in the pathogenesis of colorectal carcinoma

- 2001-2003 “The UCLA Center for In Vivo Imaging in Cancer Biology”. Project PI: Jonathan Braun. PI: Harvey Herschman. Agency: NIH/NCI, CA86306. 7/1/2000-6/30/2002. \$50,000 annual direct cost, \$100,000 total direct cost.
- 2000-2005 “Immune mechanisms in IBD.” P.I., Stephan Targan; Project PI, Jonathan Braun, NIH PO1-DK46763. \$136,614 annual direct cost; \$1,077,597 total cost.
- 2001-2006 “Index and retrieval of pathology specimens (Shared Pathology Informatics Network)”. NIH/NCI U01CA091429. Subcontract PI- Braun, Jonathan. PI- Kohane, Isaac. \$204,359 annual direct cost. \$1,452,027 total cost.
- 2002-2007 Tumor Immunology Program Area Director, Cancer Center Core Support Grant.” NIH/NCI P30-CA016042-28. PI- Judith Gasson
- 2004-2006 “The intestinal fungi: role in microbial consortia and mucosal immune homeostasis”. Broad Foundation IBD-0093. PI- Jonathan Braun. \$115,800 annual direct costs; \$254,740 total costs
- 2004-2006 “Abnormal EMP2 expression affects pregnancy outcome.” NIH R03-HD048540. PI, Jonathan Braun. \$100,000 annual direct cost. \$308,500 total award.
- 2005-2009 “Regulatory B cells in mucosal homeostasis and inflammatory bowel disease.” NIH R01-DK069434-01. PI-Jonathan Braun. \$200,000 annual direct cost. \$1,416,000 total costs.
- 2005-2010 “The UCLA Center for In Vivo Imaging in Cancer Biology.” PI-Harvey Herschman. Project Co-PI, Jonathan Braun. NIH/NCI P50-CA86306. \$60,000 annual direct cost. \$456,000 total award.
- 2006-2009 “Role of Intestinal O-glycans in the Pathogenesis of Ulcerative Colitis.” PI-Lijun Xia. Co-PI, Jonathan Braun. Crohn’s and Colitis Foundation of America. \$30,000 annual direct cost. \$110,000 total award.
- 2007-2008 “Targeting EMP2 for endometrial adenocarcinoma immunotherapy.” PI-Jonathan Braun. UCLA Stein-Opppenheimer Award. \$30,000 total award.
- 2008-2009 “Targeting EMP2 for endometrial adenocarcinoma immunotherapy.” PI-Jonathan Braun. UC CRCC. \$50,000 annual direct cost, \$100,000 total award.
- 2007-2011 “Immune mechanisms in IBD.” PI-Stephan Targan; Project PI, Jonathan Braun, NIH PO1-DK46763. \$145,200 annual direct cost; \$1,102,000 total cost.
- 2008-2014 “Identifying Microorganisms Involved in Human Health and Disease Processes.” PI- James Borneman, Co-PI, Jonathan Braun. NIH/NIAID AI078885. \$8,500 annual direct cost. \$60,000 total award (subproject).

- 2009-2014 “Tumor Immunology Program Area Director, Cancer Center Core Grant,” PI-Judith Gasson, NIH/NCI P30 CA016042. \$25,000 annual direct cost. \$194,000 total award.
- 2009-2010 “Effect of intestinal microbiota on genetic instability in Atm deficient mice” PI Robert Schiestl, Jonathan Braun. Jonsson Comprehensive Cancer Center. \$50,000 annual and \$100,000 direct cost.
- 2010-2011 “Regulatory B cells in mucosal homeostasis and IBD”. J. Braun PI. NIH/NIDDK RO1 DK069434 \$125,000 annual direct. \$193,700 total.
- 2010-2011 “Metaproteomic analysis of intestinal HIV infection,” PI-Jonathan Braun. UCLA CFAR. \$30,000 annual direct cost, \$30,000 total award.
- 2010-2013 “System Genotoxicity As An Inflammatory Disease Activity Biomarker in IBD Patients”. J. Braun PI. Prometheus Laboratories, Inc., #20101099. \$143,937 annual direct cost, \$318,138 total award.
- 2011-2012 “Hematopoietic stem cell imprinting by the intestinal microbiome,” D.A. Brooks, PI, J. Braun, co-PI. Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, #110720. \$150,000 annual direct. \$150,000 total award.
- 2011-2014 “The IBD microbiome consortium”. J. Braun PI. Crohn’s and Colitis Foundation of America, #3153-3159. \$1,108,000 annual direct. \$3.9 M total award.
- 2011-2014 “The MLI consortium: defining functional microbial communities of the human mucosal-luminal interface and their role in Crohn’s disease.” J. Braun PI. Crohn’s and Colitis Foundation of America, #3153. \$297,050 annual direct. \$980,000 total.
- 2012-2013 “Mechanisms of intestinal inflammation-associated systemic genotoxicity.” J Braun PI, RH Schiestl co-PI. NIH/NIAID 1R56AI094756-01A1. \$250,000 annual direct cost. \$378,400 total award
- 2010-2015 “Role of Mucin-type O-glycans in Intestinal Inflammation,” PI-Lijun Xia, NIH/DDK 1R01DK085691-01A1. \$40,459 annual direct cost. \$388,000 total award .
- 2011-2015 “Genetics and function of human invariant HLA-E T cells in Human Crohn's Disease Patient Subsets.” SR Targan, PI; J Braun, Project PI. NIH/NIDDK P01 DK046763. \$196,600 annual direct. \$1,540,000 total.
- 2012-2017 “Utilizing the Phenomics of IBD to Enhance Gene Discovery.” D. McGovern, PI; J. Braun, co-I. NIH/NIDDK U01 DK062413-11. \$60,000 annual direct cost. \$462,000 total award.
- 2013-2017 “Characterizing the gut microbial community for diagnosis and therapy of IBD”. R. Xavier, PI; J. Braun, co-I. NIH U54 DE023798-01. \$109,174 annual direct cost. \$667,632 total award.
- 2014-2017 “The CCFA Microbiome Consortium: Establishing mechanistically validated targets and lead molecules for microbiome-based therapy in IBD”. J. Braun-PI, Crohn’s and

Colitis Foundation of America. #323814. \$1.93M annual direct cost. \$6.6 M total award. \$180,000 UCLA annual direct cost.

- 2014-2019 “Tumor Immunology Program Area Director, Cancer Center Core Grant,” PI-Judith Gasson, NIH/NCI P30 CA016042. \$25,000 annual direct cost. \$194,000 total award.
- 2017-2019 Commensal Microbiome and Uveitis. H. Nida Sen, PI. NEI Intramural Bench-to-Bedside Program. \$40,000 annual direct cost. \$182,400 total award (J. Braun, Co-I)
- 2019-2020 Biomarking IBD patient-specific disease features using the epithelial antigenic peptide. T. Haritunians and J. Braun, Joint PI’s. CSMC Precision Health. \$90,000 annual direct cost.
- 2016-2021 “IBD Genetics and Immunopathologic Mechanisms.” Targan S, NIH/NIDDK PO1-DK46763 \$47,000 annual direct cost. \$361,000 total award. (J. Braun, Co-I).
- 2017-2022 Role of Mucin-type O-glycans in Intestinal Inflammation, Xia L, PI. NIH R01DK085691-06 to 11. \$40,000 annual direct cost, \$308,000 total award (J. Braun, Co-I).
- 2016-2022 “Road to Prevention: A Mount Sinai IBD Initiative” Dubinsky M, PI. Janssen Biotech, Inc. 6880A1. \$46,443 first year cost, \$416,023 total award (J. Braun, Co-I).
- 2020-2022 Genetic and genomic approaches to better understand clinical heterogeneity of IBD. McGovern D, PI. UO1 DK062413-01, \$132,000 annual direct cost, \$380,147 total award. (J. Braun, Co-I).
- 2020-2022 Role of RIP2 in the generation of pathogenic TH17/TH1 T-cells and ileitis. Crother T, PI. R21 AI156311, \$125,000 annual direct cost, \$417,500 total cost. ‘ (J. Braun, Co-I)
- 2020-2023 Biomarking IBD patient-specific disease features using the epithelial antigenic peptide. J. Braun, PI. NIDDK 1 R21 DK127189-01. \$150,00 annual direct cost \$459,250 total award.
- 2020-2023 Mechanisms of TL1A-driven Paneth cell dysfunction in IBD. Targan S, PI. RO1 DK123511-01, \$202,000 annual direct cost, \$1,032,000 total cost (J. Braun, Co-I).
- 2021-2023 Long-Term Responses to SARS-CoV-2 Vaccination in a Diverse Inflammatory Bowel Disease Population: a Multi-omic Study. McGovern D, PI. Helmsley Charitable Trust. 209-05500. \$887,766 annual direct cost, \$1,864,303 total cost. (J. Braun, Co-I).
- 2020-2024 Diversity and Determinants of Immune-Inflammatory Response to SARS-CoV-2. Chang S, PI. U54 CA260591-01, \$1.16 M annual direct cost, 3,386,294 total award. (J. Braun, Co-I).

2023-2027 Colon O-glycosylated mucus in the homeostasis of microbiota and host.
Braun J and Lijun Xia, PI. 2R01DK085691-10A1
Annual direct costs \$502,796 (total costs, \$2,938,827)

Patents

1. Immunoglobulin superantigen binding to gp120 from HIV. Jonathan Braun. US Patent Number 5,691,135. Date issued: 11/25/1997.
2. Methods of screening for ulcerative colitis and Crohn's disease by detecting VH3-15 autoantibody and pANCA. Jonathan Braun and Stephan Targan. US Patent Number 5,691,151. Date issued: 11/25/1997.
3. Novel anti-VH3-15 reagents, VH3-15 polypeptides, cell surface antigens, and methods for their detection and use. Jonathan Braun and Linda Berberian. US Patent Number 5,738,847. Date issued 4/14/1998.
4. Diagnosis, prevention and treatment of ulcerative colitis and clinical subtypes thereof, using microbial UC pANCA antigens. Jonathan Braun and Offer Cohavy. US Patent Number 6,033,864. Date issued 3/7/2000.
5. Diagnosis, prevention and treatment of a clinical subtype of ulcerative colitis using histone H1. Jonathan Braun, Stephan Targan, Mark Eggena. US Patent Number 6,074,835. Date issued 7/13/2000.
6. IBD-associated microbial antigens and methods of using same. Jonathan Braun, Christopher Sutton. US Patent Number 6,309,643. Date issued October 30, 2001.
7. IBD-associated microbial nucleic acid molecules. Jonathan Braun, Christopher Sutton. US Patent Number 6,320,037. Date issued November 20, 2001.
8. Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens. Jonathan Braun and Offer Cohavy. US Patent Number 6,537,768 B1. Date issued 3/25/2003.
9. IBD-associated microbial nucleic acid molecules. Jonathan Braun, Christopher Sutton. US Patent Number 6,759,530. Date issued 6/6/2004.
10. Diagnosis and treatment of Crohn's disease using pseudomonas antigens. Jonathan Braun. US Patent Number 6,821,739. Date issued 12/30/2004.
11. Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen. Stephan Targan, Jonathan Braun, Christopher Sutton. US Patent Number 7,138,237. Date issued 11/21/2006
12. Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens. Jonathan Braun, Offer Cohavy. US Patent Number 7,183,065. Date issued 2/27/2007.

13. Antibody materials for an IBD-associated polypeptide Jonathan Braun, Christopher Sutton. US Patent Number 7,557,194 B2. Date issued 7/7/2009
14. EMP2 antibodies and their therapeutic uses. Jonathan Braun, Lynn K. Gordon, Kaori Shimizaki, Madhuri Wadehra-Dhawan, Kathleen A. Kelly, Anna M. Wu. US Patent Number 8,318,906. Date issued 11/27/2012.
15. EMP2 antibodies and their therapeutic uses. Jonathan Braun, Lynn K. Gordon, Kaori Shimizaki, Madhuri Wadehra-Dhawan, Kathleen A. Kelly, Anna M. Wu. US Patent Number 9,011,857. Date issued 04/21/2015
16. Prevention of Chlamydia Infection Using SiRNA. Jonathan Braun, Lynn K. Gordon, Kaori Shimizaki, Madhuri Wadehra-Dhawan, Kathleen A. Kelly. U.S. Patent No. 8,648,052. Date issued 2/11/2014.
17. Genotoxicity as a biomarker for inflammation. Aya Westbrook, Robert Schiestl, Bo Wei, Jonathan Braun. US Patent Number 8,940,491. Date issued 1/27/2015.
18. Methods for diagnosis and treatment of endometrial cancer. Jonathan Braun, Madhuri Wadehra, Sathima Natarajan, Michael Soslow. US Patent No. 9,110,064 B2. Date issued 8/18/2015
19. Epithelial membrane protein-2 (EMP2) and proliferative vitreoretinopathy (PVR). Lynn Gordon, Shawn Morales, David Telander, Jonathan Braun. US Patent Number 61/263,228. Filed November 20, 2009. Australia #2011217785, Date issued 1 October 2015; Japan #5852968. Date issued December 11, 2015
20. Epithelial Membrane Protein 2 (EMP2) Binding Reagents and Their Therapeutic Uses in Ocular Diseases. Lynn Gordon, Shawn Morales, David Telander, Jonathan Braun. European Patent No. EP2536433. Date issued August 2, 2017.
21. Antibodies which bind Epithelial Membrane Protein 2 (EMP2). Jonathan Braun, Lynn K. Gordon, Kaori Dagostar, Madhuri Wadehra-Dhawan, Kathleen A. Kelly, Anna M. Wu. US Patent Number 9,624,304 B2. Date issued Apr 18, 2017
22. Diagnostic Tools for Response to 6-Thiopurine Therapy. Jonathan Braun, Lin Lin. US Patent Number 10,385,395. Date issued Aug 20, 2019.
23. Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life. ML Yamamoto, RH Schiestl, R Reliene, J Borneman, LL Presley, J Braun. US Patent 10,413,577. Date issued Sep 17, 2019.
24. Novel antibodies for the treatment of cancers. M. Wadehra, J. Braun. US Patent 11,053,310. Date issued Jul 6, 2021.

Invited Talks (1985-present)

1985 Los Angeles Society of Pathologists

Department of Genetics, Stanford University

- 1986 ICN/UCLA Workshop on B Cell Repertoire, Lake Tahoe, CA
UCLA Board of Governors
USC School of Medicine (Microbiology and Immunology)
- 1987 Lineberger Cancer Center, Chapel Hill, NC
B Cell Neoplasia, Basel, Switzerland
FASEB Annual Convention, Washington, D.C.
Scripps Clinic Research Foundation, La Jolla, CA
Stanford University Immunology Seminar, Stanford, CA
Gordon Conference (Immunobiology), Plymouth, NH
Howard Hughes Medical Institute (B Cell Differentiation), Coconut Grove, FL
- 1988 USC School of Medicine (Microbiology and Immunology)
UCLA Conference on B Cell Development, Taos, NM
International Association of Pathologists, Washington, D.C.
American Society of Microbiologists, Miami, FL
Emory University School of Medicine (Pathology)
Grady Memorial Hospital, Atlanta, GA
EMBO Workshop (Immunoglobulin Genes), Villefranche sur Mer
UC San Diego (Biology)
- 1989 Children's Hospital, Los Angeles, CA
2nd International Forum on Ovarian Cancer, Graz, Austria
Am. Soc. Clin. Pathol. Annual Convention, Chicago, IL
USC School of Medicine (Microbiology and Genetics)
- 1990 Cedars-Sinai Hospital, Los Angeles, CA (Medical Genetics)
Sociedad Medica del Hospital General, Mexico City, Mexico
UCLA School of Medicine Interdepartmental Conference
FASEB Annual Convention (Satellite symposium)
Wayne State University, Detroit, MI
- 1991 Gordon Conference on DNA Repair, Ventura, CA
FASEB Annual Convention (minisymposium), Atlanta, GA
UCLA Immunology Forum
UCLA Basic and Clinical Immunology Seminar
XOMA Corporation, Los Angeles, CA
USC, Department of Pathology
Harvard Medical School, Committee on Immunology, Boston, MA
Hospital St. Louis, Paris
- 1992 Scripps Research Institute, San Diego, CA
UCLA Department of Rheumatology
FASEB/AAP Workshop on Career Development, Anaheim, CA
Children's Hospital of Los Angeles, Los Angeles, CA
American Gastroenterological Association Convention, San Francisco, CA
Fogarty/NIH Conf. on Polyreact. and Monoreact. Antibodies, Bethesda, MD
19th Annual Conference of La Jolla Immunologists, San Diego, CA

- Loma Linda University, Loma Linda, CA
1st Annual UCLA AIDS Institute Symposium, Tarzana, CA
- 1993 Stanford University School of Medicine, Stanford, CA
- Department of Pathology and Immunology Program Seminars
Keystone Symposium on Lymphocyte Differentiation, Taos, NM (Plenary Talk)
USC School of Medicine (Pathobiology Program), Los Angeles, CA
Harbor-UCLA Department of Pathology Grand Rounds, Los Angeles, CA
AAI-CIS Joint Meeting, Denver, CO
NIH/NIA Workshop on Immunological Memory, Rockville, MD
NIH/AID Workshop on AIDS Pathogenesis, Bethesda, MD
- 1994 University-wide AIDS Research Conference, San Francisco, CA
UCLA/UCI AIDS Symposium, Palm Springs, CA
Basic Research and Clinical Implications in I.B.D. Victoria, British Columbia
Workshop Chair, Functional Activities of Early B Lineages, Experimental Biology 94, Anaheim, CA
NIH/NCI Workshop on Apoptosis, Bethesda, MD
Keynote Speaker, UCLA M.S.T.P. Retreat, Arrowhead, CA
NIH/NIAID Workshop on Early Events in HIV Infection, Bethesda, MD
Session Chair, UCLA AIDS Institute Scientific Symposium, Los Angeles, CA
UCLA Interdepartmental Conference on HIV Pathogenesis
- 1995 Albert Einstein College of Medicine Microbiology and Immunology Seminar, "Patches and grooves: The paradoxical role of antigen receptors genes in infectious disease".
NIH Collaborative Mucosal Immunology Group (CMIG) Investigators' Meeting, Keystone, CO "Role of VH3 in viral delivery".
Workshop on Genetics and Microbiology of Inflammatory Bowel Disease (NIDDK, CCFA, AGA), Hilton Head Island, SC. "Crossreactivity of IBD-specific antibodies with enteric bacteria".
- 1996 B-cells in normal and diseased states. ESF Conference, Luntenen, The Netherlands.
Digestive Disease Week (AGA), San Francisco, CA.
AAI/ASIP Annual Meeting, New Orleans, LA
Clinical Immunology Society Annual Meeting, New Orleans, LA
Association of Pathology Chairs, Vail, CO
NIH/NIAID Workshop on Early Trends in HIV infection, Bethesda, MD
"Patches and Grooves" The Role of Antibody Superantigens in Host Pathogen Interaction" Harbor-UCLA Medical Center, Torrance, CA
- 1997 Leukemia Society Grant Meeting, New York, NY
AAI/CIS Meeting, San Francisco, CA
AIDS Lymphoma Meeting, Rockville, MD
Foundation of HIV therapy, Palm Springs, CA
Keystone Symposia, Santa Fe, NM
Visiting Professor, University of Pennsylvania, PA
MAPS workshop, NIH, Bethesda, MD
Digestive Disease Week(AGA), Washington D.C.
S.F. Regional Association of Pathology Chairs Meeting, San Francisco, CA
- 1998 IAP Meeting, Boston, MA

- Experimental Biology '98(AAI/ASIP) Meeting, San Francisco, CA: "Identification of Candidate Bacterial Pathogens in Ulcerative Colitis Using a Disease-Specific Marker Antibody"
- Cancer Research Coordinating Committee Grant Meeting, San Francisco, CA
- Visiting Lecturer, University of California, Irvine: "Guns and Germs: The Molecular Pathogenesis of Inflammatory Bowel Disease"
- APC/GRIPE Meeting Co-Chair, Boulder, CO.
- 10th International Congress of Mucosal Immunology, Amsterdam, The Netherlands
- APC Western/Midwestern Meeting, Chair, Pasadena, CA.
- Digestive Disease Week (AGA), New Orleans, LA.
- 36th Annual Meeting of the Infectious Diseases Society of America, Denver, CO: "Use of Molecular Techniques for Identifying a Casual Agent for Crohn's Disease"
- 1999 Keystone Symposia, Silverthorne, CO: ("B Lymphocyte Biology and Disease")
- "Testing in Inflammatory Bowel Disease" Cedars-Sinai Medical Center, Los Angeles, CA
- "A Comprehensive Metric for Mission-Oriented Salary Allocation in Academic Pathology", AIMCL/EB '99, Ann Arbor, MI
- CSMC 4/22/99 Beyond gap function – 4TM proteins in growth control and malignancy
- Harbor / UCLA "The role of bacterial in inflammatory bowel disease"
- Brown University External Review Committee
- University of Alabama, Birmingham, "Needles in haystacks: Microbial pathogenesis in inflammatory bowel disease"
- 2000 Grand Rounds, Department of Pathology and Lab Medicine, UCLA
- Jonsson Comprehensive Cancer Center, UCLA
- Center for Immunology, Washington University School of Medicine
- Brigham and Women's Hospital, Boston, MA
- "Electronic Collaboration in the New Career Modes of Pathologists and Laboratory Professionals", AIMCL, University of Michigan School of Medicine
- American Registry of Pathology, Armed Forces Institute of Pathology, "Needles in haystacks: The search for microbial pathogens in Crohn's disease"
- Grand Rounds, Department of Pathology, UCSF
- National Lymphoma Think-tank, Hilton Head (Lymphoma Research Foundation)
- 2001 "Traditional techniques of identification", Gut Ecology, Las Vegas, NV, April 2001
- "Pathogenic Mechanisms in HIV & Inflammatory Bowel Disease", UCLA Dept. of Pathology & Laboratory Medicine, April, 2001.
- "Automated Information Management in the Clinical Laboratory", AIMCL, Ann Arbor, MI, May, 2001
- UCLA AIDS Institute Collaborative Vaccine Workshop - Century Plaza Hotel, June, 2001
- "Molecular Mechanisms of Disease", Caltech, October, 2001
- Leukemia Research Group Meeting, JCCC, October, 2001
- UCLA PET Imaging Meeting, October, 2001
- UCLA Ovarian Cancer Research Group, "MP2, a new gene family involved in host-tumor interaction", December, 2001
- 2002 "Being only 10% human: Bacterial-Immunologic Homeostasis in the Intestinal Mucosa. MBI, February 2002.
- "The E-Lab from the Academic Perspective". The E Laboratory: a Critical element in Laboratory Medicine. AACC Meeting, Miami FL. February 2002.
- "Immune-microbial homeostasis in the intestinal mucosa. Emory University, Atlanta, GA, April 2002

- “EMP2, an organizing protein for GPI-linked lipid raft domains”, Cal Tech, Pasadena, CA, April 2002.
 - “Engineering lipid rafts on target cells for efficient cytotoxic T cell killing”, UCLA 7th Annual Gene Medicine Symposium. May 13, 2002.
 - “Being 10% Human: Bacterial-Immunologic Homeostasis in the Intestinal Mucosa” UCLA Department of Pathology & Laboratory Medicine, May, 2002.
 - “Identification of IBD-associated antigens through fingerprinting antibody specificities”, DDW/AGA, San Francisco, CA. May 2002
 - “The new intimacy: embedding pathology diagnostics into medical therapeutics. AIMCL, Ann Arbor, MI. May 2002.
 - “Theragnostics - Functional and Genetic Testing for Immunology Disease Management”, FOCIS, San Francisco, CA. June 2002
 - “Being 10% Human: The immunology of host-microbial homeostasis in the intestine” Children’s Hospital Los Angeles, CA. October 2002.
 - “How to be only 10% human: TLR and G coupled receptor systems in microbial-immune homeostasis”, University of Pittsburgh, Pittsburgh, PA. November 2002.
 - “TLRs, G coupled receptors, and innate B cells in microbial-immune homeostasis”, Microbial/Mucosal Interactions workshop, 12th Annual Center for the Study of Inflammatory Bowel Disease Workshop, Boston, MA, November 2002.
- 2003 “Bacterial products in intestinal lymphocyte development and colitis susceptibility”, GRG Symposium, DDW, Orlando, Florida. May 2003.
- “In search of desire: uncovering the immunoregulatory B cell”, 29th Annual La Jolla Immunology Conference. La Jolla, CA. October 2003.
 - “Microbial-immune interactions and IBD”, University of Rochester School of Medicine, Rochester, NY. October 2003
 - “Microbial-immune homeostasis in IBD”, Baylor University (Gastroenterology Visiting Professor), Houston, TX. December 2003.
- 2004 “In search of desire: uncovering the immunoregulatory B cells”, 43rd Midwinter Conference of Immunology, Pacific Grove, CA. January 2004.
- “Microbial-immune interactions in mucosal homeostasis”, IBD: Advances from the Bench, Canadian Society of Gastroenterology, Banff, Alberta, March 2004.
 - “EMP2 and the cell biology of implantation”, FASEB Summer Conference on Tetraspanins, Calloway, GA, June 2004.
 - “Crohn's Disease-Associated Bacteria: lessons from *P. fluorescens* pflT (I2 protein),” APS Translational Research Conference, Snowmass, CO, September 2004
 - B-Cell Summit “Targeting B Cells in the Treatment of Immune-Mediated Disease”, December 8-10, 2004, Carlsbad, CA
- 2005 “Shared Pathology Informatics Network (SPIN)”, ASIP Symposium: Databases: From Fundamentals to Multi-Institutional Resources”. San Diego, CA. April 2005
- 5th Annual Meeting, Federation of Clinical Immunology Societies, Symposium session “Immunodiagnostic Disease Predictors”, May 16, 2005, Boston, MA
 - 12th International Congress of Mucosal Immunology, Boston, Massachusetts. June 2005
 - AMI annual meeting (co-organizer), Lake Tahoe, CA, August 2005
 - “Mucosal immune regulation”. UCSF, San Francisco, CA, September 2005
 - “Meryl Streep, commensal microbiota and immune regulation; a critical assessment”, Visiting Professor, LSU, Galveston, TX, October 2005
 - “Host microbial immune regulation”. CSIBD/MGH, Boston, MA, November 2005
 - Visiting Professor, Washington University, St. Louis, MO, November 2005
 - “Host microbial immune regulation”. CCFA Natl Res Clin Conf., Miami, FL, Dec 2005
 - Co Organizer, “CCFA National Research Clinical Conference,”, Miami, FL, Dec 2005

- 2006 “Microbial control of lymphoid development, Broad Medical Research Foundation, Los Angeles, CA Mar 2006
 Co-Organizer, Microbial-Host Interaction Workshop, St. Petersburg, FL, Mar 2006
 “Regulatory B cells,” Microbial-Host Interaction Workshop, St. Petersburg, FL, Mar 2006
 “Commensal sensing in B cell mucosal immunoregulation, AAI, Boston, MA, May 2006
 Ideashop V, San Francisco, CA, June 2006
 “A new governor from California: EMP2 in surface protein signaling, display and export,” FASEB Conference on Tetraspanins, Tuscon, AZ, July 2006
 “Intestinal immunoregulation”, Oklahoma Medical Research Foundation, Nov 2006
 Co Organizer, “CCFA National Research Clinical Conference,”, Miami, FL, Dec 2006
- 2007 “Body Traffic: Emerging Rules for Gut Immune-Microbial Interaction and Crohn’s Disease”, Boston University School Medicine Immunology, Boston, MA, Jan 2007.
 “Body Traffic: Emerging Rules for Gut Immune-Microbial Interaction and Crohn’s Disease”, Harbor-UCLA Medical Center Grand Rounds, Torrance, CA, Feb 2007.
 “Body Traffic: Emerging Rules for Gut Immune-Microbial Interaction and Crohn’s Disease”, New York University Immunology Club, New York, NY, Feb 2007.
 “Emerging roles of B cells in immunoregulation,” B Cell Symposium: From Bench to Bedside. FOCIS Center of Excellence, Los Angeles, CA, Mar 2007.
 Co-Organizer, “Assessing environmental risk factors affecting inflammatory bowel diseases. CCFA-CFC Symposium, Toronto, Ontario, Canada. June 2007.
 “Does Mycobacterium Avium Paratuberculosis Cause Crohn's Disease?” Digestive Diseases Week, Washington, DC, May 2007.
 “Molecular biomarkers and imaging strategies for patient-specific medical care”, Xi’An JiaoTong University, Xi’An, PRC, July 2007.
 “Enteric microbiota shape mucosal immunoregulation through CD8⁺ T cell”, Center for the Study of IBD Research, Massachusetts General Hospital, Boston, MA, November 2007
 Co Organizer, “CCFA National Research Clinical Conference,” Miami, FL, Dec 2007
 “Innate immunity”, CCFA National Research Clinical Conference,” Miami, FL, Dec 2007
- 2008 “Research Needs and opportunities for children with IBD”, Digestive Diseases Interagency Committee, NIH, Bethesda, MD. January 2008.
 “Looking-glass friends: intestinal microbiota, colitis, and the biology of life-style disease,” Grand Rounds, Univ. Kansas Department of Pathology, Kansas City, KS, February 2008
 Keynote Talk: “Imaging and immune regulation in the gut”. UCSD Annual GI Research Symposium, La Jolla, CA, February 2008
 “Microbial and molecular biomarkers for inflammatory bowel disease biology and management. Keynote Address. Association of Clinical Sciences, Marina Del Rey, CA. May 2008.
 “Mesenteric B cells regulate mucosal immunity”. B Cells 2008: Complexity, Integration and Translation. ESF-EMBO Symposium B Cells 2008: Complexity, Integration and Translation, Sant Feliu de Guixols, Spain. May 2008
 “Microbial programming and mechanism of regulatory CD8⁺ T cells”. Antigen Recognition at Mucosal Surfaces: Implications for Allergic, Inflammatory & Immunologic Diseases. Society for Mucosal Immunology (SMI)/American Academy of Allergy, Asthma & Immunology (AAAAI)/Crohn’s & Colitis Foundation of America (CCFA). Boston, MA. June 2008.
 “Slouching towards Bethlehem: The microbiome in mucosal and systemic disease”, UC Davis, July 2008.
 “Clinical Molecular Immune Imaging by Positron Emission Tomography”. 2nd Mediterranean Clinical Immunology Meeting. EMBO. Antalya, Turkey. October 2008.

- “New insights into the role of B cells in IBD”. The Crohn’s and Colitis Foundation 2008 National Research and Clinical Conference – 7th Annual Advances in the Inflammatory Bowel Diseases. Hollywood, FL. December 2008
- 2009 “Role of the Gut Microflora in B Cell Repertoire Determination and Immunoregulation”. Plenary Talk, Keystone Symposium on B cells in Context. Taos, NM. February 2009
- “Pathology-Radiology Integrated Diagnostics. Linking molecular pathology with interventional radiology”. Dark Report Molecular Summit. Philadelphia, PA. Feb 2009.
- “Mucosal biologic neighborhoods in health and inflammatory bowel disease”. Visiting Professor, Gastroenterology, University of Chicago, Chicago, April 2009.1
- “Mucosal biologic neighborhoods and the pathogenesis of inflammatory bowel disease”. Distinguished Lecture Series, Long Beach VA Medical Center, Long Beach, CA. June 2009.
- “Antimicrobial Defenses”, 14th International Congress of Mucosal Immunology. Boston, MA. July 2009
- “Microbial-Immune interaction in inflammatory bowel disease.” Broad Foundation Symposium. Los Angeles, CA. September 2009.
- “Mucosal Immunity: Creating a balance between barrier and function at the mucosal frontier.” Trudeau Institute, Saranac Lake, NY. October 2009
- “Commensal microbiota as an environmental modifying factor in genetic disease risk,.” Burroughs Wellcome Fund Interschool Program in Metabolic Diseases Symposium on
- “Translational Research for Metabolic Disease Prevention: Molecules to Populations” Burroughs-Wellcome Trust. Los Angeles, CA. October 2009.
- <http://www.youtube.com/watch?v=4D58U58bs84>
- “Immune mechanisms of commensal microbiota as an environmental modifying factor in cancer genetic disease risk”. NCI Workshop: Changing Concepts in Cancer Etiology, The Role of the Human Microbiome. Rockville, MD, November 2009.
- 2010 “Invariant HLA-E T cells, a ubiquitous player in microbial surveillance and immunoregulation”. UC Irvine Institute for Immunology. Irvine, CA. January 2010.
- “Host-microbial interaction in intestinal physiology and chronic inflammatory diseases”, UC Irvine/Long Beach VA Medical Center, Long Beach, CA. March 2010.
- “Inflammatory mechanisms in human carcinogenesis,” Zhejiang University, Hongzhou, China, May 2010.
- “Host response sensing in chronic inflammatory disease and vaccine design,” Institute of Virology, CAMS, Beijing, China. May 2010.
- “New genetics and imaging in inflammatory bowel disease etiology and assessment,” 10th People’s Hospital of Tongji University, Shanghai, China May 2010.
- “Invariant HLA-E T cells and the immune response to molecular stress,” American Society of Histocompatibility and Immunogenetics (ASHI), 36th Annual Meeting, Hollywood, FL, September 2010.
- “Integrating molecular imaging and molecular diagnostics.” Association of Pathology Chairs, Southeastern Conference, Asheville, NC. October 2010.
- “Integrating Radiology and Pathology”, Association of Pathology Chairs, Western and Midwestern Conference, Mauna Kea, HI Nov 2010
- “Metaproteomic analysis of the intestinal mucosal interface,” Center of Human Immunology, Institut Pasteur, Paris, France. November 2010.
- “Defining human biologic mucosal neighborhoods in inflammatory bowel disease by PET and surface metaproteome analysis,” Center for Immunology, University of Alabama, Birmingham, AL, December 2010.
- 2011 NIH Center for Human Immunology, FITMaN Conference, Bethesda, MD Feb 2011
- “Presidential Keynote Address”, FOCIS 2011, June 2011, Washington, D.C.
- “Damage control and the microbiota, Speaker & Session Chair, ICAAC, Chicago, Sep 2011

- “Voices of Progress”, Speaker & Session Chair, Crohns and Colitis Foundation of American, Las Vegas, Oct 2011
- “Reconsidering intestinal inflammation and cancer through the lens of mucosal ecology,” Plenary Speaker, Annual Research Day, University of Iowa, Iowa City, Oct 2011
- “The Intestinal Host-Microbial Ecosystem: A Systems Biology Approach to Inflammation and Cancer Risk”, Environmental Mutagen Society Annual Meeting, Montreal, Oct 2011
- “Mucocutaneous Immunity”. Cutaneous Lymphomas and their Mimics. SH Workshop 2011. Marina del Rey, CA. Oct 2011.
- “Systems Biology of the Mucosal Surface”, UCLA IBD Symposium, Oct 2011
- “Mucosal Biologic Neighborhoods and Microbial Ecology”, 21st CSIBD Annual Workshop, Massachusetts General Hospital, Boston, MA, Nov 2011
- “Understanding intestinal inflammation through the lens of microbial ecology”, Translational Research Day, Institut Pasteur, Paris, Nov 2011
- “Reconsidering Microbial Immunology through the Lens of Mucosal Ecology.” Immunology Institute Special Seminar, The Mount Sinai Medical Center, New York, NY. Nov 2011.
- 2012 “Bringing the microbiome to the bedside.” Medicine Ground Rounds. UCLA, January 2012.
- “Bringing the microbiome to the bedside.” Visiting Professor, Vanderbilt Digestive Disease Research Center. Vanderbilt University School of Medicine, Nashville, TN. Feb. 2012
- “Bringing the microbiome to the bedside.” Georgia Health Sciences University Presidential Lecture. Augusta, GA. March 2012.
- “Can Animal Models be used to identify Human Pathogens in IBD?” Digestive Disease Week. San Diego, CA. May 2012
- “Linking NK cells and the microbiome to human inflammatory bowel disease”, *Session Chair.* 12th Annual Meeting of the Federation of Clinical Immunology Societies, Vancouver, CA. June 2012
- “The microbiome and the use of higher order data in the study of chronic inflammatory disease. Association of Pathology Chairs Annual Meeting. Monterey, CA July 2012
- “Assessing the microbiome,” (Speaker) and Symposium Organizer, “Characterizing and Monitoring the Microbiome as a Modifiable Disease Factor,” AACR Conference on Integrative Cancer Prevention. Anaheim, CA Oct 2012
- “Functional mucosal communities.” Grand Rounds, Center for Cancer Research, NCI, Bethesda, MD Nov 2012
- “Microbiome and immune-mediated disease,” Microbiome-Induced Immunoregulation: Consequences on Health and Immune-Mediated Diseases. National Institute of Allergy and Infectious Diseases-Juvenile Diabetes Research Foundation International-Helmsley Charitable Trust Workshop, Bethesda MD Nov 2012
- “IBD Microbiome Consortium,” Helmsley Trust Symposium, Hollywood FL, Dec 2012
- Plenary speaker and moderator: “How can we use the microbiome to intervene in intestinal inflammation?” “How do T regulatory cells interact with the microbiome in IBD?” Advances in IBD, Hollywood FL Dec 2012.
- 2013 “The swerve: how the microbiome became modern”, University of Toronto, Ontario, Canada, Feb 2013.
- “Research and intervention for the microbiome in IBD”, CCFA Voices of Progress, Las Vegas, NV Mar 2013
- Keynote speaker, “Manipulating the Microbiome”, Helmsley Trust IBD Network Meeting, New York, NY June 2013
- Keynote speaker, “Harnessing the Power of the Human Microbiome in Health and Disease”, 2013 Pediatric Research Symposium, Emory+Children’s Pediatric Research Center, Atlanta, GA June 2013.
- Keynote speaker, “Translational Science and the Microbiome”, NIH Human Microbiome Science Vision for the Future, Bethesda, MD July 2013

- “KIR licensing and IBD pathogenesis (speaker and session chair)”, ICMI, Vancouver, Canada, July 2013
- “The MLI Consortium: Defining Functional Microbial Communities of the Human Mucosal-Luminal Interface and Their Role in Human Crohn’s Disease”, CCFA Microbiome Consortium Meeting, Philadelphia, PA Sept. 2013
- “The IBD Microbiome, what is wrong and what can be done” Nestle Nutrition Institute Workshop Clinical Nutrition, New York, NY Sept. 2013
- “Clinical exome in hereditary disease and cancer” The Second Affiliated Hospital, Zhejiang University School of Medicine”, Zhejiang, China Sept. 2013
- “Defining and monitoring the stressed mucosal ecosystem by metaproteomics”, The International Human Microbiome Consortium: IHMC, Hangzhou, China Sept. 2013
- “Applying systems biology to intestinal mucosal disease”, Moderator, Southwest Regional APC/PDAS Sedona, AZ Nov., 2013
- “Applying systems biology to intestinal mucosal disease”, Moderator, CSIBD Workshop, Signaling Circuits and Communication in Health and Disease, Boston, MA Nov., 2013
- 2014 “The IBD Microbiome: What’s Wrong, and How to Fix It,” Mayo Clinic, Rochester, MN January 2014
- “Defining and Harnessing the Intestinal Microbiome” UCLA CNS Basic and Translational Symposium: From Gut Microbes to Behavioral Interventions, Los Angeles, CA, February 2014
- “The IBD Microbiome: In search of actionable targets based on ecologic metabolism AARDA Colloquium, Leesburg, VA May 2014
- “The Role of Microbiota Metabolism on Host Function and Disease”, Gut Microbiota and Health, American Gastroenterological Association, Miami, FL March 2014
- “The IBD microbiome,” CCFA Voices of Progress, Atlanta, GA, March 2014
- “Mechanisms and preclinical rationale for probiotics in genotoxic cancer risk,” Kirin Central Laboratories for Key Technology, Yokohama, Japan, March 2014
- “Integration and Communication of Non-image based Data,” RSNA/ASCP Workshop on Radiology and Pathology Diagnostics, Oak Brook, IL, April 2014
- “The IBD microbial ecosystem, and what to do about it,” Pasteur Institute, Paris, France May 2014
- “At the interface of microbiota and metabolism,” 74th Annual Scientific Sessions, American Diabetes Association, San Francisco, CA June 2014
- “Immunologic Lessons of Rare Diseases” (Program chair), Federation of Clinical Immunology Societies, Boston, MA June 2014
- “Keynote: Probiotics Throughout the Lifespan”, Harvard Medical School Probiotics Symposium, Boston, MA September 2014
- “NCI Microbiome Quality Control Group Workshop,” National Cancer Institute, Bethesda, MD September 2014
- “Microbiome and Inflammatory Bowel Disease,” ACR/ARHP Annual Scientific Meeting, October 2014.
- “Emerging trends in microbiome research and development,” Sanofi, Boston, MA Oct 2014
- 2015 “Host genetic control of the microbiome,” Microbiome in health and disease, Boston Children’s Hospital, January 2015
- “Using metabolomics to link the microbiome to cancer,” American Society for Preventative Oncology, 39th annual meeting, Birmingham, AL, March 2015
- “Can Altering the Microbiome Prevent or Treat IBD”, American Gastroenterological Society Plenary Talk, Digestive Disease Week, Washington, DC May 2015
- “Next Generation Sequencing: Applications for Microbiome and IBD,” Federation of Clinical Immunology Societies Annual Meeting, San Diego, CA June 2015
- “Metabolites and the microbiome,” Gut Microbiome Conference, Anneberg Center for Health Sciences, Huntington Beach, CA September 2015

- “Illuminating the role of microbiome in disease through metabolomics”, Advances in Human Microbiome Science Symposium, New York Academy of Sciences, New York, NY October 2015.
- “The interplay of mucosal metabolites and host genetics in intestinal inflammation,” The Gut Microbiome in Health and Disease, Boston Children’s Hospital and Massachusetts General Hospital, Boston, MA, November 2015
- “State-of-the-art Telepathology,” Western Regional Meeting, Association of Pathology Chairs, Lake Tahoe, CA October 2015
- “Microbiome and IBD,” CCFA New York Research Alliance, New York, NY October 2015.
- “Integrating composition, function and host genetics in disease assessment of microbial ecosystems,” Molecular Biology & Biochemistry Seminar, UC Irvine, November 2015
- “Microbiome-based therapy for IBD”, and “The potential promise and limitations of research into the gut microbiota and its relevance to IBD,” 2015 Advances in Inflammatory Bowel Diseases, December 2015
- 2016 “Emerging microbiome biomarkers for clinical management of GI diseases”, CURE Annual Meeting, Los Angeles, CA March 2016
- “Microbiome biomarkers in GI disease”, Gut Microbiota for Health World Summit, AGA Institute and European Society of Neurogastroenterol Motility, Miami, FL March 2016
- “New Frontiers in Microbiome and Genetics”, CCFA Research Colloquium, New Orleans, LA Mar 2016
- “IBD Microbiome”, CCFA Research Strategy Meeting, New York, NY April 2016
- “Keynote: Monitoring and manipulating the intestinal microbiome – lessons from IBD”, Human Milk Science and Innovation 2016, Pasadena CA May 2016
- “Reengineering pathology care through telemedicine”, ASCP Pathology Informatics Summit, Pittsburgh, PA May 2016
- “Robert Nussenblatt”, 2016 FOCIS Annual Meeting, Boston, MA June 2016
- “IBD Microbiome”, IBIRI Research Retreat, Palos Verdes, CA Oct 2016
- “The search for correctable pre-disease states of the microbiome”, PISA 2016 Annual Meeting, ASIP, Houston, TX, October 2016
- “Uncovering the role of microbial ecosystem products in mucosal immune homeostasis”, Pasteur Institut, Paris, France Nov 2016
- “Crowd-sourcing in IBD research and clinical innovation,” “Microbial and microbiome biomarkers in risk and disease monitoring,” Advances in IBD Research, Orlando, FL Dec 2016.
- 2017 “Extraterrestrial travel, the dark side of vitamins, and the microbiome”, Pathology Grand Rounds, Cedars Sinai Medical Center, Los Angeles, CA Mar 2017
- “Translating the human microbiome”, 4th annual UCLA Children's Discovery and Innovation Institute Symposium, Los Angeles, CA May 2017
- “Microbiome biomarkers in the clinic”, Plenary 11th Annual ISNN Congress, Los Angeles, CA Sep 2017
- “At the microbiome frontier — ideas and methodologies for the definition of illness and its causation”; “Illness as metaphor – what the microbiome teaches us about the nature of health. UC Institute for Causal Learning and Memory, Workshop and Symposium, Sep 2017
- “Symposium Plenary”, Children's Hospital of Los Angeles Microbiome Symposium, Los Angeles, CA October 2017
- “Innovation in Genomic and Microbiome Biomarkers”, Association of Pathology Chairs. West, Midwest, and Canada Regional Meeting, Tiburon, CA Oct 2017
- “Concepts and strategies for human microbiome biomarkers in disease management”, Grand Rounds, UCLA Division of Pulmonary and Critical Care, Nov 2017
- 2018 “Metabolomic biomarkers in IBD”, Crohn’s & Colitis Congress, Las Vegas, NV Jan 2018
- James Kangos Lecture, UPMC, Pittsburgh, PA. Mar 2018

- Ramzi Cotran Lecture, Brigham and Women's Hospital, Boston, MA Apr 2018
 Charles M. Mansbach, II, MD, Memorial Lecture. "Benefits and risks of our microbial garden on health". DDW, Washington, DC. June 2018.
 "Metaproteomics of IBD". DDW, Washington, DC. June 2018.
 NIDDK/AGA Conference on Gut Microbiome in Human Subject Research, Philadelphia, PA. Sep 2018
 "Mechanistic basis of the microbiome pre-disease state", Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical School, Suzhou, Jiansu, China, Oct 2018
 "Strategies for Mendelian and Cancer Clinical Genomics", 2018 Forum in Digital Pathology, Hangzhou, Zhejiang, China, Oct 2018
- 2019
 "Sidney Truelove Lecture", International Organization for the Study of IBD (IOIBD), Havana, Cuba, Mar 2019
 "Modulation of the Gut Microbiome to Treat Dysbiosis and Cancer", Organizer and Speaker, AACR, Atlanta, GA, Mar 2019
 "Robert B. Nussenblatt MD Memorial Lecture", ARVO, Vancouver, BC, Canada, Apr 2019
 "Reengineering the microbiome in prevention and therapy of IBD". Plenary speaker, Building Bridges in IBD, Falk Foundation, Brussels, Belgium, Sep 2019.
- 2020
 "Sensation and Reality: Brain, Pain and the Biome", Organizer. Crohns & Colitis Congress, Austin, TX, Jan 2020.
 "What the bacterial metaproteome teaches us about the microbiome," Miami Winter Symposium: Molecular Mechanisms of Microbiome and IBD, Miami, FL. Jan 2020
- 2021
 "Host and microbial metabolites that predict IBD characteristics", DDW, Washington DC, May 2021
 "Guerilla Tacos and the LA quest to alter the natural history of IBD", IOIBD Annual Meeting, Bordeaux, France November 2021
- 2022
 "Class II T-cells Predominate After SARS-CoV-2 Vaccination, NCI SeroNet Investigator Meeting, March 2022

Trainees

Postdoctoral Fellows:

- Yadira Valles, M.D., Ph.D. (UNAM, Mexico City, Mexico DF '84) 1988-94 "*Hypermethylation of VH3 Genes*" [Current position: Research Director, DLZ Laboratories]
 Christopher Lee Sutton, Ph.D. (UCLA '94) 1995-97 "*Inflammatory Bowel Disease*" [Current position: Vice President, Crescendo Biosciences, Oklahoma City, OK]
 Galen R. Cortina, M.D., Ph.D. (Univ of Missouri '93) 1996-1998 "*Inflammatory Bowel Disease*" [Current position: Professor, Dept of Pathology & Laboratory Medicine, UCLA]
 Eri Oshima, Ph.D. (Osaka Univ, JP '98) 1998-00 "*Cytoplasmic Tail MXXXL Motif mediates the internalization of prostate-specific membrane antigen*" [Current position: Assoc Professor, Tokyo Univ, JP]
 Bo Wei, Ph.D. (Xi'an Medical Univ. CH '98) 1998-03 "*Inflammatory Bowel Disease*" [Current position: Deputy Director/Vice President, National Vaccine and Serum Institute, Beijing]

- George V. Thomas, M.D. (Royal College of Surgeons, UK '91) 1999-02 “*Developing transgenic mouse models of prostate cancer using the avian retrovirus system*” [Current position: Asst Professor, Institute of Cancer Research, Royal Marsden Hosp, UK]
- Siavash Khavar Kordistani, M.D. (Harvard Medical School '99) 2001-04 “*Global histone modification patterns in S. cerevisiae*” [Current Position: Professor and Chair, Biological Chemistry, UCLA]
- James S. Tomlinson, III MD., Ph.D. (Johns Hopkins Univ '00) 2001-06 “*Tumor invasion biology*” [Assoc. Professor, UCLA Dept of Surgery]
- Madhuri Wadehra, Ph.D. (UCLA '02) 2003-06 “*Control of implantation by epithelial membrane protein-2*” [Current position: Assoc Professor, UCLA Dept of Pathology & Laboratory Medicine]
- David Ziring, M.D. (Chicago Medical School '99) 2003-04 “*CB2 and IBD*” [Current position: Asst Professor of Pediatrics, David Geffen School of Medicine at UCLA]
- Lihui Luo, M.D. (Hengyang Medical College, PR CH 2004-06 “*KIR Genes and autoimmune disease*” [Current position: Unknown]
- Daisuke Fujiwara, Ph.D. (Univ of Tokyo, JP '99) 2005-07 “*Dendritic cell trafficking/ differentiation*” [Current position: Senior Investigator, Kirin Central Laboratories and RIKEN Research Institute, JP]
- Ling “Lindy” Chen, M.D. (Sun Yatsen Univ, CH '02) 2008-2011 “*Immunoregulation in inflammatory bowel disease*” [Initial position: Internal Medicine Residency, Loma Linda University]. Current Position, Associate Professor, Shanghai Eye and ENT Hospital, Fudan University, Shanghai, China]
- Maoyong “Leo” Fu, Ph.D. (China Agricultural Univ, Beijing, CH '06) 2007-2012 “*Reproductive biology*” [1 R21 CA131756] [Initial Position: Staff Research Associate in the UCLA Department of Pathology & Laboratory Medicine; Current Position, Senior Scientist, Nichols Institute, Quest Diagnostics San Juan Capistrano, CA]
- Ian McHardy, Ph.D. (UCLA, Ph.D. '11) 2011-2013 “*Proteomics and Related Bioinformatics of the Mucosal Surface and How it is Modified by Disease States*” [Current Position: Asst Professor, Microbiology, UC Davis]
- Susy Yung, M.S., M.D. (M.S. from Johns Hopkins University; M.D. from Drexel University College of Medicine) (2008-2012) “*CMV infection in individuals with KIR-mediated NK cell licensing genotype predisposes to inflammatory bowel disease*” [Current position, Asst. Professor, UCLA Pediatrics and UCLA Harbor Medical Center]
- Jonathan Jacobs, M.D. (Harvard Medical School, '08); B.A. (Harvard College, '03); Residency, Internal Medicine (Stanford University Medical Center, '10); Gastroenterology Fellowship, 2012-2016, Ph.D. candidate) “*Microbial gardening by innate lymphoid cells*” [NIH T32 DK training grant]. [Current position: Assistant Professor, Medicine/Digestive Disease, UCLA]
- Noam Jacob, M.D. (UC Berkeley, B.A., June 2005); USC Keck School of Medicine (M.D., 2012); Internal Medicine, Mt. Sinai Medical Center/Icahn School of Medicine (2012-2014); Gastroenterology Fellowship (UCLA, 2014-2019); T32 fellowship (July 2016-2019)

Thesis Committees (since 2004):

- Sandra Lan-Chi Nguyen, UCLA Microbiology, Immunology & Molecular Genetics, 2004-2017 (Lee)
- Oluwadayo Oluwadara, UCLA Pathology, 2005-2009 (Mischel)
- Gloria Preza, UCLA Cellular & Molecular Pathology, 2006-2010 (Ganz)
- Julia Goodenough, UCLA Cellular & Molecular Pathology, 2006-2010 (Ganz)
- Jill Pottratz Terra, UCLA Microbiology, Immunology & Molecular Genetics, 2007-2011 (Bradley)
- Anjuli Kumar, UCLA Human and Molecular Development, 2008-2012 (Steele)
- Aya Melody Westbrook, UCLA Molecular Toxicology, 2008-2012 (Schiestl)
- David Allen Nathanson, UCLA Molecular & Medical Pharmacology, 2009-2012 (Mischel)
- Carolyn Sham, UCLA Cellular & Molecular Pathology, 2009-2012 (Braun)
- Oscar Silva, UCLA Microbiology, Immunology & Molecular Genetics, 2010-2013 (Miceli)
- Airie Kim, UCLA Cellular & Molecular Pathology, 2010-2013 (Ganz)

Jill Crocetti, Microbiology, Immunology & Molecular Genetics, 2010-2013 (Miceli)
 David Akhavan, UCLA Molecular & Medical Pharmacology, 2011-2012 (Mischel)
 Christine Janson, UCLA Biological Chemistry, 2011-2013 (Colicelli)
 Patrick Chun, UCLA Biological Chemistry, 2011-2013 (Herschman)
 Keren Rabinowitz, Microbiology and Immunology, Mt. Sinai School of Medicine, 2011-2012 (Mayer)
 Angeline T. Dang, Microbiology, Immunology & Molecular Genetics, 2012-2013 (Modlin)
 Chao Ma, Physics, California Institute of Technology, 2013 (James Heath).
 Amanda Freise, Molecular and Medical Pharmacology, 2014 (Wu)
 Jared Liu, Molecular and Medical Pharmacology, 2015 (Li, Schiestl)
 David Meriwether, Molecular and Medical Pharmacology, 2016 (Reddy)
 Mariela Martinez, Human Genetics, 2016 (Reue, Dell'Angelica)
 Marcy Akhlaghpour, Cedars Sinai Biomedical and Translational program (Dermot McGovern)
 Brenda M. Molgora, Molecular Biology, 2016 (Bradley)
 Daniel M. Ferrer, Molecular Biology 2016 (Hill)
 Adewunmi Olumuyiwa Adelaja, Molecular Biology 2017 (Smale, Butte, Wollman)

Graduate Student Researchers, directly supervised (Pre-doctoral):

Dean Felsher, B.S. (Univ of Chicago '82) 1981-92 Ph.D. "*B cell lymphomagenesis*" [Current position: Professor of Medicine-Hematology/Oncology, Stanford University]
 Herman Govan, B.S. (UCLA '84) 1987-92 Ph.D. "*Analysis of immunoglobulin gene hypermutation in normal, human B lymphocytes*" [Current position: Staff Scientist, California Inst. of Technology]
 Wanda Krall, B.S. (Georgetown Univ '86) 1987-92 Ph.D. "*Memory B Cells*" [Current position: Staff Scientist, Amgen U.K., Cambridge,]
 Linda Berberian, B.S. (UCLA '72) 1990-94 Ph.D. "*Ontogeny and pathophysiology of VH3 cells*" [Current position: Scientist, Baxter Healthcare]
 Dolly Belle Tyan, -1994 "*Probing the enigmatic association between ankylosing spondylitis and HLA-B27: a comecular study of H:A-B27 and its flanking regions*" [Professor and Director of Immunogenetics, Department of Pathology, Stanford University School of Medicine.]
 Rick Fairhurst, B.S. (UC Irvine '90) 1992-96. M.D., Ph.D. "*Recognition: a candidate gene conversion event associated with somatic hypermutation: immunoglobulin framework-mediated antigen binding; T cell recognition of nonpeptide antigens*" [Current position: Chief, Malaria Pathogenesis and Human Immunity Unit, NIAID Division of Intramural Research]
 Janet Townsley-Fuchs, B.S. (UCLA '90) 1992-96 Ph.D. "*Immunoglobulins: Ontogeny and role as an innate host factor in the transmission and course of HIV infection*" [Scientific writer and consultant]
 Mark P. Eggena, B.S. (Yale Univ '90) 1992-98, M.D., Ph.D. "*Phage display cloning of marker antibodies as a means to identify autoantigens: Cloning of ulcerative colitis-specific perinuclear anti-neutrophil cytoplasmic antibodies and characterization of a novel IBD antigen .*" [Current position: Physician, Internal Medicine, Penobscot Bay Medical Center]
 Offer Cohavy, B.S. (UCLA '94) 1995-99 Ph.D. "*Identification of candidate pathogens and autoantigens in human inflammatory bowel disease using ulcerative colitis-specific perinuclear anti-neutrophil cutopasmic antibody.*" [Current position: Staff Scientist, IBD Research Center, UCLA and Cedar-Sinai Medical Center]
 Chun-Xiang Wang, B.S. (Peking Univ, Beijing '89, Univ of IL '94) 1995-99 Ph.D. "*Mechanisms of malignant progression in B cell lymphomagenesis*" [Current position: President/CEO, Tianwei Biotech, Ltd.]
 Daniel Cruz, B.S. MSTP Program 1999-2006. M.D., Ph.D. "*Requirements for selection and development among intestinal intraepithelial lymphocytes*" [Current position: Assoc Professor, UCLA Cardiomyopathy Center]

- Madhuri Wadehra, B.S. (Univ of IL, Urbana '95) 1996-02 Ph.D. "*Characterization of the biology and pathobiology of epithelial membrane protein-2*" [Current position: Asst. Professor, UCLA Pathology & Laboratory Medicine]
- Harnisha Nagin Dalwadi, B.S. (Rensselaer Poly Instit. '96) 1998-02. Ph.D. "*Bacteria and GAI2: Host-pathogen interactions in inflammatory bowel disease*" [Current position: Staff Scientist, Amgen, Thousand Oaks, CA]
- H. Helen Su, B.S. (Nat'l Taiwan Univ. '97) 1998-03 Ph.D. "*Molecular imaging of the immune system uncovering the dynamics of T cell trafficking in vivo by positron emission tomography*" [Current position: Staff Scientist, City of Hope, Duarte, CA]
- Tiffany Ting-Yi Huang, B.S. (UC Irvine '99) 2000-03 Ph.D. "*The requirement of commensal bacteria and Gal2 for T cell maintenance and function.*" [Current position: Staff Scientist, Cytogen, San Diego, CA]
- Ashley MacDonald Forbes, B.A. (Middlebury College '00) 2001-05 Ph.D. "*Epithelial membrane protein-2: A novel regulator of gene expression, cell signaling, and plasma membrane composition*" [Current position: Staff Scientist, Amgen]
- Matthew Ira Schrage, B.S. (UCLA '00) 2001-08, Ph.D. "*Inflammatory Bowel Disease*" [Current position: Internal Medicine Resident, UC Irvine]
- Peter Velazquez, B.S. (UC Irvine '97) 2002-05 Ph.D. "*B Lymphocyte antigenic surveillance and immunoregulation in the gut mucosa: implications for modulation of intestinal inflammation and infectious disease protection.*" [Current position: Senior Scientist, Amgen]
- Shawn A. Morales, B.S. (UC San Diego '99) 2003-08 Ph.D. "*Examining the role of Retinal pigment epithelium in PVR*" [NIH 2 T32 EY007026, Giannini Fellowship; Current position: Staff Scientist, Allergan, Irvine, CA]
- Michael G. McPherson, B.A. (UC Berkeley '98) 2004-07 Ph.D. "*FDG and antibody mediated PET monitoring of intestinal inflammation*" [Current position: Staff Scientist, Beckman Coulter]
- Kaori Shimazaki, B.S. (UCLA '03) 2006-07 Ph.D. "*The roles of epithelial membrane protein 2 (EMP-2) in host-Chlamydia interaction*" [Current position: Staff Research, SDG, Inc, Ohio]
- Sarah Nicole Brewer, B.S. (UCLA '04) 2005-09 Ph.D. "*PET Imaging of CEA labeled cells for tumor and inflammation monitoring*" [Dissertation year fellowship, 2008-2009; Current position: Radiology Resident, University of Virginia School of Medicine]
- Ling Chen, M.S. (Zhongshan Univ, CH) 2006-08 Ph.D. "*The role of PD-1 in retinal development*" [Current position: Associate Professor, Retina division, Fudan Affiliated Eye and ENT hospital, Fudan University, Shanghai, China]
- Ann Chan, B.S. (UCLA '02) 2006-2009 "*EMP-2 in ocular Chlamydia infections*" [NIH, 2 T32 EY007026; Current position, Senior Research Associate UCLA]
- Caroline Sham, B.A. (Univ of Chicago '02). 2007-2010. "*PD-1 and neural culling*" [Current position, Ophthalmology resident, Washington University, St. Louis, MO]
- Xiao-Xiao (Michelle) Li, B.M., M.S. ('06, School of Medicine and 1st Affiliated Hospital, Zhejiang University, Hangzhou, China; He Huang, M.D., Ph.D., mentor). 2006-2012. *Metaproteomic Analysis of the Mucosal Luminal Interface*. UCLA Ursula Mandel Fellowship (2010-2011); Dissertation Year Fellowship (2011-12)[Current position, Manager, Research Services, UCLA Pathology].
- Rui Li, B.S. (Zhejiang University '10) 2010-2012, "*The role of LKB1 in lung carcinogenesis*" Ph.D. UCLA Molecular and Medical Pharmacology.
- Lin Lin, B.S. (Tsinghua University, Beijing, China, '08). 2008-13. Ph.D., UCLA Molecular and Medical Pharmacology. "Kir gene cell biology in IBD susceptibility" The Federation of Clinical Immunology Societies (FOCIS 2012), Vancouver, BC, Canada. June 2012. *Oral Abstract: "The Host Always Wins;"* UCLA Whitcome Pre-doctoral Training Program in Molecular Biology Appointee (2012-2013)[Current position, Medical Student, CWU Lerner College of Medicine, Cleveland, OH].
- Maomeng Tong, B.S. (Biology) and B.A. (Economics) (Tsinghua University, Beijing, China, '09). 2009-2014. Ph.D. candidate, UCLA Molecular and Medical Pharmacology. "Network

analysis of microbiome and proteome of the mucosal interface.” [Current position, McKinsey and Company, Cambridge, MA]

Yu-Ling Chang, B.S. (National Yang-Ming University, Taiwan, Taiwan, June 2009), UCLA Pre-doctoral studies (2013 to 2018) “Functional bioactivity of the Crohn’s disease associated metabolome.” [Current position, postdoctoral fellow, UCLA Immunogenetics Center, Los Angeles, CA].

Jonathan Jacobs, M.D. (Harvard Medical School, ’08); B.A. (Harvard College, ’03); Residency, Internal Medicine (Stanford University Medical Center, ’10); Gastroenterology Fellowship, 2012-2016, Ph.D. candidate) “*Microbial gardening by innate lymphoid cells*” [NIH T32 DK training grant]. [Current position: Clinical Instructor, Medicine/Digestive Disease, UCLA]

Other Trainees:

Ying-Ren Zhao, Ph.D., M.D., (Xi’an JiaoTong Univ, CH) Visiting Professor, 2007

Naomi Hardy, (Brandeis Univ, PA) CCFA Fellowship Research Grant, “*The role of invariant CD8+ T cells in regulating susceptibility to IBD in a mouse colony.*” Summer, 2009
CCFA summer fellowship

Ryanne Daniels (UCLA undergraduate), summer fellow, 2010

Claire Hogue (UCLA undergraduate), MCDB 199 independent research (2009-2010)

Lucia Hernandez (UCSD undergraduate), Drew-UCLA research summer fellowship (2011)

Max Farber (Swarthmore undergraduate), CCFA summer fellowship (2014)

Jessica Tsui (UCLA undergraduate), M199 trainee (2013-2014); 2014 Summer Fellow, UCLA CARE Fellows SEM (Science Engineering Math) SPUR (Summer Program in Undergraduate Research), and California Alliance for Minority Participation (CAMP), and NIH Initiative to Maximize Student Diversity (IMSD) grant (GM55052)

Francisco Bautista (California State University Dominguez Hills, MARC U*STAR scholar 2017 summer fellow, SPUR-LABS

Publications (H index 81; i10 index 236)

<https://www.ncbi.nlm.nih.gov/myncbi/jonathan.braun.1/bibliography/public/>

1. Hahn GM, Braun J, Har-Kedar I. Thermochemotherapy: Synergism between hyperthermia (42-43°C). March 2011 and adriamycin (or bleomycin) in mammalian cell inactivation. Proc. Natl. Acad. Sci., USA, 1975 Mar;72:937-940. [PMID:48253, PMC432437]
2. **Braun J**, Hahn GM. Enhanced cell killing by bleomycin and 43°C hyperthermia and the inhibition of recovery from potentially lethal damage. Cancer Res. 1975 Nov, 35:2921-27. [PMID:52401]
3. Schreiner GF, **Braun J**, Unanue ER. Spontaneous redistribution of surface Ig in the motile B lymphocyte. J. Exp. Med. 1976 Dec 1;144:1683-88. [PMID:1087328, PMC2190482]
4. **Braun J**, Fujiwara K, Pollard TD, Unanue ER. Two distinct mechanisms for redistribution of lymphocyte surface macromolecules: relationship to cytoplasmic myosin. J. Cell Biol. 1978 Nov;79:408-18. [PMID:309887, PMC2110255]
5. **Braun J**, Fujiwara K, Pollard TD, Unanue ER. Two distinct mechanisms for redistribution of lymphocyte surface macromolecules: contrasting effects of local anesthetics and calcium ionophore. J. Cell Biol. 1978 Nov;79:419-26. [PMID:363728, PMC2110236]

6. Bhalla DK, **Braun J**, Karnovsky MJ. Lymphocyte surface and cytoplasmic changes associated with translational motility and spontaneous capping of immunoglobulin. *J. Cell Sci.* 1979 Oct; 39:137-48. [PMID:316817]
7. **Braun J**, Sha'afi RI, Unanue ER. Crosslinking by ligands to surface immunoglobulin triggers mobilization of intracellular calcium in B lymphocytes. *J. Cell Biol.* 1979 Sept;82(3):755-66. [PMID:315942, PMC2110493]
8. **Braun J**, Rosen FS, Unanue ER. Capping and adenosine metabolism: genetic and pharmacologic studies. *J. Exp. Med.* 1980 Jan 1;151(1):174-83. [PMID:6985647]
9. **Braun J**, Unanue ER. B lymphocyte biology studied with anti-Ig antibodies. *Immunol. Rev.* [PMID:7021397]
10. **Braun J**, Hochman PS, Unanue ER. Ligand-induced association of surface immunoglobulin with the detergent-insoluble cytoskeletal matrix in the B lymphocyte. *J. Immunol.*, 1982 Mar;128(3):1198-204. [PMID:6976988]
11. **Braun J**. Spontaneous in vitro occurrence and long-term culture of murine B lymphoblast cell lines. *J. Immunol.* 1983 May;130(5):2113-16. [PMID:6339621]
12. Allen PM, Beller DI, **Braun J**, Unanue ER. The handling of *Listeria monocytogenes* by macrophages. The search for an immunogenic molecules in antigen presentation. *J. Immunol.* 1984 Jan;132(1):323-31. [PMID:6581226]
13. **Braun J**, Kiely JM, Unanue ER. Propagation of lymphocytes in vitro. *Curr Top Microbiol Immunol.* 1984;113:237-40. [PMID:6332719]
14. Kiely JM, **Braun J**, Unanue ER. Autoregulation of B cell growth by an immunoglobulin M antibody. *J. Immunol.* 1985 Aug;135(2):1040-45. [PMID:3874225]
15. Citri Y, **Braun J**, Baltimore D. Elevated myc expression and c-myc amplification in spontaneously occurring B-lymphoid cell lines. *J. Exp. Med.* 1987 Apr 1;165(4):1188-94. [PMID:3549960, PMC2188571]
16. Greenberger JS, Daugherty C, Sakakeeny MA, **Braun J**, Pierce JH, Eckner RJ, Fitzgerald TJ. Friend virus-infected long-term bone marrow cultures producing colony stimulating factor dependent and independent granulocyte-macrophage progenitor cells for over four years in vitro. *Leukemia Res.* 1987;11(1):51-61. [PMID:3492638]
17. Sherr DJ, **Braun J**, Dorf ME. Idiotypic-specific Ly-1 B cell-mediated hybridomas that produce anti-idiotypic antibody and nonimmunoglobulin lymphokine(s). *J. Immunol.* 1987 Apr 1;138(7):2057-62. [PMID:3494058]
18. Herzenberg LA, Stall AM, **Braun J**, Weaver D, Baltimore D, Herzenberg LA, Grosschedl R. Depletion of the predominant B-cell population in immunoglobulin mu heavy-chain transgenic mice. *Nature.* 1987 Sept 3-9;329(6134):71-73. [PMID:3114639]
19. **Braun J**, Krall W, Clark ME, Govan HL 3rd, Chen U. Inducible Ig heavy chain switching in an IgM⁺ Ly-1 cell line. Evidence for switch commitment. *J. Mol. Cell. Immunol.* 1988;4(2):105-19. [PMID:3151247]

20. **Braun J**, King L. Unique V gene usage by B-Ly1 cell lines, and a discordance between isotype switch commitment and variable region hypermutation. *J Mol Cell Immunol.* 1989;4(3):127-128. [PMID:2788428]
21. Govan HL 3rd, Valles-Ayoub Y, **Braun J**. Fine mapping of DNA damage and repair in specific genomic segments. *Nucleic Acids Res.* 1990 Jul 11;18(13):3823-30. [PMID:2115669, PMC331082]
22. Valles-Ayoub Y, Govan HL 3rd, **Braun J**. Evolution of the abundance and clonal pattern of germinal center B cells during childhood. *Blood.* 1990 Jul 1;76(1):17-23. [PMID:2364168]
23. Felsher DW, Denis KA, Ando D, Weiss D, **Braun J**. A murine model for B cell lymphomagenesis in immunocompromised hosts: *c-myc* rearranged B cell lines with a malignant precursor phenotype. *Cancer Res.* 1990 Nov 1;50(21):7042-49. [PMID:2208171]
24. Felsher DW, Rhim SH, **Braun J**. A murine model for B cell lymphomagenesis in immunocompromised hosts: NK cells are an important component of host resistance to *c-myc* rearranged malignant precursor B cell lines. *Cancer Res.* 1990 Nov 1;50(21):7050-56. [PMID:2208172]
25. Saxon A, Macy E, Denis K, Witte ON, **Braun J**. B cell reconstitution in SCID-hu mice engrafted with human blood mononuclear cells. *J. Clin. Invest.* 1991 Feb;87(2):658-65. [PMID:1991850, PMC296356]
26. **Braun J**, Galbraith L, Valles-Ayoub Y, Saxon A. Human immunodeficiency resulting from a maturational arrest of B lymphocytes. *Immunol. Lett.* 1991 Mar;27(3):205-08. [PMID:1905679]
27. Felsher DW, Ando D, **Braun J**. Independent lambda light chain rearrangement in tissue culture-derived murine B cell lines. *Int. Immunol.* 1991 Jul;3(7):711-18. [PMID:1911542]
28. Berberian L, Valles-Ayoub Y, Sun N, Martinez-Maza O, **Braun J**. A VH clonal deficit in HIV-positive individuals reflects a B-cell maturational arrest. *Blood* 1991 Jul 1;78(1):175-79. [PMID:2070051]
29. Schmid I, Krall WJ, Uittenbogaart CH, **Braun J**, Giorgi JV. Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. *Cytometry.* 1992;13:204-08. [PMID:1547670]
30. **Braun J**, Berberian L, King L, Sanz I, Govan HL 3rd. Restricted use of "fetal" V_H3 genes by unselected B cells in the adult. Predominance of 56p1-like V_H genes in common variable immunodeficiency. *J. Clin. Invest.* 1992 May;89(5):1395-1402. [PMID:1569182, PMC443008]
31. Krall WJ, **Braun J**. *In Vivo* retroviral marking of antigen-specific B lymphocytes. *Semin Immunol.* 1992 Feb;4(1):19-28. [PMID:1591366]
32. **Braun J**, Galbraith L, Valles-Ayoub Y, Saxon A. *Immunol Lett.* 1992 Mar;32(1):99. [PMID:1500089]
33. Krall WJ, **Braun J**. *In situ* LacZ-marked lymphocytes define a B cell microenvironment in the lymph node medulla. *New Biol.* 1992 May;4(5):581-590. [PMID:1515419]

34. Berberian LS, Goodglick LA, Kipps TA, **Braun J**. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. *Science*. 1993 Sep 17;261(5128):1588-1591. [PMID:7690497]
35. Saxon A, Keld B, **Braun J**, Dotson A, Sidell N. Longterm administration of 13-cis retinoic acid in common variable immunodeficiency. Circulating IL-6 levels, B cell surface molecule display, and in vitro and in vivo B cell antibody production. *Immunology* 1993 Nov;80(3):477-487. [PMID:8288320, PMC1422223]
36. Goodglick LA, **Braun J**. Revenge of the microbes: Superantigens of the T and B cell lineage. *Am. J. Pathol.* 1994 Apr;144(4):623-636. [PMID:8160764, PMC1887238]
37. Berberian LS, Shukla J, Jefferis R, **Braun J**. Effect of HIV infection on VH3 (D12 idiotope) B cells in vivo. *J AIDS* 1994 Jul;7(7):641-646. [PMID:8207642]
38. Berberian LS, Valles-Ayoub Y, King L, Gordon LK, **Braun J**. Expression of a novel autoantibody defined by the VH3-15 gene in inflammatory bowel disease and *Campylobacter jejuni* enterocolitis. *J. Immunol.* 1994 Oct 15;153(8):3756-63. [PMID:7930592]
39. Storek J, King L, Ferrara S, Marcelo D, Saxon A, **Braun J**. Abundance of a restricted fetal B cell repertoire in marrow transplant recipients. *Bone Marrow Transpl.*, 1994;14(5):783-790. [PMID:7889012]
40. Goodglick L, Felsher DW, Neshat M, **Braun J**. A novel octamer regulatory element in the VH11 leader exon of B-1 cells. *J. Immunol.* 1995 May 1;154(9):4546-56. [PMID:7722308]
41. Goodglick L, Zevit N, Neshat M, **Braun J**. Mapping the gp120 superantigen-binding site of the human immunoglobulin variable region. *J. Immunol.* 1995 Dec 1;155(11):5151-59. [PMID:7594524]
42. Eggena M, Targan SR, Iwanczyk L, Vidrich A, Gordon LK, **Braun J**. Phage display cloning and characterization of an immunogenetic marker (perinuclear anti-neutrophil cytoplasmic antibody) in ulcerative colitis. *J. Immunol.* 1996 May 15;156(10):4005-11. [PMID:8621942]
43. Fairhurst RM, Valles-Ayoub Y, Neshat MN, **Braun J**. A DNA repair abnormality specific for rearranged immunoglobulin variable genes in germinal center B cells. *Molec. Immunol.*, 1996 Feb;33(3):231-244. [PMID:8649444]
44. Townsley-Fuchs J, Kam L, Fairhurst R, Gange SJ, Goodglick L, Giorgi JV, Sidell N, Detels J, **Braun J**. HIV-1 gp120 superantigen-binding serum antibodies. A host susceptibility factor in homosexual HIV-1 transmission. *J. Clin Invest.* 1996 Oct 15;98(8):1794-1801. [PMID:8878430,PMC507618]
45. Ruemmele FM, Targan SR, Levy G, Dubinsky M, **Braun J**, Seidman EG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. *Gastroenterology*. 1998 Oct; 115(4):822-29. [PMID:9753483]
46. Fairhurst RM, Wang CX, Sieling PA, Modlin RL, **Braun J**. CD1 presents antigens from a Gram-negative bacterium, *Haemophilus influenzae* type b. *Infect. Immun.* 1998 Aug;66(8):3523-26. [PMID:9673229]
47. Gordon LK, Eggena M, Holland GN, Weisz JM, **Braun J**. pANCA antibodies in patients with anterior uveitis: identification of a marker antibody usually associated with ulcerative colitis. *J. Clin. Immunol.* 1998 Jul;18(4):264-71. [PMID:9710743]

48. Cohavy O, Harth G, Horwitz M, Landers C, Sutton C, Targan SR, **Braun J**. Identification of a novel mycobacterial H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulinA from patients with Crohn's disease. *Infect. Immun.* 1999 Dec;67(12):6510-7. [PMID:10569769]
49. Gordon LK, Eggena M, Targan SR, **Braun J**. Definition of Ocular Antigens in Ciliary Body and Retinal Ganglion Cells by the Marker Antibody pANCA. *Invest Ophthalmol Vis Sci.* 1999 May;40(6):1250-55. [PMID:10235560]
50. Sutton CL, Yang H, Rotter J, Targan SR, **Braun J**. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. *Gut.* 2000 Jan;46(1):58-63. [PMID:10601056, PMC1727768]
51. Gordon LK, Eggena M, Targan SR, **Braun J**. Mast cell and neuroendocrine cytoplasmic autoantigen(s) detected by monoclonal pANCA antibodies. *Clin. Immunol.* 2000 Jan;94(1):94:42-50. [PMID:10607489]
52. Eggena M, Cohavy O, Parseghian MH, Hamkalo BA, Clemens D, Targan SR, Gordon LK, **Braun J**. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. *J Autoimmun.* 2000 Feb;14(1):83-97. [PMID:10648119]
53. Neshat MN, Goodglick L, Lim K, **Braun J**. Mapping the B cell superantigen binding site of HIV-1 gp120 on a VH3 immunoglobulin. *Intl. Immunol.* 2000 Mar;12(3):305-312. [PMID:10700465]
54. Wang CX, Fisk BC, Wadehra M, Su H, **Braun J**. Overexpression of murine *fizzy-related (fzr)* increases NK-mediated cell death and suppresses tumor growth. *Blood*, 2000 96(1):259-63. [PMID:10891459]
55. Sutton CL, Kim J, Yamane A, Dalwadi H, Wei B, Landers C, Targan SR, **Braun J**. Identification of a novel bacterial sequence associated with Crohn's disease. *Gastroenterology*, 2000 Jul;119(1):23-31. [PMID:10889151]
56. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, Targan SR, Braun, J. Colonic bacteria an ulcerative colitis pANCA-related protein epitope. *Infect. Immun.* 2000 Mar;68(3):1542-48. [PMID:10678972, PMC97313]
57. Dalwadi H, Wei B, Kronenberg M, Sutton CL, **Braun J**. The Crohn's disease-associated bacterial protein, I2, is a novel enteric T cell superantigen. *Immunity.* 2001 Jul;15(1): 149-58 (cover image). [PMID:11485746]
58. Sandusky H, Cilluffo M, **Braun J**, Gordon LK. Ocular pANCA antigens are expressed in nonpigmented ciliary body epithelium, and are conserved in multiple mammalian species. *Ocul Immunol Inflamm.* 2001 Mar;9(1):25-34. [PMID:11262665]
59. Wang CX, Wadehra M, Fisk BC, Goodglick L, **Braun J**. Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity. *Blood.* 2001 Jun 15;97(12):3890-95. [PMID:11389031]
60. Sutton CL, Kim J, Yamane A, Dalwadi H, Wei B, Landers C, Targan SR, **Braun J**. Identification of a novel bacterial sequence associated with Crohn's Disease. *Gastroenterology.* 2000 Jul;119(1):23-31. [PMID:10889151]

61. Wei B, Dalwadi H, Gordon LK, Landers C, Bruckner D, Targan SR, **Braun J**. Molecular cloning of a *Bacteroides caccae* TonB-linked outer membrane protein associated with inflammatory bowel disease. *Infect. Immunity*. 2001 Oct;69(10):6044-54. [PMID:11553542, PMC98733]
62. Wadehra M, **Braun J**, Goodglick L. One-step RT-PCR for screening microdissected tissue samples. *Biotechniques*. 2002 Feb;32(2):242-248. [PMID:11848395]
63. Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, **Braun J**, Targan SR. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. *Gastroenterology*. 2002 Sep;123(3):689-99. [PMID:12198693]
64. Wadehra M, Iyer R, Goodglick L, **Braun J**. The tetraspan protein EMP2 interacts with beta-1 integrins and regulates adhesion. *J Biol Chem*. 2002 Oct;277(43):41094-100. Epub 2002 Aug 19. [PMID:12189152]
65. Wei B, Huang T, Dalwadi H, Sutton CL, Bruckner D, **Braun J**. *Pseudomonas fluorescens* encodes the Crohn's Disease-associated I2 sequence and T-cell superantigen. *Infect Immun*. 2002 Dec;70(12):6567- 75. [PMID:12438326, PMC133002]
66. Mendoza M, Wang C, Lin M, **Braun J**, Sakamoto KM. Fizzy-related RNA expression patterns in mammalian development and cell lines. *Mol. Genet. Metab* 2002 Aug;76(4):363-66. [PMID:12208143]
67. Stempel D, Sandusky H, Lampi K, Cilluffo M, Horwitz J, **Braun J**, Goodglick L, Gordon LK. Beta B1 Crystallin - Identification of a Candidate Ciliary Body Uveitis Antigen. *Invest Ophthalmol Vis Sci*. 2003 Jan;44(1):203-09. [PMID:12506076]
68. Dubey P, Su H, Adonai N, Shouying Du, Rosato A, **Braun J**, Gambhir SS, Witte ON. Quantitative imaging of the T cell antitumor response by positron-emission tomography. *Proc Natl Acad Sci USA* 2003 Feb 4;100:1232-37. [PMID:12547911, PMC298756]
69. Dalwadi H, Wei B, Schrage M, Su TT, Rawlings DJ, Braun, J. B cell developmental requirement for the Gai2 gene. *J Immunol*. 2003 Feb 15;170(4):1707-15. [PMID:12574334]
70. De Vos S, Hofmann WK, Grogan TM, Krug U, Schrage M, Miller TP, **Braun J**, Wachsman W, Koeffler HP, Said JW. Gene expression profile of serial samples of transformed B-cell lymphomas. *Lab Invest*. 2003 Feb;83(2):271-85. [PMID:12594241]
71. Wadhera M, Sulur GG, **Braun J**, Gordon LK, Goodglick L. EMP2 is expressed in discrete anatomical regions of the eye. *Exp Mol Pathol*. 2003 Apr;74(2):106-12. [PMID:12710941]
72. Wadehra M, Su H, Gordon LK, Goodglick L, **Braun J**. The tetraspan protein EMP2 increases surface expression of class I MHC proteins and susceptibility to CTL-mediated cell death. *Clin Immunol*. 2003 May;107(2):129-36. [PMID:12763482]
73. Huang TT, Zong Y, Dalwadi H, Chung C, Miceli MC, Spicher K, Birnbaumer L, **Braun J**, Aranda R. TCR-mediated hyperresponsiveness of autoimmune Gai2^{-/-} mice is an intrinsic naïve CD4 T cell disorder selective for the Gai2 subunit. *Int Immunol*. 2003 Nov;15:1359-67. [PMID:14565934]
74. Su TT, Guo B, Wei B, **Braun J**, Rawlings DJ. Signaling in transitional type 2 B cells is critical for peripheral B cell development. *Immunol Rev*. 2004 Feb;197:161-178. [PMID:14962194]

75. Wadehra M, Goodglick L, **Braun J**. The tetraspan protein EMP2 modulates the surface expression of caveolins and GPI -linked proteins. *Mol Biol Cell*. 2004 May;15(5):2073-83. Epub 2004 Feb 20. [PMID:14978215, PMC404005]
76. Su H, Forbes A, Gambhir SS, **Braun J**. Quantitation of cell number by a positron emission tomography reporter gene strategy. *Mol. Imaging Biol*. 2004 May-Jun;6(3):139-48. [PMID:15193248]
77. Wei B, Velazquez P, Turovskaya O, Spricher K, Aranda R, Kronenberg M, Birnbaumer L, **Braun J**. Mesenteric node B cells centrally inhibit CD4⁺ T cell colitis through interaction with regulatory T cell subsets. *Proc Natl Acad Sci USA* 2005 Feb 8;102(6):2010-15. Epub 2005 Jan 31. [PMID:15684084, PMC548553]
78. Kim SC, Tonkonogy SL, Albright CA, Tsang J, Balish EJ, **Braun J**, Huycke M, Sartor RB. Variable phenotypes of enterocolitis in IL-10 deficient mice monoassociated with two different commensal bacteria. *Gastroenterology*. 2005 Apr;128(4):891-906. *Faculty of 1000*, <http://www.f1000biology.com/article/id/1015543>. [PMID:15825073]
79. Wadehra M, Forbes A, Pushkarna N, Goodglick L, Gordon LK, Williams CJ, **Braun J**. Epithelial membrane protein-2 regulates surface expression of $\alpha V\beta 3$ integrin in the endometrium. *Dev. Biol*. 2005 Nov 15;287(2):336-45. Epub 2005 Oct 10. [PMID:16216233]
80. Huang T, Wei B, Velazquez P, Borneman J, **Braun J**. Commensal microbiota alter the abundance and TCR responsiveness of splenic naïve CD4⁺ T lymphocytes. *Clin Immunol*. 2005 Dec;117(3): 221-30. Epub 2005 Nov 14. [PMID:16290233]
81. Scupham AJ, Presley LL, Wei B, Bent E, Griffith N, McPherson M, Zhu F, Oluwadara O, Rao N, **Braun J**, and Borneman J. Abundant and diverse fungal microbiota in the murine intestine. *Appl. Environ. Microbiol*. 2006 Jan;72(1):793-801. [PMID:16391120, PMC1352209]
82. Su H, Chang D, Gambhir SS, **Braun J**. Monitoring the anti-tumor response of naïve and memory CD8 T cells by positron emission tomography. *J. Immunol*. 2006 Apr 1;176(7):4459-67. [PMID:16547284]
83. Sun L, Peng Y, Sharrow A, Iqbal J, Zhang Z, Papachristou D, Zaidi S, Zhu LL, Yaroslavskiy B, Zhou H, Zallone A, Sairam MR, Kumar TR, Wei B, **Braun J**, Landa LC, Schaffler MB, Moonga BS, Blair HC, Zaidi M. FSH directly regulates bone mass: implications for understanding the pathogenesis of osteoporosis due to hypogonadism. *Cell*. 2006 Apr 21;125(2):247-260. *Faculty of 1000*, <http://www.f1000medicine.com/article/id/13775>. [PMID:16630814]
84. Wadehra M, Dayal M, Mainigi M, Ord T, Iyer R, **Braun J**, Williams CJ. Knockdown of the tetraspan protein epithelial membrane protein-2 inhibits implantation in the mouse. *Dev. Biol*. 2006 Apr 15;292(2):430-441. Epub 2006 Feb 20. [PMID:16487956]
85. Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, **Braun J**, Soslow RA. Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. *Cancer*. 2006 Jul 1;107(1):90-8. [PMID:16736513]
86. Iltanen S, Tervo L, Halttunen T, Wei B, **Braun J**, Rantala I, Honkanen T, Kronenberg M, Cheroutre H, Turovskaya O, Autio V, Ashorn M. Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD. *Inflamm Bowel Dis*. 2006 May;12(5):389-94. [PMID:16670528]

87. Ziring D, Wei B, Velazquez P, Schrage M, Buckley NE, **Braun J**. Formation of B and T cell subsets require the cannabinoid receptor CB2. *Immunogenetics*. 2006 Sep;58(9):714-25. Epub 2006 Aug 19. [PMID:16924491]
88. Veale JL, Liang LW, Zhang Q, Gjertson DW, Du Z, Bloomquist EW, Jia J, Qian L, Wilkinson AH, Danovitch GM, Pham PT, Rosenthal JT, Lassman CR, **Braun J**, Reed EF, Gritsch HA. Noninvasive diagnosis of cellular and antibody-mediated rejection by perforin and granzyme B in renal allografts. *Human Immunol*. 2006 Oct; 67(10):777-86. Epub 2006 Aug 4. [PMID17055354]
89. 88. Patel AA, Gupta D, Seligson D, Hattab EM, Balis UJ, Ulbright TM, Kohane IS, Berman JJ, Gilbertson JR, Dry S, Schirripa O, Yu H, Becich MJ, Parwani AV, Shared Pathology Informatics Network (SPIN) . Availability and quality of paraffin blocks identified in pathology archives: A multi-institutional study by the Shared Pathology Informatics Network (SPIN). *BMC Cancer* 2007 Feb 28;7:37 doi:10.1186/1471-2407-7-37. [PMID:17386082, PMC1810540]
90. Drake TA, **Braun J**, Marchevsky A, Kohane IS, Fletcher C, Chueh H, Beckwith B, Berkowicz D, Kuo F, Zeng QT, Balis U, Holzbach A, McMurry A, Gee CE, McDonald CJ, Schadow G, Davis M, Hattab EM, Blevins L, Hooks J, Becich M, Crowley RS, Taube SE, Berman J, Shared Pathology Informatics Network. A system for sharing routine surgical pathology specimens across institutions: the shared pathology informatics network (SPIN). *Human Pathology*. 2007 Aug; 38(8):1212-25. Epub 2007 May 8. [PMID: 17490722]
91. An G, Wei B, Xia B, McDaniel JM, Ju T, Cummings RD, **Braun J**, Xia L. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. *J Exp Med*. 2007 Jun 11;204(6):1417-29. Epub 2007 May 21. [PMID:17517967, PMC2118614] *Featured in commentaries by Von Elstermann M, July 2007 Nature Functional Glycomics Gateway (<http://www.functionalglycomics.org/fg>), and in December 2007 Gastroenterology by Ravi A (Gastroenterology 133:2085, doi:10.1053/j.gastro.2007.10.049). Faculty of 1000, <http://www.f1000biology.com/article/id/1085995>.*
92. Shimazaki K, Wadehra M, Forbes A, Chan AM, Goodglick L, Kelly KA, **Braun J**, Gordon LK. Epithelial membrane protein 2 modulates infectivity of Chlamydia muridarum (MoPn). *Microbes Infect*. 2007;9(8):1003-10. Epub 2007 Apr 18. [PMID:17544801]
93. Forbes A, Wadehra M, Mareninov S, Morales S, Shimazaki K, Gordon LK, **Braun J**. The tetraspan protein EMP2 regulates expression of caveolin-1. *J Biol Chem*. 2007 Sep 7;282(36):26542-51. Epub 2007 Jul 3 [PMID:17609206]
94. Lin JA, Watanabe J, Rozengurt N, Narasimha A, Martin MG, Wang J, **Braun J**, Langenbach R, Reddy ST. Atherogenic diet and cholic acid cause lethal inflammation of the ileocolic junction in cyclooxygenase-2 deficient mice. *Prostaglandins Other Lipid Mediat*. 2007 Nov;84(3-4):98-107. Epub 2007 Apr 25. [PMID:17991612]
95. Morales SA, Mareninov S, Prasad P, Wadehra M, **Braun J**, Gordon LK. Collagen Gel Contraction by ARPE-19 cells is mediated by a FAK-Src dependent pathway. *Exp Eye Res*. 2007 Dec;85(6):790-8. Epub 2007 Aug 29. [PMID:17915217]
96. Nemetz N, Abad C, Lawson G, Nobuta H, Chhith S, Duong L, Tse G, **Braun J**, Waschek JA. Induction of colitis and rapid development of colorectal tumors in mice deficient in the neuropeptide PACAP. *Int J Cancer*. 2008 Apr 15;122(8):1803-09. [PMID:18098289]

97. Velazquez P, Wei B, McPherson M, Mendoza LM, Nguyen SL, Turovskaya O, Kronenberg M, Huang TT, Schrage M, Lobato LN, Fujiwara D, Brewer S, Arditi M, Cheng G, Sartor RB, Newberry RD, **Braun J**. Villous B-Cells of the Small Intestine are Specialized for Invariant NK T Cell Dependence. *J Immunol*. 2008 Apr 1;180(7):4629-38. [PMID:18354186]
98. Wadehra M, Mainigi M, Morales SA, Rao RG, Gordon LK, Williams CJ, **Braun J**. Steroid hormone regulation of EMP2 expression and localization in the endometrium. *Reprod Biol Endocrinol*. 2008 Apr 9;6:15. [PMID:18400107, PMC2329639]
99. Fujiwara D, Wei B, Brewer S, McPherson M, **Braun J**. Systemic control of plasmacytoid dendritic cells by CD8⁺ T cells and commensal microbiota. *J Immunol*. 2008 May 1; 180(9): 5843-52. *Faculty of 1000* <http://www.f1000biology.com/article/id/1107088/evaluation> [PMID:18424703]
100. Wei B, McPherson M, Turovskaya O, Velazquez P, Fujiwara D, Brewer S, **Braun J**. Integration of B cells and CD8⁺ T in the protective regulation of systemic inflammation. 2008. *Clin Immunol*. 127:303-312. *Commentary by* [doi:10.1016/j.clim.2008.02.007](https://doi.org/10.1016/j.clim.2008.02.007), L Mayer, *Clin Immunol June 2008* [PMID:18282744, PMC2478703]
101. Ye J, Lee JW, Presley LL, Bent E, **Braun J**, Schiller NL, Straus DS, Borneman J. Bacteria and Bacterial rRNA Genes Associated with the Development of Colitis in IL-10^{-/-} Mice. *Inflamm Bowel Dis*. 2008 Aug;14(8):1041-50. [PMID:18381614]
102. Takedatsu H, Michelsen KS, Wei B, Landers CJ, Thomas LS, Dhall D, **Braun J**, Targan SR. TL1A (TNFSF15) Regulates the Development of Chronic Colitis By Modulating both TH1 and TH17 Activation. *Gastroenterology*. 2008 Aug;135(2):552-67. Epub 2008 May 7. *Faculty of 1000*, <http://www.f1000medicine.com/article/id/1119132> [PMID:18598698, PMC2605110]
103. Brewer S, McPherson M, Fujiwara D, Turovskaya O, Ziring D, Chen L, Takedatsu H, Targan SR, Wei B, **Braun J**. Molecular Imaging of Murine Intestinal Inflammation with 2-Deoxy-2-[¹⁸F]Fluoro-D-glucose and Positron Emission Tomography. *Gastroenterology*. 2008 Sep;135(3):744-755. Epub 2008 Jul 17. [PMID:18639553]
104. Ashorn S, Raukola H, Välineva T, Ashorn M, Wei B, **Braun J**, Rantala I, Kaukinen K, Luukkaala T, Collin P, Mäki M, Iltanen S. Elevated Serum anti-Saccharomyces Cerevisiae, anti-I2 and anti-OmpW Antibody Levels in Patients with Suspicion of Celiac Disease. *J Clin Immunol*. 2008 Sep;28(5):486-94. Epub 2008 May 22. [PMID:18496744]
105. Shimazaki K, Lepin EJM, Nagy A, Coulam P, Mareninov S, Marks JD, Wu AM, **Braun J**, Gordon LK, Wadehra M. Bivalent biospecific diabodies targeting epithelial membrane protein 2 decrease tumorigenicity in human endometrial cancer cell lines. *Clin Cancer Res*. 2008. Nov 15;14(22):7367-77. [PMID:19010852]
106. Wei B, Su TT, Dalwadi H, Stephan RP, Fujiwara D, Huang TT, Brewer S, Borneman J, Rawlings DJ, **Braun J**. Resident enteric microbiota and CD8⁺ T cells shape the abundance of marginal zone B cells. *Eur J Immunol*. 2008 Dec;38(12):3411-25. [PMID:19009526]
107. McPherson M, Wei B, Turovskaya O, Fujiwara D, Brewer S, **Braun J**. Colitis immunoregulation by CD8⁺ T cell requires T cell cytotoxicity and B cell peptide antigen presentation. *Am J Physiol Gastrointest Liver Physiol*. 2008 Sep;295(3):G485-92. Epub 2008 July 10. [PMID:18617557, PMC2536787]

108. Kenanova V, Barat B, Olafsen T, Chatziioannou A, Herschman HR, **Braun J**, and Wu AM. Recombinant carcinoembryonic antigen as a reporter gene for molecular imaging. *Eur J Nucl Med Mol Imaging*. 2009 Jan;36(1):104-14. Epub 2008 Aug 22 [PMID:18719907]
109. Morales SA, Mareninov S, Wadehra M, Zhang L, Goodglick L, **Braun J**, Gordon LK. FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction. *Invest Ophthalmol Vis Sci* 2009 Jan;50(1):462-9. Epub 2008 May 9. [PMID:18469192]
110. Shimazaki K., Chan AM, Moniz RJ, Wadehra M, Nagy A, Coulam CP, Mareninov S, Lepin EM, Wu AM, Kelly KA, **Braun J**, Gordon LK. Blockade of epithelial membrane protein 2 (EMP2) abrogates infection of Chlamydia muridarum murine genital infection model. *FEMS Immunol Med Microbiol* 2009 Mar;55(2):240-49. Epub 2009 Jan 12. [PMID:19159428]
111. Chen L, Pai V, Levinson R, Sharpe AH, Freeman GJ, **Braun J**, and Gordon LK. Constitutive neuronal expression of the immune regulator, programmed death 1 (PD-1), identified during experimental autoimmune uveitis. *Ocul Immunol Inflamm*. 2009 Jan-Feb;17(1):47-55. [PMID:19294574]
112. Ashorn S, Valineva T, Kaukinen K, Ashorn M, **Braun J**, Raukola H, Rantala I, Collin P, Maki M, Luukkaala T, and Iltanen S. Serological responses to microbial antigens in celiac disease patients during a gluten-free diet. *J Clin Immunol*. 2009 Mar;29(2):190-95. Epub 2008 Nov 6. [PMID:18987962]
113. Ashorn S, Honkanen T, Kolho KL, Ashorn M, Valineva T, Wei B, **Braun J**, Rantala I, Luukkaala T, Iltanen S. Fecal Calprotectin levels and Serological Responses to Microbial Antigens among Children and Adolescents with Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2009 February; 15(2): 199–205. doi: 10.1002/ibd.20535. [PMCID: PMC2627785].
114. Morales SA, Mareninov S, Wadehra M, Zhang L, Goodglick L, **Braun J**, Gordon, LK. FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction. *Invest Ophthalmol Vis Sci*. 2009 Jan;50(1):462-69. epub 2008 May 9. [PMID:18469192]
115. Westbrook AM, Wei B, **Braun J**, Schiestl RH. Intestinal mucosal inflammation leads to systemic genotoxicity in mice. 2009. *Cancer Res*. 69(11): 4827-34. epub 2009 June 6. [PMID: 19487293]
116. Morales SA, Mareninov S, Coulam P, Wadehra M, Goodglick L, **Braun J**, Gordon LK. Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2). *Invest Ophthalmol Vis Sci*. 2009 50(10):4949-56. Epub 2009 Jun 3. [PMID: 19494199]. PMCID: 3752982.
117. Chen L, Yang XJ, Mareninov S, Sharpe AH, Freeman GJ, **Braun J**, Gordon LK. 2009. Role of the immune modulator programmed cell death-1 during development and apoptosis of retinal ganglion cells. *Invest Ophthalmol Vis Sci*. 2009 Oct;50(10):4941-8. PMID: 19420345. PMCID:3222380.
118. Wei B, Wingender G, Fujiwara D, Chen DY, McPherson M, Brewer S, Borneman J, Kronenberg M, **Braun J**. Commensal microbiota and CD8+ T cells shape the formation of invariant NKT cells. *J Immunol*. 2010 184(3):1218-26. Epub 2010 Jan 4. [PMID: 20048124] *Faculty of 1000*, <http://f1000biology.com/article/id/1474956/evaluation>.
119. Presley LL, Wei B, **Braun J**, Borneman J. Bacteria associated with immunoregulatory cells in mice. *Appl. Environ. Microbiol*. 2010 Feb;76(3):936–941. Epub 2009 Dec 11 [PMID: 20008175; PMC2813032].

120. Brewer S, Nair-Gill E, Wei B, Chen L, Li X, Riedinger M, Campbell DO, Wiltzius S, Satyamurthy N, Phelps ME, Radu C, Witte ON, **Braun J**. Epithelial uptake of [18F]1-(2'-deoxy-2'-arabinofuranosyl) cytosine indicates intestinal inflammation in mice. *Gastroenterology*. 2010. Apr;138(4):1266-1275. Epub 2010 Jan 18. [PMID: 20080095].
121. Moniz RJ, Chan AM, Gordon LK, **Braun J**, Arditi M, Kelly KA. Plasmacytoid dendritic cells modulate non-protective T cell responses to genital infection by *C. muridarum*. *FEMS Immunol*. 2010. Apr; 53(3): 397-404. Epub 2010 Feb 26.
122. Zhang Z, Cui X, Jeske DR, Li XX, **Braun J**, Borneman J. Clustering Scatter Plots Using Data Depth Measures. *DMIN*. 2010. DMI5643.
123. Fu M, Maresh EL, Soslow RA, Alavi M, Mah V, Zhou Q, Iasonos A, Goodglick L, Gordon LK, **Braun J**, Wadehra M. Epithelial Membrane Protein-2 is a Novel Therapeutic Target in Ovarian Cancer . *Clin Cancer Res*. 2010. Aug 1, 16(15):3954-63. Epub 2010. June 1. PMID: 20670949. PMCID: PMC2913478
124. Habeeb O, Goodglick L, Soslow RA, Rao R, Schirripa O, Horvath S, **Braun J**, Seligson DB, Wadehra M. Epithelial Membrane Protein-2 Expression is an Early Predictor of Endometrial Cancer Development. *Cancer*. 2010. Oct 15;116(20):4718-26. Epub Jun 24. PMID: 20578181. PMCID: PMC2950887.
125. Fu, J, Wei B, Wen T, Johansson M, Liu X, Bradford E, Thomsson K, McGee S, Mansour L, McDaniel M, Sferra T, Turner J, Hansson G, **Braun J**, Xia L. Loss of intestinal core 1-derived O-glycans causes spontaneous colitis. *J Clin Invest*. 2011 Apr 1;121(4):1657-66. doi: 10.1172/JCI45538. Epub 2011 Mar 7. PMID:21383503. PMCID: PMC3069788
126. Fujiwara D, Wei B, Brewer S, **Braun J**. Role of small intestinal intraepithelial CD11c+ T cells in mucosal immunoregulation. *Am J Physiol Gastrointest Liver Physiol*. 2011 Jun;300(6):G939-47. Epub 2011 Mar 24. PMID:21436315
127. Rao R, Amici S, Morales S, Gordon LK, Goodglick L, **Braun J**, Notterpek L, Wadehra M. Peripheral myelin protein 22 (PMP22) modulates alpha6 integrin expression in human endometrial epithelial cells. *Reprod Biol Endocrinol*. 2011 Apr 25;9:56. doi: 10.1186/1477-7827-9-56. PMID:21518455[PubMed - in process] PMCID: PMC3110552
128. Wadehra M, Rao R, Fu M, Sudhakar D, Morales S, Gordon LK, **Braun J**. Epithelial Membrane Protein-2 Promotes Endometrial Tumor Cell Invasion Through the Activation of Focal Adhesion Kinase. *PLoS One*. 2011;6(5):e19945. Epub 2011 May 27. PMID:21637765[PubMed - in process] PMCID: PMC3103522
129. Kumar A, Li XX, LeBlanc J, Farmer DG, Elashoff D, **Braun J**, Ziring D. Proteomic Analysis Reveals Innate Immune Activity In Intestinal Transplant Dysfunction. *Transplantation*. 2011. July 15; 92(1):112-9. doi:10.1097/TP.0b013e31821d262b. PMID:21527871
130. Morales SA, Telander D, Notterpek L, Wadehra M, **Braun J**, Gordon LK. Rewiring integrin-mediated signaling and cellular response with the peripheral myelin protein 22 (PMP22) and epithelial membrane protein 2 (EMP2) components of the tetraspan web. *IOVS*. 2011. Jul 23;52(8):5465-72. doi: 10.1167/iovs.10-6139. PMID:21421883
131. Westbrook AM, Wei B, **Braun J**, Schiestl RH. Intestinal inflammation induces genotoxicity to extraintestinal tissues and cell types in mice. *Int J Cancer*. 2011 Oct 15;129(8):1815-25. doi: 10.1002/ijc.26146. Epub 2011 Aug 2. PMID:21520038

132. Davidson PL, Azziz R, Morrison J, Rocha J, **Braun J**. Identifying and Developing Leadership Competencies in Health Research Organizations: A Pilot Study. *J Health Admin Educ*. 2012 Jan; 29(2).
133. Westbrook AM, Wei B, Hacke K, Xia M, **Braun J**, Schiestl RH. The role of tumor necrosis factor- α and tumor necrosis factor receptor signaling in inflammation-associated systemic genotoxicity. *Mutagenesis*. 2012 Jan;27(1):77-86. Epub 2011 Oct 6. doi: 10.1093/mutage/ger063. PMID:21980144
134. Li X, LeBlanc J, Truong A, Vuthoori R, Chen SS, Lustgarten JL, Roth B, Allard J, Ippoliti A, Presley LL, Borneman J, Bigbee WL, Gopalakrishnan V, Graeber TG, Elashoff D, **Braun J**, Goodglick L. A metaproteomic approach to study human-microbial ecosystems at the mucosal luminal interface. *PloS One*. 2011; 6(11):e26542. PubMed PMID: 22132074; PMCID: PMC3221670
135. Presley LL, Ye J, Li X, LeBlanc J, Zhang Z, McGovern D, Ippoliti A, Roth B, Cui X, Jeske DR, Elashoff D, Goodglick L, **Braun J**, Borneman J. Host-Microbe Relationships in Inflammatory Bowel Disease Detected by Bacterial and Proteomic Analysis of the Intestinal Mucosal-Luminal Interface. *Inflamm Bowel Dis*. 2012 Mar;18(3):409-417. Epub 2011 Jun 22. doi: 10.1002/ibd.21793. PMID:21698720
136. Jounai K, Ikado K, Sugimura T, Ano Y, **Braun J**, Fujiwara D. Spherical lactic acid bacteria activate plasmacytoid dendritic cell immunomodulatory function via TLR9-dependent crosstalk with myeloid dendritic cells. *PLoS One*. 2012. 7(4): e32588. doi:10.1371/journal.pone.0032588
137. Wingender G, Stepniak D, Krebs P, Lin L, McBride S, Wei B, **Braun J**, Mazmanian SK, Kronenberg M. Intestinal microbes modulate the phenotype and function of mouse invariant natural killer T cells. *Gastroenterology*. 2012. 143:418-428. Epub 2012 Apr 19. PMID:22522092. *Editorial, Coppieters KT, Elewaut D. Gastroenterology 2012. 143:236-239. PMID:22727664. <http://dx.doi.org/10.1053/j.gastro.2012.06.026>*
138. Ruegger PM, Bent E, Li W, Jeske DR, Cui X, **Braun J**, Jiang T, Borneman J. Improving oligonucleotide fingerprinting of rRNA genes by implementation of polony microarray technology. *J Microbiol Methods* 2012. 90:235-240. Epub 2012 May 25. PMID:22640891.
139. Morales SA, Telander D, Mareninov S, Nagy A, Wadehra M, **Braun J**, Gordon LK. Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells. *Exp Eye Res*, 2012 Sep;102:10-6. Epub 2012 Jun 19. PMID 22728127
140. Sham CM, Chen L, Chan A, Lee J, Gandhi N, Francisco L, Sharpe A, Chen B, Nusinowitz S, **Braun J**, Gordon L. Neuronal Programmed Cell Death-1 Ligand Expression Regulates Retinal Ganglion Cell Number in Neonatal and Adult Mice. *J Neuroophthalmol*. 2012 Sep;32(3):227-237. Epub 2012 May 24. PMID:22635166. PMCID: 3839320.
141. Fu M, Brewer S, Olafsen T, Wu AM, Gordon LK, Said J, **Braun J**, Wadehra M. Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments. *Molec Imaging Biol*. 2013 Feb;15(1):68-78. Epub 2012 May 15. PMID:22585360

142. Morales S, Telander D, Leon D, **Braun J**, Wadehra M, Gordon L. Epithelial membrane protein 2 (EMP2) controls VEGF expression in ARPE-19 cells. *Invest Ophthalmol Vis Sci*. 2013 Mar 28;54(3):2367-72. Epub 2013 Jan 21. 2012 doi: 10.1167/iovs.12-11013. PMID: 23439602. PMCID: 3626528.
143. McHardy IH, Goudarzi M, Tong M, Ruegger PM, Schwager E, Weger JR, Graeber TG, Sonnenburg JL, Horvath S, Huttenhower C, McGovern DPB, Fornace Jr. AJ, Borneman J and **Braun J**. Integrative analysis of the microbiome and metabolome of the human intestinal mucosal surface reveals exquisite inter-relationships. *Microbiome*. 2013. 1:17. Epub 2013 May 13. DOI: 10.1186/2049-2618-1-17. PMID:24450808.
144. Yamamoto ML, Maier I, Dang AT, Berry D, Liu J, Ruegger PM, Yang JI, Soto PA, Presley LL, Reliene R, Westbrook AM, Wei B, Loy A, Chang C, **Braun J**, Borneman J, Schiestl RH. Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leucocyte genotoxicity. *Cancer Research*. 2013 Jul 15;73(14):4222-4232 PMID: 23860718.
145. McHardy IH, Li X, Tong M, Ruegger P, Jacobs J, Borneman J, Anton P, **Braun J**. HIV Infection is Associated with Compositional and Functional Shifts in the Rectal Mucosal Microbiota. *Microbiome*.2013, 1:26. Epub 2013 Oct 12. doi: 10.1186/2049-2618-1-26. PMID:24451087.
146. Gordon LK, Kiyohara M, Fu M, **Braun J**, Chan A, Goodglick L, Wadehra M. EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF. *Oncogene*. 2013 14;32(46):5369-76 doi: 10.1038/onc.2012.622. Epub 2013 Jan 21. PMID: 23334331
147. Tong M, Li X, Parfrey LW, Roth B, Ippoliti A, Wei B, Borneman J, McGovern DPB, Frank DN, Li E, Horvath S, Knight R, **Braun J**. A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease. *PLoS One*, 8(11):e80702. Epub 2013 Nov 19. doi:10.1371/journal.pone.0080702. PMID:24260458.
148. Liu L, Chen H, Li Z, Wei B, Nandi B, Zhang J, Ling H, Winslow G, **Braun J**, Li H. Pfit is a structurally novel Crohn's disease-associated superantigen. *PLoS Pathog*. 2013 Dec;9(12):e1003837. doi: 10.1371/journal.ppat.1003837. Epub 2013 Dec 26.
149. Fu M, Maresh E, Helguera G, Daniels T, Gordon L, **Braun J**, Soslow R, Penichet M, Goodglick L, Wadehra M. EMP2 is a novel therapeutic target for invasive breast cancer. *Mol Cancer Ther*. 2014 Apr;13(4):902-15. doi: 10.1158/1535-7163.MCT-13-0199. Epub 2014 Jan 21. PMID:24448822.
150. Ashki N, Chan AM, Qin Y, Wang W, Kiyohara M, Lin L, **Braun J**, Wadehra M, Gordon LK. Peroxynitrite Up-Regulates Angiogenic Factors VEGF-A, bFGF, and HIF-1 α In Human Corneal Limbal Epithelial Cells. *Invest Ophthalmol Vis Sci*. 2014 Mar 19;55(3):1637-46. doi: 10.1167/iovs.13-12410. Epub 2014 Jan 7. PMID:24398102.
151. Lin L, Ma C, Wei B, Aziz N, Rajalingam R, Yusung S, Erlich H, Trachtenberg E, Targan S, McGovern D, Heath J, **Braun J**. Human Natural Killer Cells Licensed by KIR Genes Have an Altered Cytokine Program That Modifies CD4⁺ T Cell Function. *J Immunol* 2014;193(2):940-949. doi:10.4049/jimmunol.1400093. PMID: 24935928. PMCID:PMC4096688
152. Viitasalo L, Niemi L, Ashorn M, Ashorn S, **Braun J**, Huhtala H, Collin P, Mäki M, Kaukinen K, Kurppa K, Iltanen S. Early Microbial Markers of Celiac Disease. *J Clin Gastroenterol*. 2014 Aug;48(7):620-4. Feb 10 [Epub ahead of print]. doi: 10.1097/MCG.0000000000000089. PMID: 24518796; PMCID: PMC4082475.

153. Fu M, Iwanami A, Kuga D, Qin Y, Rao J, Sudhakar D, Huang T, Gordon LK, Kiyohara M, **Braun J**, Goodglick L, Mischel P, Wadehra M. EMP2 Activates Src and is a Novel Therapeutic Target for Glioblastoma Multiforme. *J Biol Chem*. 2014 May 16; 289(20):13974-85. doi: 10.1074/jbc.M113.543728. PMID:24644285.
154. Ruegger P, Clark RT, **Braun J**, Borneman J. Improved resolution of bacteria by high throughput sequence analysis of the rRNA internal transcribed spacer. *J Microbiol Methods*. 2014 Oct; 105:82-7. doi: 10.1016/j.mimet.2014.07.001 Epub 2014 Jul 15 PMID:25034229. PMCID:PMC4160368.
155. The Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project (iHMP): Dynamic Analysis of Microbiome-Host Omics Profiles During Periods of Human Health and Disease. *Cell Host Microbe*. 2014 Sep 10;16(3):276-289. doi: 10.1016/j.chom.2014.08.014
156. Tong M, McHardy I, Ruegger P, Goudarzi M, Kashyap PC, Haritunians T, Li X, Graeber TG, Schwager E, Huttenhower C, Fornace AJ, Sonnenburg JL, McGovern DPB, Borneman J, **Braun J**. Reprograming of Gut Microbiome Energy Metabolism by the FUT2 Crohn's Disease Risk Polymorphism. *ISME J*. 2014. Nov;8(11):2193-20. doi:10.1038/ismej.2014.64. PMID:24781901. PMCID: PMC4992076
157. Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, **Braun J**, Ruchalski K, Seifert H, Larkin J, Lo RS. Tunable-combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Co-targeting but Result in Melanoma Drug Addiction. *Cancer Cell*. 2015. Feb 9; 27(2):240-56. Doi: 10.1016/j.ccell.2014.11.018. Epub 2015 Jan 15. PMID: 25600339. PMCID: PMC4326539
158. Liu Z, Sun F, **Braun J**, McGovern D, Piantadosi S. Multilevel Regularized Regression for Simultaneous Taxa Selection and Network Construction with Metagenomic Count Data. *Bioinformatics*. 2015 Apr 1;31(7):1067-74. doi: 10.1093/bioinformatics/btu778. Epub 2014 Nov 20. PMID: 25416747 PMCID: PMC4382903.
159. Horvath S, Mah V, Lu AT, Woo JS, Choi OW, Jasinska A, Riancho-Moral JA, Tung S, Coles NS, **Braun J**, Vinters HV, Coles LS. The cerebellum ages slowly according to the epigenetic clock. *Aging*. 2015 May;7(5):294-306. PMID: 26000617. PMCID: PMC4468311
160. Volkmann ER, Chang YL, Barroso N, Furst DE, Clements PP, Gorn AH, Roth BE, Conklin JL, Getzug T, Borneman J, McGovern DP, Tong M, Jacobs JP, **Braun J**. Systemic sclerosis is associated with a unique colonic microbial consortium. *Arthritis Rheumatol*. 2016 Jan 8. doi: 10.1002/art.39572. PMID: 26749064.
161. Bergstrom K, Liu X, Gao N, Song K, Cui Y, Li Y, McDaniel M, McGee S, Chen W, Huycke MM, Houchen CW, Zenewicz LA, West C, Chen H, **Braun J**, Fu J, Xia L. Impaired colonic mucus barrier caused by defective mucin-type O-glycosylation leads to spontaneous colitis-associated cancer in mice. *Gastroenterology* 151:152–164. e11. doi:10.1053/j.gastro.2016.03.039. Epub 2016 Apr 6. PMID: 27059389. PMCID in process

162. Li X, LeBlanc J, Elashoff D, McHardy I, Tong M, Roth B, Ippoliti A, McDonald K, Newberry R, McGovern DPM, Graeber T, Goodglick L, **Braun, J.** Micro-geographic Functional Communities of the Human Colonic Mucosa and Their Association with Inflammatory Bowel Disease. *Cell Molec Gastro Hepatol.* 2016; 2(5): 567-583. Epub May 2016. doi:10.1016/j.jcmgh.2016.05.003. *Journal Cover; Editor's essential reading; Editorial: Tamburini S, Clemente JC. Zooming in on Inflammatory Bowel Disease: Microbial and Proteomic Features Associated With IBD in Colonic Microenvironments. Cell Molec Gastroenterol Hepatol* 2016(5)2:540- 541
163. Li D, Achkar JP, Haritunians T, Jacobs JP, Hui KY, D'Amato M, Brand S, Radford-Smith G, Halfvarson J, Niess JH, Kugathasan S, Buning C, Schumm P, Klei L, Ananthakrishnan A, Aumais G, Baidoo L, Dubinsky M, Fiocchi C, Glas J, Milgrom R, Proctor DD, Regueiro M, Simms LA, Stempak JM, Targan SR, Torkvist L, Sharma Y, Devlin B, Borneman J, Hakonarson H, Xavier RJ, Daly M, Brant SR, Rioux JD, Silverberg MS, Cho J, **Braun J**, McGovern DPB, Duerr RH. A pleiotropic missense variant in SLC39A8 associated with Crohn's disease and human gut microbiome composition. *Gastroenterology.* Oct;151(4):724-32. doi: 10.1053/j.gastro.2016.06.051. Epub 2016 Aug 1. PMID: 27492617
164. Goudarzi M, Mak TD, Jacobs JP, Moon BH, Strawn SJ, **Braun J**, Brenner DJ, Fornace AJ, Li HH. (2016). An Integrated Multi-Omic Approach to Assess Radiation Injury on the Host-Microbiome Axis. *Radiat Res.* 016 Sep;186(3):219-34. doi: 10.1667/RR14306.1. Epub 2016 Aug 11. PMID: 27512828.
165. Jacobs JP, Goudarzi M, Singh N, Tong M, McHardy IH, Ruegger P, Asadourian M, Moon BH, Ayson A, Borneman J, McGovern DPB, Fornace AJ, **Braun J**, Dubinsky M. A Disease-associated Enterotype and Metabotype in Healthy Relatives of Pediatric Inflammatory Bowel Disease Patients. *Cell Molec Gastro Hepatol.* 2016;2:750–766. PMID:28174747. PMC5247316. doi:10.1016/j.jcmgh.2016.06.004. Epub 26 June 2016. *Editorial: Frey MR. Disease-Associated Microbial Communities in Healthy Relatives: A Bacteria-Filled Crystal Ball? Cell Molec Gastroenterol Hepatol* 2016 2016;2:710–711.
166. Bergstrom K, Fu JX, Johansson ME, Liu XW, Gao N, Wu Q, Song J, McDaniel JM, McGee S, Chen W, **Braun J**, Hansson GC, and Xia L. Core 1- and core 3-derived O-glycans collectively maintain the colonic mucus barrier and protect against spontaneous colitis in mice, *Muc Immunol.* 2017 Jan;10(1):91-103. Epub May 4 2016. doi: 10.1038/mi.2016.45. PMID: 27143302. PMC5097036
167. Jacobs JP, Lin L, Goudarzi M, Ruegger P, McGovern DPB, Fornace AJ, Borneman J, Xia L, **Braun J.** Microbial, metabolomic, and immunologic dynamics in a relapsing genetic mouse model of colitis induced by T-synthase deficiency. *Gut Microbes.* Gut Microbes. 2017 Jan 2;8(1):1-162016. Epub Nov 22 2016. doi: 10.1080/19490976.2016.1257469. PMID: 27874308. PMC5341916.
168. Yusung S, McGovern DP, Lin L, Lagishetty V, **Braun J.** NK cells are biologic and biochemical targets of 6-mercaptopurine in Crohn's Disease patients. *Clin Immunol.* 2017 Feb;175:82-90. 2016 Epub Dec 20. doi: 10.1016/j.clim.2016.12.004. PMID: 28011186. PMCID in process.
169. Volkmann ER, Hoffmann-Vold AM, Chang YL, Jacobs JP, Tillisch K, Mayer EA, Clements PJ, Hov JR, Kummel M, Midtvedt Ø, Lagishetty V, Chang L, Labus JS, Molberg Ø, **Braun J.** Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. *BMJ Open Gastroenterol.* 2017 Apr 1;4(1):e000134. doi: 10.1136/bmjgast-2017-000134. PMID: 28761687.

170. Qin Y, Takahashi M, Sheets K, Soto H, Tsui J, Pelargos P, Antonios JP, Kasahara N, Yang I, Prins RM, **Braun J**, Gordon LK, Wadehra M. Epithelial Membrane Protein-2 (EMP2) Promotes Angiogenesis in Glioblastoma Multiforme. *J Neurooncol*. 2017 Aug;134(1):29-40. Epub Jun 9. doi: 10.1007/s11060-017-2507-8. PMID: 28597184.
171. Casero D, Gill K, Sridharan V, Koturbash I, Nelson G, Jensen MH, Boerma J, **Braun J**, Cheema AK. Functional perturbations of the mouse gut microenvironment after exposure to high LET radiation. *Microbiome*. 2017 Aug;5:105. Epub Aug 18. doi.org/10.1186/s40168-017-0325-z. PMID: 28821301 PMCID: PMC5563039
172. Wadehra M, Kiyohara MH, Dillard C, Tsui J, Kim SR, Lu J, Sachdev D, Goodglick L, Tao M, Torous V, Wang W, Gordon LK, **Braun J**, McDermott S, Wicha M, Aryasomayajula C, Najafzadeh P, Tsui J. EMP2 is a novel therapeutic target for endometrial cancer stem cells. *Oncogene*. 2017 Oct 19;36(42):5793-5807. doi: 10.1038/onc.2017.142. Epub 2017 Jun 12. PMID: 28604744 PMCID: PMC5648618
173. Ni J, Ting-Chin, DS, Chen Ez, Bailey A, Roggiani M, Sirota-Madi A, Friedman ES, Wang L, Lin A, Nissim I, Albenberg LA, Baldassano RN, **Braun J**, Xavier RJ, Clish CB, Yudkoff M, Li Hongzhe, Goullian M, Bushman FD, Lewis JD, Wu GD. The Role of Urease in Crohn's Disease Gut Microbiota Dysbiosis. *Science Transl Med*. 2017 Nov 15;9(416):eaah6888, doi: 10.1126/scitranslmed.aah6888. PMID: 29141885 PMCID: PMC5808452
174. Schirmer M, Franzosa EA, Lloyd-Price J, McIver LJ, Schwager R, Poon T, Andrews E, Barron G, Lake K, Prasad M, Sauk J, Stevens B, Sturgeon HC, Wilson RG, Braun J, Denson LA, Kugathasan S, McGovern DPB, Vlamakis H, Xavier RJ, Huttenhower C. Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. *Nature Microbiol*. 2018 Mar;3(3):337-346. doi: 10.1038/s41564-017-0089-z. Epub 2018 Jan 8. PMID: 29311644
175. Friese AC, Zettlitz KA, Salazar FB, Tavaré R, Tsai WK, Chatziioannou AF, Rozengurt N, **Braun J**, Wu A. Imaging CD4⁺ T cells in a murine model of colitis. *J Nucl Med*. 2018 Jun;59(6):980-985. doi: 10.2967/jnumed.117.199075. Epub 2018 Jan 11. PMID: 29326360
176. Jacob N, Jacobs JP, Kumagai K, Ha CWY, Kanazawa Y, Lagishetty V, Altmayer K, Hamill AM, Von Arx A, Sartor RB, Devkota S, **Braun J**, Michelsen KS, Targan SR, Shih DQ. Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome. *Mucosal Immunol*. 2018. 11(5): 1466-1476. Epub 2018 Jul 9. doi: 10.1038/s41385-018-0055-y. PMID: 29988118
177. Britton GJ, Contijoch EJ, Mogno I, Vennaro OH, Llewellyn SR NG R, Li Z, Mortha A, Merad M, Das A, Gevers D, McGovern D, Singh M, **Braun J**, Jacobs JP, Clemente JC, Grinspan A, Sands B, Colombel JF, Dubinsky MC, Faith JJ. Inflammatory bowel disease microbiotas exacerbate colitis and alter the balance of gut Th17 and ROR γ ⁺ regulatory T cells in mice. *Immunity*. 2019. 50:212-224.e214. Epub 2019 Jan 15. doi: 10.1016/j.immuni.2018.12.015. PMID: 30650377.
178. Chang YL, Rossetti M, Vlamakis H, Casero D, Sunga G, Harre N, Miller S, Humphries R, Stappenbeck T, Simpson K, Sartor RB, Wu GD, Lewis J, Bushman F, McGovern DPB, Salzman N, Borneman J, Xavier R, Huttenhower C, **Braun J**. A screen of Crohn's disease-associated microbial metabolites identifies ascorbate as a novel metabolic inhibitor of activated human T cells. *Mucosal Immunol*. 2019. 12:457-467. Epub 2018 Apr 25. doi: 10.1038/s41385-018-0022-7. PMID: 29695840.

179. Limon J, Tang J, Li D, Wolf A, Michelsen K, Funari V, Gargus M, Maymi V, Iliev I, Brown J, Borneman J, **Braun J**, McGovern D, Underhill D. Malassezia is Associated with Crohn's Disease and Exacerbates Colitis in Animal Models. *Cell Host Microbe*. 2019. 25:377-388. Epub 2019 Mar 13. doi:10.1016/j.chom.2019.01.007 Previews: TL Dawson, Malassezia: The Forbidden Kingdom Opens. *Cell Host Microbe* 2019. 25:345-347. PMID: 30850233. Kaleigh Rogers. You're covered in fungi. *New York Times*, April 9, 2019.
180. Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pecheco J, Poon TW, Andrews E, Ajami NJ, Bonham KS, Brislawn CJ, Caser D, Gonzalez A, Graeber TG, Lake K, Landers CJ, Mallick H, Plichta DR, Prasad M, Shungin D, Vazquez-Baeza Y, White RA, **Braun J**, Denson LA, Jansson JK, Knight R, Kugathasan S, McGovern DPB, Petrosino JF, Stappenbaeck TS, Winter HS, Clish CB, Franzosa EA, Vlamakis H, Xavier RJ, Huttenhower C. Multi'omics Detail the Gut Microbial Ecosystem in Inflammatory Bowel Disease. *Nature*. 2019. 569(7758):655-662. Epub 2019/05/01. doi.org/10.1038/s41586-019-1237-9. PMID: 31142855
181. Karstens L, Asquith M, Davin S, Fair D, Gregory WT, Wolfe AJ, **Braun J**, McWeeney S. Controlling for contaminants in low biomass 16S rRNA gene sequencing experiments. *mSystems*. 2019 Jun 4;4(4). Epub 2019/05/14. doi: 10.1128/mSystems.00290-19. PMID: 31164452 PMCID: PMC6550369.
182. Wang WL, Ren J, Tang K, Dart E, Ignacio-Espinoza JC, Fuhrman JA, **Braun J**, Sun F, Ahlgren NA. A network-based integrated framework for predicting virus-host interactions with applications. *NAR Genom Bioinform*. 2020. 2(2):lqaa044. Epub 2020/06/23. Doi.org/10.1093/nargab/lqaa044. PMID: 32626849. PMC7324143.
183. Li D, Lv J, Botwin G, **Braun J**, Cao Weihua, Li L, McGovern DPB. Estimating the scale of COVID-19 Epidemic in the United States: Simulations Based on Air Traffic directly from Wuhan, China. *MedRxiv*. 2020.03.06.20031880. doi: <https://doi.org/10.1101/2020.03.06.20031880>.
184. Dillard CM, Kiyohara M, Mah V...**Braun J**, Lazar G, Wicha MS, Wadehra M. EMP2 is a novel regulator of stemness in breast cancer cells. *Mol Cancer Ther*. 2020. 19(8):1682-1695. Epub 2020/05/25. doi: 10.1158/1535-7163
185. Bergstrom K, Shan X, Casero D, Batushansky A, Lagishetty V, Jacobs JP, Hoover C, Kondo Y, McDaniel JM, McGee S, Houchen CW, Rao CV, Griffin T, Sonnenburg JL, McEver RP, **Braun J**, Xia L. Ascending colon-derived O-glycosylated mucus encapsulates the colonic microbiota and modulates the mucosal ecology. 2020. *Science* Oct 23;370(6515):467-472 doi: 10.1126/science.aay7367. *Perspective: Birchenough GMH, Johansson MEV. Forming a mucus barrier along the colon. Science* 370(6515):402-403. doi: 10.1126/science.abe7194
186. Volkmann ER, Hoffmann-Void AM, Chang Y.L., Lagishetty V, Clements PR, Midtvedt, Molberg O, **Braun J**, Jacobs J. Longitudinal characterization of the gastrointestinal tract microbiome in systemic sclerosis. *Eur Med J* 2020;5(4):110-118.
187. Rubin DT, Abreu MT, Rai V, Siegel CA...**Braun J**...Ungaro R. Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. *Gastroenterology*. 2020;159(1):6-13.e6. Epub 20200406. doi: 10.1053/j.gastro.2020.04.002. PubMed PMID: 32272113; PMCID: PMC7194599

188. Siegel CA, Siegel LS, Dubinsky MC, Targan S, **Braun J**, Landers C, Bilsborough J, Princen F, Lasch K, Candela N, McGovern DPB, Dervieux T. Performance Characteristics of a Clinical Decision Support Tool for Disease Complications in Crohn's Disease. *Crohns Colitis* 360. 2021 Oct 30;3(4):otab074. doi: 10.1093/crocol/otab074. PMID: 36777269.
189. Noval-Rivas M, Ebinger JE, Wu M, Sun N, **Braun J**, Sobhani K, van Eyk JE, Cheng S, Arditi M. BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers. *J Clin Invest*. 2021 Jan 19;131(2):145157. doi: 10.1172/JCI145157. PMID: 33211672.
190. Smith SA, Chau L, Ogawa SA, Whelan KA, Hamilton K, Chen J, Tan L, Chen E, Keilbaugh S, Fogt F, Bewtra M, **Braun J**, Xavier RJ, Clish CB, Slaff B, Weljie AM, Bushman FD, Lewis JD, Li H, Bennett MJ, Nakagawa H, Wu GD. Mitochondrial dysfunction in inflammatory bowel disease alters intestinal epithelial metabolism of hepatic acylcarnitines. *J Clin Invest*. 2021 Jan 4;131(1):e133371. doi: 10.1172/JCI133371. PMID: 33141762. PMCID: PMC7773399
191. Potdar AA, Debe S, Naito T, Li K, Botwin G, Haritunians T, Li D, Yang S, Bilsborough J, Perrigoue JG, Denson LA, Daly M, Targan SR, Fleshner P, **Braun J**, Kugathasan S, Stappenbeck TS, McGovern DPB. Altered expression of SARS-CoV-2 host receptor, ACE2 is associated with small bowel inflammation, more severe disease and response to anti-cytokine therapy in Crohn's disease. *Gastroenterology*. 2021 Feb;160(3):809-822.e7. doi: 10.1053/j.gastro.2020.10.041. Epub 2020 Nov 5. PMID: 33160965.
192. Ebinger JE, Botwin GJ, Albert CM, Alotaibi M, Arditi M, Berg AH, Binek A, Botting P, Fert-Bober J, Figueiredo JC, Grein JD, Hasan W, Henglin M, Hussain SK, Mohit J, Joung S, Karin M, Kim EH, Li D, Liu Y, Luong E, McGovern DPB, Merchant A, Merin N, Miles PG, Minissian M, Nguyen TT, Raedschelders K, Rashid MA, Riera CE, Riggs RV, Sharma S, Sternbach S, Sun N, Tourtellote WG, Van Eyk JE, Sobhani K, **Braun JG**, Cheng S. Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a cross-sectional study. *BMJ Open*. 2021 Feb 12;11(2):e043584. doi: 10.1136/bmjopen-2020-043584. PMID: 335679769. PMCID: PMC7883610.
193. Siegel CA, Melmed GY, McGovern DP...**Braun J**...Panis V. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. *Gut*. 2021 Apr;70(4):635-640. doi: 10.1136/gutjnl-2020-324000. Epub 2021 Jan 20. PMID: 33472895. PMCID: PMC7818789
194. Naito T, Botwin GJ, Haritunians T, Li D, Yang S, Khrom M, **Braun J**; NIDDK IBD Genetics Consortium, Abbou L, Mengesha E, Stevens C, Masamune A, Daly M, McGovern DPB. Prevalence and Effect of Genetic Risk of Thrombo-embolic Disease in Inflammatory Bowel Disease. *Gastroenterology*. 2021 160(3):771-780. Epub 2020 Oct 19. doi: 10.1053/j.gastro.2020.10.019. PMID: 33098885.
195. Jain U, Ver Heul AM, Xiong S, Gregory MH, Demers EG, Kern JT, Lai CW, Muegge BD, Barisas DAG, Leal-Ekman JS, Deepak P, Ciorba MA, Liu TC, Hogan DA, Debbas P, **Braun J**, McGovern DPB, Underhill DM, Stappenbeck TS: *Debaryomyces* is enriched in Crohn's disease intestinal tissue and impairs healing in mice. *Science* 2021, 371:1154-9. doi: 10.1126/science.abd0919. PMID: 33707263.

196. Tanes C, Bittinger K, Gao Y, Friedman ES, Nessel L, Paladhi UR, Chau L, Panfen E, Fischbach JA, **Braun J**, Xavier RJ, Clish CB, Li H, Bushman FD, Lewis JD, Wu GD. Reconstitution of the Human Gut Microbiome and its Metabolome by Dietary Fiber. 2021. *Cell Host Microbe*. 29(3):394-407.e5. Epub 2021 Jan 8. doi: 10.1016/j.chom.2020.12.012. PMID: 33440171.
197. Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, Frias EC, Stewart JL, Van Eyk JE, **Braun JG**, Cheng S, Sobhani K. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nat Med*. 2021. 27:981–984. Epub 2021/04/03. doi: 10.1038/s41591-021-01325-6. PubMed PMID: 33795870.
198. Botwin GJ, Li D, Figueiredo J, Cheng S, **Braun J**, McGovern DPB, Melmed GY. Adverse Events Following SARS-CoV-2 mRNA Vaccination: Among Patients with Inflammatory Bowel Disease. *Am J Gastroenterol*. 2021 Aug 1;116(8):1746-1751. Epub 2021/05/29. doi: 10.14309/ajg.0000000000001342. PMID: 34047304.
199. Pozdnyakova V, Botwin GJ, Sobhani K, Prostko J, **Braun J**, Melmed GY, CORALE-IBD Study Group. Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients with Inflammatory Bowel Disease. *Gastroenterology*. 2021 Aug 12;161(6):2041-2043.e1. doi: 10.1053/j.gastro.2021.08.014. PMID: 34391771
200. Melmed GY, Botwin GJ, Sobhani K, PhD, Prostko J, Figueiredo J, **Braun J**, McGovern DPB. Effects of Immune Modifying Therapies on Antibody Responses Following SARS-CoV-2 mRNA Vaccination in Adults with Inflammatory Bowel Disease. *Ann Int Med*. 2021. Dec;174(12):1768-1770. doi: 10.7326/M21-2483. Epub 2021 Oct 12. PMID: 34633830.
201. Ebinger JE, Lan R, Sun N, Wu M, Joung S, Botwin GJ, Botting P, Al-Amili D, Aronow H, Beekley J, Coleman B, Contreras S, Cozen W, Davis J, Debbas P, Diaz J, Driver M, Fert-Bober J, Gu Q, Heath M, Herrera E, Hoang A, Hussain SK, Huynh C, Kim L, Kittleson M, Liu Y, Lloyd J, Luong E, Malladi B, Merchant A, Merin N, Mujukian A, Nguyen N, Nguyen T-T, Pozdnyakova V, Rashid M, Raedschelders K, Reckamp KL, Rhoades K, Sternbach S, Vallejo R, White S, Tompkins R, Wong M, Arditi M, Figueiredo JC, Van Eyk JE, Miles PB, Chavira C, Shane R, Sobhani K, Melmed GY, McGovern DPB, **Braun JG**, Cheng S, Minissian MB. Symptomology following mRNA vaccination against SARS-CoV-2. *Prev Med*. 2021 Dec;153:106860. doi: <https://doi.org/10.1016/j.ypmed.2021.106860>. PMID: 3468773.
202. Mirzayi C, Renson A, Zohra F, Elsafoury S, Geistlinger L, Kasselmann LJ, Eckenrode K, van de Wijgert J, Loughman A, Marques FZ, MacIntyre DA, Arumugam M, Azhar R, Beghini F, Bergstrom K, Bhatt A, Bisanz JE, **Braun J**, Bravo HC, Buck GA, Bushman F, Casero D, Clarke G, Collado MC, Cotter PD, Cryan JF, Demmer RT, Devkota S, Elinav E, Escobar JS, Fettweis J, Finn RD, Fodor AA, Forslund S, Franke A, Furlanello C, Gilbert J, Grice E, Haibe-Kains B, Handley S, Herd P, Holmes S, Jacobs JP, Karstens L, Knight R, Knights D, Koren O, Kwon DS, Langille M, Lindsay B, McGovern D, McHardy AC, McWeeney S, Mueller NT, Nezi L, Olm M, Palm N, Pasolli E, Raes J, Redinbo MR, Rühlemann M, Balfour Sartor R, Schloss PD, Schriml L, Segal E, Shardell M, Sharpton T, Smirnova E, Sokol H, Sonnenburg JL, Srinivasan S, Thingholm LB, Turnbaugh PJ, Upadhyay V, Walls RL, Wilmes P, Yamada T, Zeller G, Zhang M, Zhao N, Zhao L, Bao W, Culhane A, Devanarayan V, Dopazo J, Fan X, Fischer M, Jones W, Kusko R, Mason CE, Mercer TR, Sansone SA, Scherer A, Shi L, Thakkar S, Tong W, Wolfinger R, Hunter C, Segata N, Huttenhower C, Dowd JB, Jones HE, Waldron L. Reporting guidelines for human microbiome research: the STORMS checklist. *Nat Med*. 2021 Nov;27(11):1885-1892. Epub 2021/11/19. doi: 10.1038/s41591-021-01552-x. PubMed PMID: 34789871.

203. Ebinger JE, Botwin GJ, Albert CM, Alotaibi M, Arditi M, Berg AH, Binek A, Botting P, Fert-Bober J, Figueiredo JC, Grein JD, Hasan W, Henglin M, Hussain SK, Jain M, Joung S, Karin M, Kim EH, Li D, Liu Y, Luong E, McGovern DPB, Merchant A, Merin N, Miles PB, Minissian M, Nguyen TT, Raedschelders K, Rashid MA, Riera CE, Riggs RV, Sharma S, Sternbach S, Sun N, Tourtellotte WG, Van Eyk JE, Sobhani K, **Braun JG**, Cheng S. Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a cross-sectional study. *BMJ Open*. 2021;11(2):e043584. Epub 20210212. doi: 10.1136/bmjopen-2020-043584. PubMed PMID: 33579769; PMCID: PMC7883610.
204. Figueiredo JC, Merin NM, Hamid O, Choi SY, Lemos T, Cozen W, Nguyen N, Finster LJ, Foley J, Darrah J, Gong J, Paquette R, Mita AC, Vescio R, Mehmi I, Basho R, Tourtellotte WG, Huynh CA, Melmed GY, **Braun J**, McGovern DP, Mengesha E, Botwin G, Prostko JC, Frias EC, Stewart JL, Joung S, Van Eyk J, Ebinger JE, Cheng S, Sobhani K, Reckamp KL, Merchant A. Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in cancer patients. *Cancer Res*. 2021 Dec 15;81(24):6273-6280. doi: 10.1158/0008-5472.CAN-21-3554. Epub 2021 Nov 10. PMID: 34759001.
205. Liu Y, Ebinger JE, Mostafa R, Budde P, Gajewski J, Walker B, Joung S, Wu M, Brautigam M, Hespings F, Rupieper E, Schubert A-S, Zucht H-D, **Braun J**, Melmed GY, Sobhani K, Arditi M, Van Eyk JE, Cheng S, Fert-Bober J. Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection. *J Trans Med*. 2021 Dec 30;19(1):524. doi: 10.1186/s12967-021-03184-8. PMID: 34965855 PMCID: PMC8716184.
206. Xu A, Li J, Ebinger JE, Mengesha E, Elyanow R, Gittelman RM, Chapman H, Joung S, Botwin GJ, Pozdnyakova V, Debbas P, Mujukian A, Prostko JC, Frias EC, Stewart JL, Horizon AA, Merin N, Sobhani K, Figueiredo JC, Cheng S, Kaplan IM, McGovern DPB, Merchant A, Melmed GY, **Braun J**. Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease. *Front Immunol*. 2022. Apr 8;13:880190. doi: 10.3389/fimmu.2022.880190. PMID: 35464463. PMCID: PMC9024211.
207. Li D, Xu A, Mengesha E, Elyanow R, Gittelman RM, Chapman H, Prostko JC, Frias EC, Stewart JL, Pozdnyakova V, Debbas P, Mujukian A, Horizon AA, Merin N, Joung S, Botwin GJ, Sobhani K, Figueiredo JC, Cheng S, Kaplan IM, McGovern DPB, Merchant A, Melmed GY, **Braun J**. The T-cell response to SARS-CoV-2 vaccination in inflammatory bowel disease is augmented with anti-TNF therapy. *IBD J*. 2022. July;28(7):1130-1133. Epub Apr 9, 2022. doi: 10.1093/ibd/izac071. PMID: 35397000 PMCID: PMC9047232 *IBD Journal award, Most downloaded paper, 2022*.
208. Ebinger J, Joung S, Liu Y, Wu M, Weber B, Claggett B, Botting P, Sun N, Driver M, Kao YH, Khuu B, Wynter T, Nguyen TT, Alotaibi M, Prostko J, Frias E, Stewart J, Goodridge H, Chen P, Jorda S, Mohit J, Sharma S, Fert-Bober J, Van Eyk J, Minissian M, Arditi M, Melmed G, **Braun J**, McGovern D, Cheng S, Sobhani K. Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical center: a longitudinal cohort analysis. *BMJ Open*. 2022. May 24;12(5):e059994. PMID: 35613792 PMCID: PMC9130668 DOI: 10.1136/bmjopen-2021-059994.
209. Figueiredo JC, Hirsch FR, Kushi LH, Nembhard WN, Crawford JM, Mantis N, Finster L, Merin NM, Merchant A, Reckamp KL, Melmed GY, **Braun J**, McGovern D, Parekh S,

- Corley DA, Zohoori N, Amick BC, Du R, Gregersen PK, Diamond B, Taioli E, Sariol C, Espino A, Weiskopf D, Gifoni A, Brien J, Hanege W, Lipsitch M, Zidar DA, Scheck McAlearney A, Wajnberg A, LaBaer J, Yvonne Lewis E, Binder RA, Moormann AM, Forconi C, Forrester S, Batista J, Schieffelin J, Kim D, Biancon G, VanOudenhove J, Halene S, Fan R, Barouch DH, Alter G, Pinninti S, Boppana SB, Pati SK, Latting M, Karaba AH, Roback J, Sekaly R, Neish A, Brincks AM, Granger DA, Karger AB, Thyagarajan B, Thomas SN, Klein SL, Cox AL, Lucas T, Furr-Holden D, Key K, Jones N, Wrammerr J, Suthar M, Yu Wong S, Bowman NM, Simon V, Richardson LD, McBride R, Krammer F, Rana M, Kennedy J, Boehme K, Forrest C, Granger SW, Heaney CD, Knight Lapinski M, Wallet S, Baric RS, Schifanella L, Lopez M, Fernández S, Kenah E, Panchal AR, Britt WJ, Sanz I, Dhodapkar M, Ahmed R, Bartelt LA, Markmann AJ, Lin JT, Hagan RS, Wolfgang MC, Skarbinski J. Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. *Open Forum Infect Dis*. 2022 Apr 27;9(6):ofac171. doi: 10.1093/ofid/ofac171. eCollection 2022 Jun. PMID: 35765315
210. Jacobs JP, Goudarzi M, Lagishetty V, Li D, Mak T, Tong M, Ruegger P, Haritunians T, Landers C, Fleshner P, Vasiliasauskas E, Ippoliti A, Melmed G, Shih D, Targan S, Borneman J, Fornace AJ, McGovern DPB, **Braun J**. Crohn's disease in endoscopic remission, obesity, and cases of high genetic risk demonstrates overlapping shifts in the colonic mucosal-luminal interface microbiome. *Genome Med*. 2022;14(1):91. doi: 10.1186/s13073-022-01099-7
 211. Huang Y, Shin JE, Xu AM, Yao C, Joung S, Wu M, Zhang R, Shin B, Foley J, Mahov SB, Modes ME, Ebinger JE, Driver M, **Braun JG**, Jefferies CA, Parimon T, Hayes C, Sobhani K, Merchant A, Gharib SA, Jordan SC, Cheng S, Goodridge HS, Chen P. Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination. *iScience*. 2022 Oct 21;25(10):105209. doi: 10.1016/j.isci.2022.105209. Epub 2022 Sep 26. PMID: 36188190
 212. Li D, Debbas P, Mujukian A, Cheng S, **Braun J**, McGovern DPB, Melmed GY, CORALE-IBD Study Group. Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD. *Inflamm Bowel Dis*. 2022 Aug 23:izac174. doi: 10.1093/ibd/izac174. PMID: 35998072
 213. Ebinger J, Joung S, Wang M, Liu Y, Prostko J, Frias E, Steward J, **Braun J**, McGovern D, Melmed G, Jordan S, Claggett B, Sobhani K, Cheng S. Long-term durability of antibody responses after SARS-CoV-2 Vaccination and Influencing Factors. *J Intern Med*. 2023 Jan 10. doi: 10.1111/joim.13601. PMID: 36625223
 214. Shih T, Yusung S, Gonsky R, Dutra-Clarke R, Ziring D, Rabizadeh S, Kagathasan S, Denson LA, Li D, **Braun J**. Environmental interaction of resolved human cytomegalovirus infection with Crohn's disease location. 2023 Feb 1;29(2):328-331. doi: 10.1093/ibd/izac251. PMID: 36508344.
 215. Kakuta Y, Shirai T, McGovern DPB, **Braun J**, Fujii H, Masamune A. Novel Diagnostic Autoantibodies Against Endothelial Protein C Receptor in Patients With Ulcerative Colitis. *Clin Gastroenterol Hepatol*. 2023 Mar;21(3):844-846. doi: 10.1016/j.cgh.2021.12.035. Epub 2021 Dec 28. PMID: 34971808

216. Wang L, Yang J, You CC, Lai KKY, **Braun J**, McGovern DPB, Xie Y, Pandol SJ, Lu SC, Li D. Magnetic Resonance Imaging for Characterization of Hepatocellular Carcinoma Metabolism. *Front Physiol.* 2022; Dec 15;13:1056511. doi: 10.3389/fphys.2022.1056511.
217. Li D, Pavlovitch-Bedzyk AJ, Ebinger JE, Khan A, Hamideh M, Merchant A, Figueiredo JC, Cheng S, Davis MM, McGovern DPB, Melmed GY, Xu AM, **Braun J**. A paratope-enhanced method to determine breadth and depth TCR clonal metrics of the private human T-cell vaccine response after SARS-CoV2 vaccination. *Int J Molec Sci* 2023;24, 14223-14236. <https://doi.org/10.3390/ijms241814223>.
218. Caremoli F, Huynh J, Lagishetty J, Markovic D, **Braun J**, Dong TS, Jacobs JP, Sternini. Microbiota-Dependent Upregulation of Bitter Taste Receptor Subtypes in the Mouse Large Intestine in High-Fat Diet-Induced Obesity. *Nutrients* 2023, 15(19), 4145-4162; <https://doi.org/10.3390/nu15194145>. PMID: 37836428.
219. Sobhani K, Cheng S, Binder RA, Mantis NJ, Crawford JM, Okoye N, **Braun JG**, Joung S, Wang M, Lozanski G, King CL, Roback JD, Granger DA, Boppana SB, Karger AB. Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of Protection. *Vaccines.* 2023;11(11):1644. doi:10.3390/vaccines11111644.
220. Li D, Debbas P, Mujukian A, Cheng S, **Braun J**, McGovern DPB, Melmed GY; CORALE-IBD Study Group. Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD. *Inflamm Bowel Dis.* 2023 Jun 1;29(6):883-887. doi: 10.1093/ibd/izac174. PMID: 35998072.
221. Chan AM, Olafsen T, Tsui J, Salazar FB, Aguirre B, Zettlitz KA, Condro M, Wu AM, Braun J, Gordon LK, Ashki N, Whitelegge J, Xu S, Ikotun O, Lee JT, Wadehra M. 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors. *Mol Cancer Ther.* 2024 Jun 4;23(6):890-903. doi: 10.1158/1535-7163.MCT-23-0465. PMID: 38417138
222. Gonsky R, Adams E, Potdar AA, Botwin G, Biener-Ramanujan E, McGovern DPB, **Braun JG**, Fleshner P, Targan SR. A blood-based transcriptomic signature stratifies severe Crohn's disease and defines potentially targetable therapeutic pathways. *Front. Gastroenterol.* 2023 Oct 18;2. doi.org/10.3389/fgstr.2023.1251133.
223. Lee YJ, Li D, Mujukian A, Debbas P, Hampton M, Mengesha E, Cheng S, Ebinger JE, Chiorean M, Lum D, Damas OM, **Braun J**, McGovern DPB, Melmed GY; CORALE-IBD Study Group. Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2024 Aug 1;30(8):1430-1434. doi: 10.1093/ibd/izad198. ePub 2023 Sep 29. PMID: 37773982. PMC11291623
224. Mujukian A, Kumar R, Li D, Debbas P, Botwin GJ, Cheng S, Ebinger J, **Braun J**, McGovern D, Melmed GY; CORALE-IBD Study Group. Postvaccination Symptoms After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease: A Prospective, Comparative Study. *Inflamm Bowel Dis.* 2024 Apr 3;30(4):602-616. ePub 2023 Aug 9. doi: 10.1093/ibd/izad114. PMID: 37556401.

225. Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families. Jacobs JP, Spencer E, Helmus D, Yang JC, Lagishetty V, Bongers G, Britton G, Gettler K, Reyes-Mercedes PM, Hu J, Hart A, Lamousé-Smith E, Wehkamp J, Landers C, Debbas P, Torres J, Colombel JF, Cho J, Peter I, Faith J, **Braun J**, Dubinsky MC. 2024. Gut. Nov 11;73(12):1953-1964. ePub 2024 Aug 9. doi: 10.1136/gutjnl-2024-332475. PMID: 39122361.
226. Fu Q, Vegesna M, Sundararaman N, Damoc E, Arrey TN, Pashkova A, Mengesha E, Debbas P, Joung S, Li D, Cheng S, **Braun J**, McGovern DPB, Murray C, Xuan Y, Van Eyk JE. A Proteomics Pipeline for Generating Clinical Grade Biomarker Candidates from Data-Independent Acquisition Mass Spectrometry (DIA-MS) Discovery. Angew Chem Int Ed Engl. 2024 Dec 20;63(52):e202409446. doi: 10.1002/anie.202409446. Epub 2024 Nov 11. PMID: 39432331.
227. Yang JC, Lagishetty V, Aja E, Arias-Jayo N, Chang C, Hauer M, Katzka W, Zhou Y, Sedighian F, Koletic C, Liang F, Dong TS, Situ J, Troutman R, Buri H, Bhute S, Simpson CA, **Braun J**, Jacob N, Jacobs JP. Biogeographical distribution of gut microbiome composition and function is partially recapitulated by fecal transplantation into germ-free mice. ISME J. 2025 Jan 2;19(1):wrae250. Epub 2024 Dec 16. PMID: 39680691
228. Inflammatory disease microbiomes share a functional pathogenicity predicted by C-reactive protein. Britton GJ, Mogno I, Chen-Liaw A, Plitt T, Helmus D, Bongers G, Brough I, Colmenero P, Lam LH, Bullers SJ, Penkava F, Reyes-Mercedes P, **Braun J**, Jacobs JP, Desch AN, Gevers D, Simmons S, Filer A, Taylor PC, Bowness P, Huttenhower C, Littman D, Dubinsky MC, Raza K, Tankou SK, Faith JJ. bioRxiv. 2025 Jan 18:2025.01.14.633015. doi: 10.1101/2025.01.14.633015. PMID: 39868147

Publications submitted

229. Human inflammatory disease microbiomes exhibit shared and disease-specific pathogenic functions across inflammatory mouse models, Britton GJ, Bartu L, Mogno I, Chen-Liaw A, Plitt T, Helmus D, Bongers G, Brough I, Colmenero P, Lam LH, Bullers SJ, Penkava F, Reyes-Mercedes P, Braun J, Jacobs JP, Desch N, Gevers D, Simmons S, Filer A, Taylor PC, Bowness P, Huttenhower C, Littman D, Dubinsky MC, Raza K, Tankou SK, Faith JJ. Sci Immunol 2026, submitted Aug 1 2026
230. Cedillo-Castelan V, Li D, Sobhani K, Anand R, Chiorean M, Mengesha E, Myers M, Mujukian A, Khan A, Joung S, Cheng S, Ebinger J, Braun J, McGovern DPB, Melmed GY. SARS-CoV-2 Vaccine Response and Breakthrough Infection in High-Risk Populations and Healthy Controls

Chapters

1. Hahn, G.M., Li, G.C., and **Braun, J**. A comparative study of several survival responses of mammalian cells after ultraviolet and after X-irradiation. In: *Research in Photobiology*. Ed., A Castellani, Ed. Plenum Press, pp. 185-196, 1977
2. Ault, K.A., and **Braun, J**. Cell surface recognition and transmembrane control. In: *Biological Basis of Immunodeficiency*. Eds., EW Gelfand, and HW Dosch. Raven Press, New York, pp. 155-168, 1980.

3. **Braun, J.**, and Unanue, E.R. Calcium and lymphocyte surface macromolecules. In: *Calcium in Normal and Pathological Biological Systems*. Ed., LJ Anghileri. CRC Press, Boca Raton, Florida, Vol. 1, pp. 175-182, 1982.
4. **Braun, J.**, and Unanue, E.R. Biological basis for the function of surface immunoglobulin. In: *B lymphocytes in the Immune Response*. Eds., N Klinman, DE Mosier, I Sher, and ES Vitetta. Elsevier Publishing Company, Amsterdam, pp. 169-175, 1981.
5. **Braun, J.**, Receptor-cytoskeleton interactions in the lymphocyte. *Immunol. Today*, 4:21-25, 1982; reprinted in: *B lymphocytes Today*. Ed., JR Inglis. Elsevier Biomedical Press, Amsterdam, pp. 80-84, 1982.
6. Unanue, E.R., and **Braun, J.** Immunofluorescence methods to study cell surface and cytoplasmic proteins and their dynamics. In: *Handbook of Experimental Immunology*. Eds., DM Weir and LA Herzenberg. Blackwell Press, Fourth Edition, 1984.
7. **Braun, J.**, Ando, D., Denis, K., Felsher, D., Govan, H. III, Krall, W. Generation and characterization of murine Ly-1 (CD-5) B cell lines. In: *B Cell Development*, Eds., M Howard, N Klinman, O Witte, Alan Liss, New York, pp. 55-67, 1984
8. **Braun, J.**, Stiehm, E. R. The B lymphocyte system. In: *Immunologic Disorders in Infants and Children*. Ed., ER Stiehm. W. B. Saunders Company, Philadelphia. 4th Edition, pp.35-74, 1995.
9. **Braun, J.**, Valles-Ayoub, Y., Berberian, L., Eggena, M., Gordon, L.K., Targan, S. "On the pathogenesis trail: What marker B cell clones tell us about IBD", in *Inflammatory Bowel Disease: Basic Research, Clinical Implications, and Trends in Therapy*, Editor, Sutherland, L.R., Collins, S.M., Martin, F., McLeod, R., Targan, S.R., Wallace, J.L., Williams, C.N. Kluwer Academic Publishing, Dordrecht, The Netherlands, pp. 96-103, 1994.
10. Goodglick, L., Townsley-Fuchs, J., Fairhurst, R.M., Neshat, M., Marcelo, D., Mosier, D.E., **Braun, J.** The HIV-1 gp120 superantigen: structural features and its role in viral host-pathogen interaction, In *B cell superantigens*, Editor M. Zouali, Landes, New York, pp.145-160, 1996.
11. Goodglick, L., Aldrovandi, G.M., Zack, J.A., **Braun, J.** HIV-1 gp120, an immunoglobulin superantigen, In *Viral Superantigens*, Editor K. Tomonari, CRC Press, Boca Raton, pp.171-188, 1997.
12. **Braun J**, Wei B. The gut microflora: functional identification techniques. In: Hart A et al. *Gut Ecology*. London: Martin Dunitz, 2001, pp.19-24.59.
13. **Braun, J.**, Cohavy, O, Eggena, M. Antibodies in the exploration of inflammatory bowel disease pathogenesis. In *Inflammatory Bowel Disease: From Bench to Bedside*. 2nd edition. Editors, SR Targan, F Shanahan, LC Karp. pp. 211-223, 2003.
14. **Braun J**, Targan SR. Multiparameter analysis of immunogenetic mechanisms in clinical diagnosis and management of IBD. In, *Immune Mechanism in Inflammatory Bowel Disease*. M. Neurath and RS Blumberg, editors. Landes, Amsterdam. 2005. Chapter 13. Pp. 209-218. ISBN 1-58706-232-1.
15. Mazmanian S, **Braun J.** The Commensal Microbiota and Its Relationship to Homeostasis and Disease. Chapter 17, pp. 245-260. In *Principles of Mucosal Immunology*. Editors: Smith PD, MacDonald TT, Blumberg RS. 2012. Garland Science, New York. ISBN 9780815344438.

16. Jacobs J, **Braun J**. The Mucosal Microbiome: Imprinting the Immune System of the Intestinal Tract. In, Mucosal Immunology. Editors: Mistecky J, Strober W, Kelsall B, Lambrecht B, Russell M, Cheroutre H. Elsevier, Amsterdam. 4th Edition, 2014.
17. Tong M, Jacobs JP, McHardy IH, **Braun J**. Sampling of intestinal microbiota and targeted amplification of bacterial 16S rRNA genes for microbial ecologic analysis. *Curr Protoc Immunol*. 2014 Nov 3;107:7.41.1-7.41.11. doi: 10.1002/0471142735.im0741s107. PMID:25367129
18. Dhyani M, Joshi N, Bemelman WA, Gee MS, Yajnik V, D'Hoore A, Traverso G, Donowitz M, Mostoslavsky G, Lu TK, Lineberry N, Niessen HG, Peer D, **Braun J**, Delaney CP, Dubinsky MC, Guillory AN, Pereira M, Shtraizent N, Honig G, Polk DB, Hurtado-Lorenzo A, Karp JM, Michelassi F. Challenges in IBD Research: Novel Technologies. *Inflamm Bowel Dis*. 2019. 25:S24-S30. <https://doi.org/10.1093/ibd/izz077>
19. **Braun J**, Hsaio EY, Powell N. Commensal microbiota and its relationship to homeostasis and disease. In Principles of Mucosal Immunology. Smith PD, MacDonald TT, Blumberg RS. CRC Press. 2nd Edition, Chapter 19, 2020. ISBN: 9780367348946.

Reviews

1. **Braun J**. DNA repair. Stanford Review, Spring, 1973.
2. **Braun J**, and Unanue ER. Surface immunoglobulin and the lymphocyte cytoskeleton. *Fed. Proc.*, 42:2446-2451, 1983.
3. **Braun J**, and Unanue ER. The lymphocyte cytoskeleton and its control of surface receptor functions. *Semin. Hematol.*, 20:322, 1983.
4. **Braun, J.**, Citri, Y., Baltimore, D., Forouzanpour, F., King, L., Teheranizadeh, K., Bray, M., Kliever, S. B-Lyl cells: Immortal Ly-1⁺ B lymphocyte cell lines spontaneously arising in murine splenic cultures. *Immunol. Rev.*, 93:5-22, 1986.
5. Krall, W. J., **Braun, J**. Retroviral and clonal analysis of post-antigenic B cell populations. 1992. *Semin. Immunol.* 4:19-28.
6. **Braun, J.**, Kiely, J.M., and Unanue, E.R. Propagation of B lymphocytes in vitro. *Curr. Topics. Micro. Immunol.*, 113:237-240, 1984.
7. **Braun, J.**, Dean W. Felsher, Lee A. Goodglick. *c-myc*, MHCI, and NK resistance in immunodeficiency lymphomas. 1992. *Ann. NY Acad. Sci.* 561:467-469.
8. **Braun, J**. B cells: The only good ones are dead ones. 1990. *UCLA Immunology Newsletter* 1(2):1.
9. **Braun, J**. Book Review. Immunoglobulin Genes. 1990, *Cancer Cells*, 2(4)127-128.
10. **Braun, J.**, Saxon, A., Wall, R., Morrison, S. L. The Second Century of the Antibody: Molecular Perspectives in Regulation, Pathophysiology, and Therapeutic Applications. 1992. *West. J. Med.* 157:158-168.

11. **Braun, J.**, Valles-Ayoub, Y., Berberian, L., Eggena, M., Gordon, L.K., Targan, S. On the pathogenesis trail: What marker B cells tell us about inflammatory bowel disease. 1996. *Can J Gastroenterol* 10:115-119.
12. Townsley-Fuchs, J., Margolin, D. H., **Braun, J.**, Goodglick, L. HIV-1 gp120: A novel viral B cell superantigen. *Int Rev Immunol* 16:325-338, 1997.
13. Fairhurst, R.M., C.X. Wang, P.A. Sieling, R. Modlin, and **J. Braun**. CD1-restricted T cells and resistance to polysaccharide-encapsulated bacteria. 1998. *Immunology Today*, 19:257-259.
14. Dalwadi, H, Wei, B., **Braun, J.** Defining new pathogens and non-culturable infectious agents: The case of inflammatory bowel disease. 2000. *Curr. Opin. Gastroenterol.* 16:56-59.
15. Su TT, Guo B, Wei B, **Braun J**, Rawlings DJ. Signaling in transitional type 2 B cells is critical for peripheral B cell development. 2004. *Immunol Rev.* 197:161-178.
16. Velazquez P, Wei B, **Braun J.** Surveillance B lymphocytes and mucosal immunoregulation. *Springer Semin Immunopathol.* 2005. 26:453-462.
17. **Braun J**, Targan SR. Multiparameter analysis of immunogenetic mechanisms in clinical diagnosis and management of inflammatory bowel disease. *Adv Exp Med Biol.* 2006. 579:209-218.
18. **Braun J**, Wei B. Body traffic: ecology, genetics, and immunity in inflammatory bowel disease. 2007. *Annu Rev Pathol. Mech. Dis.* 2:401–29.
19. Sartor RB, Blumberg RS, **Braun J**, Mayer LF, CCFA Microbial-Host Interactions Workshop: Highlights and Key Observations. 2007. *Inflamm Bowel Dis.* 13:600-619.
20. Lin J, Ziring D, Desai S, Kim S, Wong W, Korin Y, **Braun J**, Reed E, Gjertson D, Singh RR. TNF α Blockade in Human Diseases: An Overview of Efficacy and Safety. 2008. *Clin Immunol.* 126:13-30. Epub 2007 Oct 4
21. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, Gjertson D, **Braun J**, Reed E, Singh RR. TNF α Blockade in Human Diseases: Mechanisms and Future Directions. 2008. *Clin Immunol.* 126:121–136. doi:10.1016/j.clim.2007.08.013. *Cover article*
22. Ziring D, **Braun J.** Pediatric inflammatory bowel disease research: on the cutting-edge. 2008. *Pediatr Res.* 64:119-20.
23. Underhill D, **Braun J.** The current understanding of fungal microflora in inflammatory bowel disease pathogenesis. 2008. *Inflamm Bowel Dis.* 14:1147:1153
24. Li XX, **Braun J**, Wei B. Regulatory B cells in autoimmune diseases and mucosal immune homeostasis. *Autoimmunity.* 2011 Feb;44(1):58-68. Epub 2010 Aug 11. PMID:20701454

25. Maecker HT, McCoy JP Jr; FOCIS Human Immunophenotyping Consortium, Amos M, Elliott J, Gaigalas A, Wang L, Aranda R, Banchereau J, Boshoff C, **Braun J**, Korin Y, Reed E, Cho J, Hafler D, Davis M, Fathman CG, Robinson W, Denny T, Weinhold K, Desai B, Diamond B, Gregersen P, DiMeglio P, Nestle F, Peakman M, Villnova F, Ferbas J, Field E, Kantor A, Kawabata T, Komocsar W, Lotze M, Nepom J, Ochs H, O'Lone R, Phippard D, Plevy S, Rich S, Roederer M, Rotrosen D, Yeh JH. A model for harmonizing flow cytometry in clinical trials. *Nat Immunol.* 2010 Nov;11(11):975-8. PMID: 20959798
26. Lin L, **Braun J**. Another earth: innate lymphoid cells and intestinal inflammation. *Gastroenterology.* 2011 Nov;141(5):1542-4. Epub 2011 Sep 28. PMID:21959073
27. Jacobs JP, Braun, J. Immune and genetic gardening of the intestinal microbiome. *FEBS Lett.* 2014 Mar 5. pii:S0014-5793(14)00181-1. doi:10.1016/j.febslet.2014.02.052. PMID:24613921
28. Huttenhower C, Knight R, Brown T, Caporaso G, Clemente JC, Gevers D, Franzosa EA, Kelley ST, Knights D, Ley RE, Mahurkar A, Ravel J, The Scientists for Advancement of Microbiome Research, White O. Advancing the Microbiome Research Community. *Cell.* 2014. 9 Oct. 159:227-30. doi: <http://dx.doi.org/10.1016/j.cell.2014.09.022>
29. Ravel J, Blaser MJ, **Braun J**, Bushman FD, Chang EB, Julian DE, Dewey KG, Timothy D, Dominguez-Bello M, Erdman SE, Finlay BB, Garrett WS, Huffnagle GB, Huttenhower C, Jansson J, Jeffrey IB, Jobin C, Khoruts A, Kong HH, Lampe JW, Ley RE, Littman DR, Mazmanian SK, Mills DA, Neish AS, Petrof E, Relman DA, Rhodes R, Turnbaugh PJ, Young VB, Knight R, White O, Brown E. Human Microbiome Science: Vision for the Future, Bethesda, MD, July 24-26 2013. June 2013, the launch of the microbiome. *Microbiome.* 2014. 18 Jul. 2:16. <http://www.microbiomejournal.com/content/2/1/16>
30. Dubinsky M, **Braun J**. Diagnostic and Prognostic Microbial Biomarkers in IBD. *Gastroenterology.* 2015 Aug 15. pii: S0016-5085(15)01138-5. doi: 10.1053/j.gastro.2015.08.006. [Epub ahead of print]. PMID: 26284597. NIHMS 716217.
31. Louis DN, Feldman M, Carter AB, Dighe AS, Pfeifer JD, Bry L, Almeida JS, Saltz J, **Braun J**, Tomaszewski JE, Gilbertson J, Sinard JH, Gerber G, Galli SJ, Golden JA, Becich MJ. Computational Pathology: a path ahead. *Arch Pathol Lab Med.* 2016 Jan;140(1):41-50. doi: 10.5858/arpa.2015-0093-SA. Epub 2015 Jun 22. PMID: 26098131
32. Karstens L, Asquith M, Caruso V, Rosenbaum J, Fair D, **Braun J**, Gregory T, Nardos R, McWeeney S. Community profiling of the urinary microbiota: Methodological considerations for low microbial biomass biological samples. *Nature Rev Urol.* 2018. 15(12):735-749. Epub 2018 Oct 14. doi:10.1038/s41585-018-0104-z. PMID: 30315209
33. **Braun, J**. A Chemical Time Machine for Mucosal Healing. *Cell Host Microbe.* 2018. Sep 12;24(3):325-326. Epub 2018 Sep 12. <https://doi.org/10.1016/j.chom.2018.08.013>
34. Underhill DM, **Braun J**. Fungal microbiome in inflammatory bowel disease: a critical assessment *J Clin Invest.* 2022 Mar 1;132(5):e155786. Epub 2022 Mar 1. doi: 10.1172/JCI155786. PMID: 35229726

35. Wang L, Yang J, You CC, Lai KKY, **Braun J**, McGovern DPB, Xie Y, Pandol SJ, Lu SC, Li D. Magnetic Resonance Imaging for Characterization of Hepatocellular Carcinoma Metabolism. *Front Physiol.* 2022;13. doi: 10.3389/fphys.2022.1056511.

Editorials

1. **Braun J.** Unsettling facts of life: bacterial commensalism, epithelial adherence, and inflammatory bowel disease. 2002. *Gastroenterology*, 122, 228-230.
2. **Braun, J.** The sorcerer's apprentice. 2002. *Inflammatory Bowel Diseases*, 8:310.
3. **Braun, J.** Introduction. 2003. *Exper. Molec. Pathol.* 74:85.
4. **Braun, J.** Primativism, siderophilic bacteria and Crohn's disease. 2004. *Inflamm. Bowel Dis.* 10:884-885
5. **Braun J.** In search of desire: MAP, bacteria, and Crohn's disease. 2006. *Gastroenterology* 131:312-4.
6. **Braun J.** A NOD to the Dodgers. 2007. *Gastroenterology* 133:1721-3.
7. Westbrook AM, Wei B, **Braun J**, Schiestl RH. More damaging than we think: systemic effects of intestinal inflammation. *Cell Cycle.* 2009 Aug 15;8(16):2482-3. Epub 2009 Aug 15.
8. Sachar DB, Jewell D, Gasche C, **Braun J.** Inflammatory bowel disease. *Int J Inflamm.* 2012;2012:341052. Epub 2012 Mar 27. PMID: 22536542
9. **Braun J.** Tightening the case for gut microbiota in autism-spectrum disorder. *Cell Mol Gastroenterol Hepatol.* 2017. Mar; 3(2): 131–132. PMCID: PMC5331834
10. **Braun J.** Flaviviruses Hit a Moving Target. *Cell.* 2018. 175(5): 1175-1176 Epub 2018 Nov 15
11. **Braun J.** Happy families. *Cell Host Microbe.* 2021. Aug 11;29(8):1218-1220. Doi.org/10.1016/j.chom/2021.07.012. PMID: 34384525.

Abstracts

1. Govan, H.L., **Braun, J.** Autonomously-replicating vectors designed to detect hypermutation mediated by an immunoglobulin gene microenvironment. 1991. *FASEB J.* 5:A999.
2. Valles-Ayoub, Y., Govan, H. L., **Braun, J.** Immunoglobulin variable region hypermutation is associated with a DNA repair deficit. 1991. *FASEB J* 5:A1355.
3. Valles-Ayoub, Y., Govan H. L., **Braun, J.** Abundance and clonal pattern of human germinal center B cells during childhood. 1991. *J Cell Biochem. Suppl.* 12B:90.
4. Berberian, L.S., Valles, Y., Targan, S.R., **Braun, J.** 20p1 V gene anti-RBC antibody defines a patient subset with inflammatory bowel disease. AGA, May 1992.
5. Valles, Y., Berberian, L., Targan, S.R., **Braun, J.** Marker B cell clones in ulcerative colitis and Crohn's disease. AGA, May 1992.
6. Goodglick, L.A., Berberian, L., Valles-Ayoub, Y., **Braun, J.** Molecular and pathophysiologic control of VH genes in mouse and man. *J. Cell Biochem.* 17B:198 (FZ008), 1993. (Keystone Symposium on Molecular Aspects of B Lymphocyte Differentiation, Taos, NM, February 1993).

7. Goodglick, L., Berberian, L., **Braun, J.** A second natural ligand for HIV gp120. J. Cell Biochem. 17B:217 (FZ205), 1993. (Keystone Symposium on Molecular Aspects of B Lymphocyte Differentiation, Taos, NM, February 1993).
8. Fairhurst, R.M., Neshat, M., Valles-Ayoub, M., **Braun, J.** Recurrent isolation of a novel immunoglobulin heavy-chain (VH5) gene from human follicular B cells. J. Cell Biochem. 17B:179 (F307). (Keystone Symposium on B Cell Immunobiology and Human Disease, Taos, NM, February 1993).
9. Goodglick, L. A., Berberian, L. S., **Braun, J.** A second natural receptor for HIV gp120. (AAI/CIS Convention, Denver, CO, May 1993).
10. Berberian, L.S., Eggena, M., Targan, S.R., **Braun, J.** 20p1 V-gene defines a patient subset with inflammatory bowel disease. (AAI/CIS Convention, Denver, CO, May 1993).
11. Fairhurst, R. M., Valles-Ayoub, Y., Neshat, M., **Braun, J.** A candidate gene conversion event associated with hypermutation of the human VH5 gene. AAI/CIS Convention, Denver, CO, May 1993.
12. Neshat MN, Goodglick L., **Braun J.** A novel octamer regulatory element in the VH11 leader exon of B1 cells. Experimental Biology 94, Anaheim, CA, April 1994.
13. Goodglick L, Zevit N, Townsley-Fuchs, J, Valles-Ayoub Y, **Braun J.** HIV gp120 Binds to CD4 and Endogenous VH3 Immunoglobulin at a Similar Site. Experimental Biology 94, Anaheim, CA, April 1994.
14. Fairhurst, R. M., Valles-Ayoub, Y., Neshat, M., **Braun, J.** A candidate gene conversion event associated with hypermutation of a human VH5 gene. Experimental Biology 94, Anaheim, CA, April 1994.
15. Eggena M, Targan S, **Braun J.** Characterization of ulcerative colitis specific pANCA using phage display technology. Experimental Biology 94, Anaheim, CA, April 1994.
16. **Braun J,** Goodglick L, Berberian L., Townsley-Fuchs J, Mosier D. Pathogenesis of gp120 as a B cell superantigen. 1994, UCLA/UCI AIDS Symposium, Palm Springs, CA, March 1994.
17. **Braun J.** Structural, biologic, and clinical evidence that gp120 is a B cell superantigen. Universitywide AIDS Research Conference, San Francisco, CA, March 1994.
18. **Braun J.** On the pathogenesis trail: Marker antibodies in inflammatory bowel disease. Basic research and clinical implications in I.B.D. Victoria, B.C. Canada April 1994.
19. Marcelo, D., Goodglick, L., **Braun, J.** Homologous binding of gp120 and thyroglobulin by the natural subset of VH3 anti-gp120 antibodies. European Conference on Immunobiology, Barcelona, Spain, June 1994.
20. Goodglick, L., Neshat, M., **Braun, J.** Mapping the VH3 superantigen binding site of HIV-1 gp120. European Conference on Immunobiology, Barcelona, Spain, June 1994.

21. **Braun, J.**, Townsley-Fuchs, J., Kam, L., Goodglick, L. Serum levels of superantigen/gp120-binding VH3 antibody is a polymorphic phenotype associated with susceptibility to HIV transmission. Keystone Symposium on HIV Pathogenesis, Keystone, CO, April 1995.
22. Townsley-Fuchs, J., Goodglick, L., **Braun, J.** VH3 immunoglobulins of the natural antibody repertoire bind gp120, activate complement and sequester gp120 away from T-cells. Keystone Symposium on HIV Pathogenesis, Keystone, CO, April 1995.
23. Neshat, M. S., Goodglick, L., Chuang, P., Morrison, S. L., **Braun, J.** Characterization of the immunoglobulin VH binding motif for HIV-1 gp120. 9th International Congress of Immunology, San Francisco, CA, July 1995.
24. Swenson, L. R., Reimann, K. B., Targan, S. R., **Braun, J.** Cloning of a marker antibody (AEA-15) found in Crohn's disease, ulcerative colitis, and Campylobacter jejuni enterocolitis. 9th International Congress of Immunology, San Francisco, CA, July 1995.
25. Eggena, M. P., Targan, S. R., Vidrich, A., Perillo, N. L., Baum, L. G., **Braun, J.** Characterization of the ulcerative colitis specific marker autoantibody (pANCA) and its target antigen. 9th International Congress of Immunology, San Francisco, CA, July 1995.
26. Eggena, M. P., Targan, S. R., Vidrich, A., **Braun, J.** Phage display cloning and characterization of the ulcerative colitis specific perinuclear anti-neutrophil cytoplasmic antibody (pANCA). AGA/AASLD Convention, San Diego, CA, May 1995.
27. Eggena, M. P., Targan, S. R., Vidrich, A., **Braun, J.** Cloning and characterization of the ulcerative colitis specific perinuclear anti-neutrophil cytoplasmic antibody (pANCA) and its target antigen. 8th International Congress of Mucosal Immunology, San Diego, CA, July 1995.
28. Swenson, L. R., Reimann, K. B., Targan, S. R., **Braun, J.** Cloning of a marker antibody (AEA-15) found in Crohn's disease, ulcerative colitis, and Campylobacter jejuni enterocolitis. 8th International Congress of Mucosal Immunology, San Diego, CA, July 1995.
29. Eggena, M.P., Targan, S.R., Vidrich, A., Clemens, D.F., Iwanczyk, L., Gordon, L.K., **Braun, J.** Characterization of the ulcerative colitis specific pANCA target antigen. DDW/AGA Annual Meeting, San Francisco, CA, May 1996.
30. Eggena, M.P., Targan, S.R., Vidrich, A., Clemens, D.F., Iwanczyk, L., Gordon, L.K., **Braun, J.** Identification of histone H1 as the ulcerative colitis specific pANCA target antigen. AAI/ASIP Annual Meeting, New Orleans, LA, June 1996.
31. Eggena, M.P., Targan, S.R., Gordon, L.K., **Braun, J.** Histone H1, a candidate antigen for the ulcerative colitis specific pANCA. Clinical Immunology Society Annual Meeting, New Orleans, LA, June 1996.

32. Fairhurst, R.M., Wang, C.X., Sieling, P., Modlin, R., and **Braun, J.** CD1 presentation of H. influenzae type B nonpeptide antigens. AAI/ASIP Annual Meeting, New Orleans, LA, June 1996.
33. Eggena, M.P., Parseghian, M., Hamkalo, B., Cohavy, O., Targan, S.R., Gordon, L. K., **Braun, J.** Histone H1 is the pANCA antigen in ulcerative colitis. International ANCA meeting, Rochester, 1996.
34. Chodos, M., Eggena, M.P., Targan, S.R., **Braun, J.**, Gordon, L.K. Identification of a mucosal target cell expressing the cognate antigen of the ulcerative colitis marker antibody, pANCA. American Association of Immunologists, San Francisco, CA, 1997.
35. Gordon, L.K., Eggena, M.P., Targan, S.R., **Braun, J.** Expression of the Cognate Antigen of the Ulcerative Colitis Marker Antibody pANCA in Ocular and Extraocular Tissues. American Association of Ophthalmology, Washington D.C., 1997.
36. Gordon, L.K., Eggena, M.P., Targan, S.R., **Braun, J.** Tissue expression of antigens recognized by the ulcerative colitis marker antibody pANCA. American Gastroenterologic Association, Washington D.C., 1997.
37. Cohavy, O., Eggena, M.P., Parseghian, M., Hamkalo, B., Targan, S.R., Gordon, L.K., **Braun, J.** Histone H1, a candidate pANCA antigen in ulcerative colitis. American Gastroenterologic Association, Washington D.C., 1997.
38. Gordon, L.K., Eggena, M.P., Targan, S.R., **Braun, J.** Ocular expression of the Cognate Antigen of the Ulcerative Colitis Marker Antibody, pANCA. Association of Research in Vision and Ophthalmology. Ft. Lauderdale, 1997.
39. **Braun, J.**, Goodglick, L., Anton, P., Wadhera, M., Lim, K. Mechanisms of the VH3 antibody role in HIV-1 transmission. NIH MAPS Workshop, Bethesda, 1997.
40. **Braun, J.**, Wang, C.X., Said, J. Identification of new complementing genes in c-myc lymphomagenesis. NIH AIDS Lymphomagenesis Workshop, Bethesda, 1997.
41. Sutton, C., Reimann, K., Barry, M., Yang, H-Y, Rotter, J., Targan, S.R., **Braun, J.** Disease-related and familial expression of a marker antibody in Crohn's disease. American Gastroenterologic Association, Washington D.C., 1997.
42. Wang, C.X., Fisk, B.C., Mendoza, M.J., Sakamoto, K.M., **Braun, J.** Differential expression of a novel 2.5 kB WD propellar domain gene in low versus high-grade murine B cell lymphomas. Midwinter Immunology Conference, Asilomar, CA, January 1998.
43. Gordon, L.K., **Braun, J.** Identification of tissue antigens recognized by the marker antibody pANCA. ARVO, Ft. Lauderdale, March 1998.

44. Dubinsky, M., Ruemmele, F., Targan, S., **Braun, J.**, Seidman, E. Prospective Study on the Predictive Value of Novel Serological Assays in Pediatric Inflammatory Bowel Disease. Canadian Association of Gastroenterology, March 1998
45. Cohavy, O., Tayebali, A.B., Phou, P., Bruckner, D., Harth, G., Horwitz, M., Targan, S., **Braun, J.** Identification of candidate bacterial pathogens in ulcerative colitis using a disease-specific marker antibody. Experimental Biology, San Francisco, CA, April 1998.
46. Wang, C.X., Fisk, B.C., Chow, Y.-K., **Braun, J.** Subtractive cloning of a novel GAS gene family member associated with the lymphoid lineage and B lymphomagenesis. Experimental Biology, San Francisco, CA, April 1998.
47. Cohavy, O., Tayebali, A.B., Phou, P., Eggena, M.P., Bruckner, D., Harth, G., Horwitz, M., Targan, S., **Braun, J.** Identification of candidate bacterial pathogens in ulcerative colitis using a disease-specific marker antibody. American Gastroenterologic Association, New Orleans, May 1998.
48. Cohavy, O., Tayebali, A.B., Phou, P., Eggena, M.P., Parseghian, M.H., Hamkalo, B.A., Targan, S., **Braun, J.** Characterization of the pANCA core epitope in the histone H1 C terminus. American Gastroenterologic Association, New Orleans, LA, May 1998.
49. **Braun, J.**, Sutton, C., Dalwadi, H., Use of molecular techniques for identifying a casual agent for Crohn's Disease. Infectious Diseases Society of America, Denver, CO, November 1998.
50. **Braun, J.**, Cohavy, O. Targan, S., Gordon, L. Bacterial species and antigens identified by an ulcerative colitis marker antibody. Keystone Symposium, Denver Colorado, January 16-21, 1999.
51. Gordon, L.K., Goldman, M., Sandusky, H.L., Goodglick, T., **Braun, J.**, Goodglick, L., Molecular Approaches to Identify Candidate Pathogens in Giant Cell Arteritis. North American Neuro-Ophthalmology Society, Albuquerque, NM, March 1999.
52. Cohavy, O., Targan, S., Gordon, L., **Braun, J.** Molecular mimicry? Molecular characteristics of E. coli and Bacteroides proteins that are reactive with pANCA monoclonal antibodies. AGA Conference, May 16-19, 1999.
53. Dalwadi, H., Sutton, C., Wei, B., Yamane, A., Targan, S., **Braun, J.** Identification of a novel IBD-associated microbial agent by representational difference analysis. AGA Conference, May 16-19, 1999.
54. Wei B, Sutton C, Targan SR, Dalwadi H, **Braun J.** Isolation of a Crohn's disease related bacterial sequence from lamina propria lymphocyte by representative difference analysis. The Keystone Symposia 2000, Taos, NM, January 18-23, 2000.

55. Dalwadi H, Wei B, Kronenberg M, Sutton CL, **Braun J**. The Crohn's disease-associated I2 bacterial antigen is the target of a memory CD4⁺ T cell response in normal and colitic mice. The Keystone Symposia 2000, Taos, NM, January 18-23, 2000.
56. Landers CJ, **Braun J**, Targan SR. I2, a Mucosal Crohn's Disease (CD) Associated Bacterial Antigen, Induces Both Humoral and T-Cell Responses in CD Patients: I2 Induced Interferon- γ (IFN- γ) Production is Associated with Higher Levels of Serum IgA Reactivity. American Gastroenterological Association, May 21-24, 2000.
57. Landers CJ, Yang H, Lin Y-C, Vasilias EA, **Braun J**, Targan SR. IgA Serum Antibody Reactivity with I2, a Novel Crohn's Disease Marker: Anti-I2 Level is Independent From ASCA and ANCA Levels, Even Though IgA ASCA Positivity is Correlated with Anti-I2 Positivity. American Gastroenterological Association, May 21-24, 2000.
58. Wei B, Dalwadi H, Sutton C, **Braun J**. The Crohn's disease-associated bacterial protein, I2, is a novel enteric T cell superantigen. American Association of Immunologists, Seattle, WA, May 16-22, 2000.
59. Dalwadi H, Wei B, Kronenberg M, Sutton CL, **Braun J**. The Crohn's disease-associated I2 bacterial antigen is the target of a memory CD4⁺ T cell response in normal and colitic mice. American Association of Immunologists, Seattle, WA, May 16-22, 2000.
60. Wadehra M., Iyer R., Goodglick L., **Braun, J**. The role of epithelial membrane protein 2 in the trafficking of $\alpha 1$ integrin. EB 2001, Orlando, FL, March 2001.
61. Wadehra M., **Braun J.**, Iyer R., Williams C. Epithelial membrane protein 2 plays a critical role in embryo development. EB 2001, Orlando, FL, March 2001.
62. Oh E., La Certe C., Sutton C.L., Rose S., Landers C., **Braun J**, Targan S. Optimization of four IBD serology markers for increased IBD diagnostic accuracy. DDW, Atlanta, GA, May 2001.
63. Dalwadi H., Wei B., Kronenberg M., Sutton C.L., Birnbaumer L., **Braun J**. G α i2 mediated signaling in mucosal immune homeostasis. CURE, Los Angeles, March 2001.
64. Dalwadi H., Wei B., Kronenberg M., Sutton C.L., Birnbaumer L., **Braun J**. The Crohn's disease-associated bacterial protein, I2, is a novel enteric T cell superantigen. CURE, Los Angeles, March 2001.
65. Dalwadi H., Wei B., Kronenberg M., Sutton C.L., Birnbaumer L., **Braun J**. G α i2 mediated signaling in mucosal immune homeostasis. FOCIS, Boston, May 2001.
66. Dalwadi H., Wei B., Kronenberg M., Sutton C.L., Birnbaumer L., **Braun J**. The Crohn's disease-associated bacterial protein, I2, is a novel enteric T cell superantigen. FOCIS, Boston, May 2001.

67. Dalwadi H., Wei B., Kronenberg M., Sutton C.L., Birnbaumer L., **Braun J.** G α i2 mediated signaling in mucosal immune homeostasis. AGA/DDW, Atlanta, GA, May 2001.
68. Dalwadi H., Wei B., Kronenberg M., Sutton C.L., Birnbaumer L., **Braun J.** The Crohn's disease-associated bacterial protein, I2, is a novel enteric T cell superantigen. AGA/DDW, Atlanta, GA, May 2001.
69. Wei B., Dalwadi H., Gordon L.K., Landers C., Targan S.R., **Braun J.** Molecular cloning of a *Bacteroides caccae* TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody. AGA/DDW, Atlanta, GA, May 2001.
70. Wei B., Huang T., Dalwadi H., **Braun J.** Identification of *Pseudomonas fluorescens* as the microorganism expressing the Crohn's disease-associated I2 gene. AGA/DDW, Atlanta, GA, May 2001.
71. Wei B., Huang T., Dalwadi H., **Braun J.** The Crohn's disease lesion derived gene, I2, encodes the core peptide of a transcriptional regulator of *Pseudomonas fluorescens*, and the functional domain of a novel T cell superantigen. AGA/DDW, Atlanta, GA, May 2001.
72. Landers, CJ, Cohavy, O, Yang, H, Lina, S, **Braun, J**, Targan, S. Associated immune responses to auto- and specific bacterial antigens. AGA/DDW, Atlanta, GA, May 2001.
73. M. Wadehra, R. Iyer, L Goodglick, and J. Braun. The Role of Epithelial Membrane Protein-2 in the Trafficking of α 1 Integrin. American Society of Cell Biology, Washington DC. Dec. 2001.
74. Bo Wei, Harnisha Dalwadi, Tomas T Su, David Rawlings, Lutz Birnbaumer, Jonathan Braun. T2 and MZ B cells: role in mucosal immunologic homeostasis, and developmental requirement for enteric microflora Keystone symposia. Breckenridge, Colorado Apr 5 - 10, 2002
75. Bo Wei, Harnisha Dalwadi, Tomas T Su, David Rawlings, Jonathan Braun. T2 and MZ B cells: role in mucosal immunologic homeostasis, and developmental requirement for enteric microflora Keystone symposia. DDW, San Francisco, CA. Jun 2002
76. Bo Wei, Harnisha Dalwadi, Tomas T Su, David Rawlings, Jonathan Braun. T2 and MZ B cells: role in mucosal immunologic homeostasis, and developmental requirement for enteric microflora CURE Meeting. UCLA, CA. May 2002
77. M. Wadehra, L Goodglick, and J. Braun, Epithelial Membrane Protein-2 Organizes the Cross-Talk Between Lipid Raft Domains and Caveolae. Experimental Biology; New Orleans, Louisiana. April 2002 (FASEB J, 2002, 16:1178)
78. M. Wadehra, MB Dayal MB, CJ Williams, J Braun. Epithelial membrane protein 2 (EMP2) expression is required for implantation in the mouse. Experimental Biology; New Orleans, Louisiana. April 2002 (FASEB J, 2002, 16:A1204)

79. MB Dayal, M Wadehra, J Braun, and CJ Williams. Epithelial membrane protein 2 (EMP2) expression is required for implantation in the mouse. Society of Gynecologic Investigation; Los Angeles, California. March 2002
80. Bo Wei, Peter Velazquez, Matthew Schrage, Tiffany Huang, Jonathan Braun. Mesenteric CD19+, IGM^{HIGH} B cells play a protective function in Gα i2 T cell transferred colitis mouse model. CURE 2003 Annual Research Meeting, Los Angeles, CA. March 2003
81. Tiffany Huang, Bo Wei, Jonathan Braun. A role for enteric microflora and chemokine receptor signaling in T cell activation. CURE 2003 Annual Research Meeting, Los Angeles, CA. March 2003
82. Matthew Schrage, Bo Wei, Peter Velazquez, Jonathan Braun, Nancy Buckley. The role of the cannabinoid type 2 (CB2) receptor in Gαi2-dependent B cell development. CURE 2003 Annual Research Meeting, Los Angeles, CA. March 2003
83. Peter Velazquez, Bo Wei, Matthew Schrage, Tiffany Huang, Jonathan Braun. Identification and genetic requirements for intestinal intraepithelial B cells. CURE 2003 Annual Research Meeting, Los Angeles, CA. March 2003
84. Bo Wei, Harnisha Dalwadi, Tomas T Su, T Huang; David Rawlings[¶], Jonathan Braun. T2 and MZ B cells: role in mucosal immunologic homeostasis, and developmental requirement for enteric microflora. Keystone Symposium on Mucosal Immunology, Keystone, CO, April 2002
85. Bo Wei, Harnisha Dalwadi, Tiffany Huang, Tomas T Su, David Rawlings, Lutz Birnbaumer, Jonathan Braun. Gαi2 protein-associated signaling participates in B cell development and mucosal immunologic homeostasis. FOCIS, San Francisco, June 2002.
86. Wadehra M, Dayal M, Ord T, Williams C, **Braun J**. The requirement of EMP2 for implantation utilizes lipid rafts. SGI, Washington DC, March 2003
87. Wadehra M, Chang WY, Williams C, DeCherney A, **Braun J**. The hormonally regulated tetraspan protein EMP2. SGI, Washington DC, March 2003
88. Liang LW, Zhang Q, Du Z, Gjertson D, Takemoto S, **Braun J**, Danovitch G, Wilkinson A, Lassman C, Reed EF, Gritsch HA. Non-invasive immune monitoring of perforin/granzyme B and anti-HLA antibodies predicts renal allograft rejection. American Transplant Congress. Washington DC, May/June 2003.
89. Velazquez P, Wei B, Huang T, **Braun J**. Identification and genetic requirements for intestinal intraepithelial B cells. DDW, Orlando, FL, May 2003 (platform presentation).
90. Wei B, Velazquez P, Schrage M, Huang T, **Braun J**. Mesenteric CD19+ IgM^{Hi} B cells play a protective function in Gαi2 T cell transferred colitis mouse model. DDW, Orlando, FL, May 2003 (Honorary mention).

91. Schrage M, Velazquez P, Wei B, **Braun J**, Buckley NE. The Role of the Cannabinoid Type 2 (CB2) Receptor in Gai2-Dependent B Cell Development. DDW, Orlando, FL, May 2003 (Honorary mention).
92. Scupham AJ, Wei B, **Braun J**, Borneman J. Identification of Intestinal Fungal and Bacterial Microflora in a Crohn's Disease Mouse Model Using Array-based Oligonucleotide Fingerprinting of rRNA Genes. DDW, Orlando, FL, May 2003.
93. Schrage M, Velazquez P, Wei B, **Braun J**, Buckley NE. The Role of the Cannabinoid Type 2 (CB2) Receptor in Gai2-Dependent B Cell Development. FOCIS, Paris, France, May 2003.
94. Wei B, Velazquez P, Schrage M, Huang T, **Braun J**. Mesenteric CD19+ IgMHi B cells play a protective function in Gai2 T cell transferred colitis mouse model. FOCIS, Paris, France, May 2003.
95. Su H, Forbes A, Gambhir S, **Braun J**. Quantitative Imaging of T Cell Trafficking In Vivo by Positron-Emission Tomography. FOCIS, Paris, France, May 2003.
96. Forbes AM, **Braun J**. The Tetraspan Protein EMP3 Facilitates TCR Signaling and Lipid Raft Delivery of Immune Synapse Proteins. FOCIS, Paris, France, May 2003.
97. Velazquez P, Schrage P, **Braun J**. Identification and Genetic Requirements for Intestinal Intraepithelial B-Cells. FOCIS, Paris, France, May 2003.
98. Huang TT, Wei B, **Braun J**. A Role for Enteric Microflora and Chemokine Receptor Signaling in T Cell Activation. FOCIS, Paris, France, May 2003.
99. Wei B, Velazquez P, Schrage M, Huang TTY, **Braun J**. Mesenteric node B cells inhibit Gai2-/- T cell colitis through interaction with CD8 T cells. Washington DC, AAI 2004.
100. Velazquez P, Wei B, Lobato L, Mendoza L, **Braun J**. Phenotype and Developmental requirements of gastrointestinal intraepithelial B-cells.
101. Ziring D, Wei B, **Braun J**, Borneman J. Fungal-bacterial consort in the development of an immunoregulatory B cell subset. New Orleans, LA, DDW 2004
102. Arnott IDR, Li C, Shintaku P, McGowan I, Anton P, **Braun J**. Is deposition of split complement fraction C4d a marker of antibody-mediated gut damage in inflammatory bowel disease? New Orleans, LA, DDW 2004.
103. Itanen S, Tervo L, Halttunen T, Rantala I, Wei B, **Braun J**, Ashorn M. Increased serum anti-i2 and -ompw IGA levels in paediatric IBD patients. Paris, France. WCPGHAN 2004.
104. Mohan D, Wadehra M, Seligson D, **Braun J**, Natarajan S. Characterization of the Epithelial Membrane Protein 2 in the Progression of Endometrial Adenocarcinoma. US and Canadian Academy of Pathology, February 2005.

105. Wadehra M, Soslow R, Williams CJ, **Braun J**, and Natarajan S. EMP2 expression identifies endometrial adenocarcinoma with unfavorable outcome. Society for Gynecologic Investigation, Los Angeles, CA, March 2005.
106. Mainigi M, Wadehra M, Dayal M, Ord TS, **Braun J**, Williams CJ. Knockdown of EMP2 protein demonstrates a role for this tetraspan protein in mouse implantation. Society for Gynecologic Investigation, Los Angeles, CA, March 2005.
107. Wadehra W, Ord T, Mainigi M, Williams CJ, **Braun J**. Epithelial membrane protein-2 expression is hormonally regulated during implantation. Society for Gynecologic Investigation, Los Angeles, CA, March 2005.
108. Velazquez P, Wei B, Mendoza L, Schrage M, **Braun J**. CD1d is required for development of mucosal isolated lymphoid follicle B-cells. San Diego CA, AAI 2005.
109. Wei B, Velazquez P, **Braun J**. Immunoregulatory function of B cells in a murine model of sarcoidosis. San Diego CA, AAI 2005.
110. Morales S, Mareninov S, **Braun J**, Gordon L. Role of Epithelial Membrane Protein 2 (EMP2) in Retinal Pigment Epithelial Cell-Mediated Gel Contraction. ARVO. Ft. Lauderdale, FL, May 2006
111. Shimazaki K, Chan AM, **Braun J**, Kelly KA, Gordon LK. Expression of EMP2 controls Chlamydia infectivity. ARVO. Ft. Lauderdale, FL, May 2006
112. Presley LL, McPherson M, Bent E, Wei B, Brewer S, **Braun J**, Borneman J. Antibiotic Induced Shifts in Intestinal Bacterial Composition and Lymphocyte Populations in Mice. ASM. Orlando FL, May 2006
113. McPherson M, Wei B, Brewer S, Ziring D, **Braun J**. MHCII-independent function of B cells in colonic immunoregulation. AAI. Boston, MA, May 2006.
114. Shimazaki K, Wadehra M, Forbes A, Chan AM, Kelly KA, **Braun J**, Gordon LK. EMP2, a candidate host receptor in Chlamydia trachomatis infection. 11th International Symposium on Human Chlamydial Infections, Niagara-on-the-Lake, Ontario, Canada, June 2006
115. Wei B, Fujiwara D, Brewer S, McPherson M, Kronenberg M, **Braun J**. Altered commensal microbiota shape the development of innate-like lymphocytes. FOCIS, San Francisco, CA, June 2006
116. McPherson M, Wei B, Brewer S, Ziring D, **Braun J**. MHCII-independent function of B cells in colonic immunoregulation. FOCIS, San Francisco, CA, June 2006
117. Fujiwara D, Wei B, Brewer S, McPherson M, **Braun J**. Enteric microbiota and CD8 T cells affects the formation of plasmacytoid dendritic cells. FOCIS, San Francisco, CA, June 2006.

118. Ziring CA, Shimazaki K, Dry S, **Braun J**. Inflammatory Bowel Disease Immune Monitoring: Multiplex Analysis of Quantum Dot Immunophenotyping. FOCIS, San Francisco, CA, June 2006
119. Veale JL, Liang LW, Zhang Q, Gjertson DW, Bloomquist EW, Jia J, Qian L, Wilkinson AH, Danovitch GM, Pham PTT, Rosenthal JT, Lassman JT, Lassman CR, **Braun J**, Reed EF, Gritsch HA. The diagnosis of antibody mediated or cellular rejection of renal allografts by measuring perforin and granzyme B gene expression in peripheral blood. World Transplant Congress, Boston, MA, July 2006.
120. **Braun J**, Chen A, Gordon LK, Kelly K, Mareninov S, Morales S, Seligson D, Shimazaki K, Wadehra M. A new governor from California: EMP2 in surface protein signaling, display and export. FASEB Conference on Tetraspanins, Tucson, AZ, July 2006
121. Morales S, Mareninov S, **Braun J**, Gordon LK. Epithelial membrane protein 2 modulates gel contraction, an in vitro marker for proliferative vitreoretinopathy, through activation of FAK. JSEI Annual Research Conference, Los Angeles, CA. September 2006
122. Shimazaki K, Chan AM, **Braun J**, Kelly K, Gordon LK. Epithelial membrane protein-2: a candidate host receptor in Chlamydia trachomatis infection. JSEI Annual Research Conference, Los Angeles, CA. September 2006
123. McPherson M, Brewer S, **Braun J**. Molecular imaging of intestinal inflammation with ¹⁸F-FDG and Positron Emission Tomography (PET). La Jolla Immunology Conference. San Diego, CA. October 2006
124. Chen L, Chang V, Levinson R, **Braun J**, Gordon LK. Developmental Expression of PD1 in the Retina. ARVO, Ft. Lauderdale, FL. Mar 2007.
125. Morales S, Mareninov S, **Braun J**, Gordon LK. Epithelial Membrane Protein 2 (EMP2) controls in vitro collagen gel contraction by ARPE-19 through a FAK-Src dependent pathway. ARVO, Ft. Lauderdale, FL. Mar 2007.
126. Ashorn S, Raukola H, Välineva T, Ashorn M, Kaukinen K, Rantala I, Wei B, **Braun J**, Collin P, Mäki M, Luukkaala T, Hurme M, Iltanen S. Serological Responses to Bacterial Antigens in Celiac Disease Patients. DDW. Washington DC. May 2007.
127. Fujiwara D, Wei B, McPherson M, **Braun J**. Definition of enteric DC subsets in the mouse. DDW. Washington DC. May 2007.
128. McPherson M, Brewer S, **Braun J**. Molecular imaging of intestinal inflammation with ¹⁸F-FDG and Positron Emission Tomography (PET). DDW. Washington DC. May 2007.
129. B. Wei; M. Macpherson; P. Velazquez; D. Fujiwara; J. Braun. Genetic evidence for CD8+ T cell immunoregulation in murine CD4+ T cell colitis. DDW. Washington DC. May 2007.
130. Fujiwara D, Wei B, McPherson M, **Braun J**. Role of enteric luminal TLR ligand sampling in the formation of novel resident mucosal dendritic cells. FOCIS. San Diego, CA. June 2007.

131. Chen L, Chang V, Levinson R, **Braun J**, Gordon LK. Role of PD1 in the eye. FOCIS. San Diego, CA. June 2007.
132. Wingender G, **Braun J**, Borneman, Kronenberg M. Gut derived antigens trigger the final steps of V α 14 iNKT cell differentiation. German Society for Immunology. Berlin, Germany. September 2007.
133. Iltanen S, Ashorn S, Honkanen T, Rantala I, Wei B, **Braun J**, Välineva T, Raukola H, Kaukinen K, Mäki M, Ashorn M. Serological responses to microbial and autoantigens in children with gut inflammation. DDW, San Diego, CA, May 2008
134. Xiaowen Su, Ling Mei, Carol J Landers, Jonathan Braun, David Ziring, Stephan R Targan, Kent D Taylor, Jerome I. Rotter. Haplotypes of the CNR2 gene are associated with different seroreactivity to microbial antigens in patients with Crohn's disease. DDW, San Diego, CA, May 2008
135. Hidetoshi Takedatsu, Kathrin S. Michelsen, Bo Wei, Carol J. Landers, Lisa S. Thomas, Deepti Dhall, Jonathan Braun, and Stephan R. Targan. TL1A (TNFSF15) is Involved in the Pathogenesis of Two T cell-Mediated Chronic Colitis Models through Modulation of Both TH1 and TH17 Activation. DDW, San Diego, CA, May 2008
136. Wei B; McPherson M, Brewer S, Fujiwara D, **Braun J**. Colitis immunoregulation by CD8⁺ T cells is induced by B cell peptide antigen presentation and requires T cell cytotoxicity. DDW, San Diego, CA, May 2008
137. Fujiwara D, Wei B; Presley LL, Brewer S, McPherson M, Borneman J, **Braun J**. Systemic control of plasmacytoid dendritic cells by CD8⁺ T cells and commensal microbiota. DDW, San Diego, CA, May 2008
138. Wadehra M, Shimazaki K, **Braun J**, Gordon LK. Using recombinant antibodies to target EMP2 in endometrial cancer. AACR, San Diego, CA, April 2008
139. Sham CW, Chen L, Lin W, Sharpe AH, Freeman GJ, **Braun J**, Gordon LK. Programmed Cell Death-1 is a New Molecule Controlling Retinal Ganglion Cell Death. ARVO, Ft. Lauderdale, FL. April 2008.
140. Chen L, Sham CW, Yang XJ, Sharpe AH, Freeman GJ, **Braun J**, Gordon LK. Role of the Immune Modulator Programmed Cell Death-1 During Development and Apoptosis of Retinal Ganglion Cells. ARVO, Ft. Lauderdale, April 2008.
141. Presley LL, McPherson M, Bent E, Brewer S, **Braun J**, Borneman J. Intestinal bacterial rRNA genes associated with lymphocyte populations in mice. American Society of Microbiology, Boston, MA, June 2008
142. Sham CW, Chen L, Lin W, Sharpe AH, Freeman GJ, **Braun J**, Gordon LK. Programmed cell death 1 regulates neuronal cell death in the developing mouse retina. FOCIS, Boston, June 2008

143. Brewer S, McPherson M, **Braun J**. Whole body molecular imaging of intestinal inflammation with positron emission tomography. FOCIS, Boston, June 2008
144. Chan AM, Shimazaki K, Moniz RJ, Lepin EM, Nagy A, Coulam P, Mareninov S, Marks JD, Wu AM, Kelly KA, **Braun J**, Gordon LK. Mucosal Host Receptor Diabody Therapy for Chlamydia Infection In the Murine Genital Tract. FOCIS, Boston, June 2008
145. Fu M, Peterson C, **Braun J**, Pyle A, Wadehra M. Characterization of tetraspan proteins EMP2 and PMP22 in hESC Differentiation. Broad Institute Stem Cell Conference. Los Angeles, February 2008.
146. Li XX, Wei B, Goodglick L, Wen T, Xia L, **Braun J**. Investigating Therapeutic Approach of IBD Using Recombinant Glycoprotein Mucin2. Experimental Biology/American Society for Investigative Pathology, New Orleans, April 2009.
147. Li XX, LeBlanc J, Elashoff D, Goodglick L, Presley L, Borneman J, **Braun J**. Identifying Diagnostic Markers And Studying Etiologic Factors of Inflammatory Bowel Diseases Using a High-Throughput Proteomic Approach. Experimental Biology/American Society for Investigative Pathology, New Orleans, April 2009.
148. Sham CW, Chan AM, Francisco LM, Sharpe AH, Freeman GJ, Yang XY, **Braun J**, Gordon LK. ARVO, Ft. Lauderdale, FL, April 2009.
149. Fujiwara D, Wei B, **Braun J**. Role of small intestinal intraepithelial CD11c+ CD8+ T cells in mucosal immunoregulation. AAI, Boston, Mar 2009.
150. Iltanen S, Ashorn S, Kurppa K, Ashorn M, Collin P, Mäki M, Wei B, **Braun J**, Kaukinen K. Serological responses to microbial antigens in patients with mild enteropathy celiac disease. 13th International Meeting on Celiac Disease, Amsterdam, April 2009.
151. Aziz N, Li X, Wei B, Butch AW, **Braun J**. Invariant HLA-E T cells, a prevalent population in human blood associated with resident microbiota and immunoregulation. FOCIS, San Francisco, June 2009
152. Chan AM, Champion C, Chao G, Shimazaki K, Moniz RJ, Nagy A, Coulam CP, Mareninov S, Kelly KA, **Braun J**, Gordon LK. Antibody Blockade of a Mucosal Host Protein Decreases Chlamydia Infection In the Murine Genital Tract. FOCIS, San Francisco, June 2009
153. Brewer S, Chan A, Gordon LK, **Braun J**, Wadehra M. Therapeutic targeting and imaging of EMP2 in endometrial cancer. FOCIS, San Francisco, June 2009
154. Fujiwara D, Wei B, **Braun J**. Role of small intestinal intraepithelial CD11c+ CD8+ T cells in mucosal immunoregulation. FOCIS, San Francisco, June 2009
155. Westbrook AM, Wei B, Hacke K, **Braun J**, Schiestl RH. Characterization of inflammation-associated systemic genotoxicity. AACR, Washington, D.C. April 2010

156. von Euw E, Lin L, Aziz N, Attar N, Wei B, Butch A, Ribas A, **Braun J**. Invariant HLA-E T cells, a prevalent human T cell population endogenously programmed for cytolysis, IL-22 production, and immune regulation. DDW, New Orleans, LA. May 2010
157. Wei B, Lin L, Li XX, Chen L, **Braun J**. CD8 T cells suppress CD4 T cell colitis via detection of Qa-1 stress response. DDW, New Orleans, LA. May 2010
158. Li XX, LeBlanc J, Elashoff D, Borneman J, Goodglick L, **Braun J**. Detecting disease-related biological neighborhoods by human mucosal interface metaproteome analysis. DDW, New Orleans, LA. May 2010
159. Morales SA, Telander D, Mareninov S, **Braun J**, Gordon LK. Epithelial membrane protein 2 (EMP2) controls VEGF expression in ARPE-19 cells. ARVO, Ft. Lauderdale, FL, April 2010.
160. Gordon LK, Morales SA, Wadehra M, Telander D, Braun, J. Rewiring pathologic cellular responses using the tetraspan web alters collagen gel contraction by ARPE-19 cells. ARVO, Ft. Lauderdale, FL, April 2010.
161. X. Li, J. LeBlanc, D. Elashoff, J. Borneman, L. Goodglick, and **J. Braun**. Detecting disease-related biological neighborhoods by mucosal interface metaproteome analysis. Symposium on Biological Complexity: Emerging Concepts and Trends, San Diego, CA, 2010.
162. Sham CW, Kwong JMK, Chan AM, Lee JG, Caprioli J, **Braun J**, Gordon LK. Characterization of the PD-1 Expression Pattern After Optic Nerve Transection in the Rat. ARVO, Ft. Lauderdale, FL, April 2010.
163. Lin L, von Euw E, Aziz N, Attar N, Wei B, Butch A, Ribas A, **Braun J**. Invariant HLA-E T cells, a prevalent human T cell population endogenously programmed for cytolysis, IL-22 production, and immune regulation. FOCIS, Boston, MA. June 2010
164. Wei B, Lin L, Li XX, Chen L, **Braun J**. CD8 T cells suppress CD4 T cell colitis via detection of Qa-1 stress response. FOCIS, Boston, MA. June 2010
165. Li XX, LeBlanc J, Elashoff D, Borneman J, Goodglick L, **Braun J**. Detecting disease-related biological neighborhoods by human mucosal interface metaproteome analysis. FOCIS, Boston, MA. June 2010
166. Azziz R, Davidson P, Morrison J, Wang C, Salusky I, Norris K, **Braun J**. The UCLA Clinical and translational sciences institute (CTSI) leadership in research organizations development program: determining the competencies. Association for Clinical Research Training/Society for Clinical and Translational Science (ACRT/SCTS) Annual Meeting. Washington, DC. April 2010.
167. P Penner K, Wadehra M, Steinhardt A, Hogue C, **Braun J**, Dorigo O. Progesterone receptors A and B in grade 1 endometrial adenocarcinoma and complex atypical hyperplasia predict response to progestin therapy, College of American Pathologists Annual Meeting. Montreal, Quebec. September 2010.

168. X. Li, J. LeBlanc, D. Elashoff, B. Wei, P. Anton, and **J. Braun**. Defining HIV-induced mucosal biologic neighborhoods by metaproteomic analysis. The Center for AIDS Research (CFAR) symposium, Los Angeles, CA, 2010.
169. Westbrook AM, Wei B, Hacke K, **Braun J**, Schiestl R. Characterization of intestinal inflammation-induced systemic genotoxicity and its potential use. AAPS. New Orleans, LA. November 2010.
170. Presley LL, Ye J, Li XX, LeBlanc J, Zhang Z, Ruegger P, Allard J, McGovern D, Ippolitti, A, Roth B, Cui X, Jeske DR, Elashoff D, Goodglick L, **Braun J**, Borneman J. Most-Microbe Relationships in Inflammatory Bowel Disease Detected by Bacterial and Proteomic Analysis of the Intestinal Mucosal-Luminal Interface. ASM Conference on Beneficial Microorganisms, Miami, FL. October 2010.
171. Li XX, LeBlanc J, Elashoff D, Borneman J, Goodglick L, **Braun J**. Detecting Disease-Related Biologic Neighborhoods by Metaproteomic Analysis at Mucosal-Luminal Interface. US HUPO 2011, Raleigh, NC. March 2011.
172. X. Li, J. LeBlanc, D. Elashoff, J. Borneman, L. Goodglick, and **J. Braun**. Detecting disease-related biological neighborhoods by metaproteomic analysis at mucosal-luminal interface. Keystone Symposia on Molecular and Cellular Biology: Mucosal Biology: A Fine Balance between Tolerance and Immunity, Vancouver, BC, Canada, 2011.
173. M. Tong, X. Li, L. Parfrey, A. Ippoliti, B. Wei, D. McGovern, D. Frank, E. Li, R. Knight and **J. Braun**. Defining a Mosaic of Functional Microbial Communities at the Human Mucosal Surface, and their Association with IBD. International Human Microbiome Congress organized by MetaHIT, Paris, France. March 2012
174. L. Goodglick, M. Fu, **J. Braun**, and M. Wadehra. EMP2 regulates the tumor microenvironment and is a novel therapeutic target for triple negative breast cancer. American Association for Cancer Research (AACR) Annual Meeting, Chicago, IL. April 2012.
175. X. Li, I. McHardy, J. LeBlanc, D. Elashoff, M. Tong, J. Akin, P. Anton and **J. Braun**. Mucosal Surface Sampling and Metaproteomic Analysis Identify HIV-Associated Biologic Neighborhoods of the Colonic Mucosa. Digestive Disease Week 2012, San Diego, CA. May 2012. *Poster Session: P-Novel Diagnostics and Therapeutics in Intestinal Disorders*.
176. X. Li, J. LeBlanc, D. Elashoff, I. McHardy, M. Tong, B. Roth, J. Allard, A. Ippoliti, T. Graeber, L. Goodglick and **J. Braun**. Mucosal Surface Sampling and Metaproteomic Analysis Identify Disease-Related Biologic Neighborhoods. Digestive Disease Week 2012, San Diego, CA. May 2012. *Research (Lecture) Forum: Microbiota in inflammatory bowel disease*.
177. L. Lin, C. Ma, B. Wei, I. McHardy, J. Heath, S. Targan, D. McGovern and **J. Braun**. KIR2DL3- and 3DL1-mediated NK cell education confers Crohn's Disease susceptibility. Digestive Disease Week 2012, San Diego, CA. May 2012. Recipient of the 2012 AGA-Horizon Pharma Student Abstract Prize.

178. M. Tong, X. Li, L. Parfrey, B. Wei, D. McGovern, D. Frank, E. Li, R. Knight and **J. Braun**. Defining a Mosaic of Functional Microbial Communities at the Human Mucosal Surface, and Their Association with IBD. Digestive Disease Week 2012, San Diego, CA. May 2012.
179. M. Chao, A. Cheung, T. Chodon, R. Koya, B. Comin-Andiux, **J. Braun**, A. Ribas and J. Heath. Comprehensive, longitudinal T cell functional analyses correlated with clinical outcome of a melanoma immunotherapy trial. The American Association of Immunologists Annual Meeting (Immunology 2012™), Boston, MA. May 2012
180. L. Lin, J. Jacobs, C. Ma, B. Wei, S. Targan, D. McGovern and **J. Braun**. KIR-mediated NK education: Potential mechanism for KIR-associated IBD susceptibility. ICMI, Vancouver BC, Canada, July 2013.
181. M. Wadehra, M. Kiyohara, M. Fu, L.K. Gordon and **J. Braun**. Therapeutic targeting of the oncogene EMP2 in triple negative breast cancer reduces tumor load through its control on neoangiogenesis. American Society of Clinical Oncology Annual Meeting, Chicago, IL. June 2012
182. McHardy I, Goudarzi M, Tong M, Ruegger P, Graeber T, Horvath S, Huttenhower C, McGovern DP, Borneman J, Fornace A, **Braun J**. Comprehensive inter-omic analysis reveals exquisite metabolism driven microbial relationships. DDW, Orlando, FL May 2013
183. Lin L, Ma C, Wei B, Aziz N, Rajalingam J, Yusung S, Erlich HA, Trachtenberg EA, Targan SR, McGovern DPB, Heath JR, **Braun J**. Genetically-determined cytokine programs of human natural killer (NK) cells uncover a novel mechanism of NK cells and KIR genes in Crohn's Disease susceptibility. DDW, Orlando, FL May 2013
184. Yusung S, Lin L, **Braun J**. Genetic licensing uncovers a role for NK cells in immune colitis by co-activation of CD4+ T cells. DDW, Orlando, FL May 2013.
185. Tong M, McHardy I, Ruegger PM, Schwager E, Fleshner P, Li X, McGovern DPB, Huttenhower C, Borneman J, **Braun J**. Role of Crohn's Disease Risk Loci (FUT2) on the Functional State of the Normal Colonic Mucosal Microbiota. ICMI, Vancouver BC, Canada, July 2013
186. Erlich H, Wolinsky S, Penugonda S, Hayes E, Nichols R, Saeteurn K, Dugga P, Berry I, Reddy S, Swantek P, Ladner M, Lin L, **Braun J**, Trachtenberg E. The role of KIR and HLA Polymorphism in HIV acquisition: Association and in vitro functional studies. AAI, New Orleans, May 2015
187. Jacobs J, Tong M, McHardy I, Goudarzi M, Ruegger P, McGovern D, Borneman J, Fornace A, Dubinsky M, **Braun J**. Disease-associated enterotypes and metatypes in families with pediatric inflammatory bowel disease. DDW, San Diego, May 2015
188. Volkmann E, Chang YL, Barroso N, Furst D, Clements P, Tong M, Roth B, Conklin J, Getzug T, **Braun J**. Systemic sclerosis is associated with a unique colonic microbial consortium. EULAR, Rome, June 2015

189. Torres J, Shen N, Torres J, Tamburini S, Goudarzi M, Jacobs J, Duerr RH, McGovern D, Brant SR, Schum P, Sharma Y, Cho J, **Braun J**, Clemente J, Microbial and metabolomics features associated with endoscopic recurrence after CD surgical resection—a NIDDK IBDGC (IBD genetics Consortium) study. DDW, San Diego, May 2016.
190. Yung S, Kugathasan S, Udel J, **Braun J**. Cytomegalovirus infection enhances susceptibility to Crohn's disease in individuals with KIR and HLA pairs enabling NK cell licensing. DDW, San Diego, May 2016.
191. Jacobs J, Lin L, Lagishetty V, Ruegger P, Borneman J, **Braun J**. ROR γ t-dependent CD4⁺ T cells garden the mucosa-associated microbiome of the small intestine and colon. DDW, San Diego, May 2016.
192. Chang Y, Huttenhower C, Subramanian A, Xavier R, Kostic A, Sartor RB, Simpson K, Wu G, Lewis J, Bushman R, McGovern D, Salzman N, Borneman J, **Braun J**. Identification of IBD-related microbial metabolites affecting human Th17 differentiation. DDW, San Diego, May 2016.
193. Oikonomopoulos A, Crooks G, Kohn D, Seet C, De Oliveira S, Cooper P, Krogstad P, Martin MG, **Braun J**, van Deen WK, Hommes D, Moore T, Shah A, Ziring D. Autologous Stem Cell Transplantation in Pediatric Crohn's Disease: A Unique Window into Immunopathogenesis. DDW, San Diego, May 2016.
194. Yung S, McGovern D, Lagishetty V; Lin L, **Braun J**. NK cells are biologic and biochemical target of 6-Mercaptopurine in Crohn's Disease patients. DDW, San Diego, May 2016
195. Huynh J, Duraffourd C, Casero D, **Braun J**, Sternini C. Upregulation of gut bitter taste receptor subtypes, T2R138 and T2R16, in high fat diet-induced obesity is reversed following antibiotic treatment. DDW, San Diego, May 2016
196. Goudarzi M, Mak TD, Jacobs JP, Moon BH, Strawn SJ, Brenner DJ, **Braun J**, Fornace AJ, Li H. Environmental exposure to ionizing radiation induces imbalance in gut microbiome and fecal metabolome. 64th ASMS (American Society for Mass Spectroscopy) Conference, San Antonio, May 2016
197. Freise A, Tavaré R, Salazar FB, Zettlitz KA, **Braun J**, Wu AM. ImmunoPET imaging CD4⁺ T cells in a mouse model of colitis using an 89Zr-labeled anti-CD4 cys-diabody. WMIC (World Molecular Imaging Congress), New York, NY, Sep 2016
198. Karstens L, Rosenbaum J, **Braun J**, Gregory T, Fair D, Nardos R, McWeeney S. Community-wide profiling of the urinary microbiome: Considerations for analysis of a tissue site with low microbial biomass. IHMC, Houston, TX, Nov 2016
199. Casero D, Gill K, Sridharan V, Boema M, **Braun J**. Cheema AK. Modulation of Rat and Rabbit Fecal metabolome by Exposure to Heavy Ion Radiation. NASA Human Research Program Investigator Workshop, Galveston, TX, Feb 2017.

200. Caremoli F, Huynh J, Lagishetty V, Jacobs J, **Braun J**, Sternini C. Bitter taste receptors, T2R16 and T2R138, are induced in the large intestine of male and female mice on a high fat diet in a microbiota-dependent manner. DDW, Chicago IL May 2017
201. Li D, Jacobs J, **Braun J**, Targan SR, McGovern DPB. Gut microbiome dysbiosis in Crohn's Disease is also associated with disease severity. DDW, Chicago IL May 2017
202. Jacobs JP, Tong M, Ruegger P, Baron G, Li D, Haritunians T, Fleshner P, Vasilaiuskas E, Ippoliti A, Gelmed G, Shih D, Kaur M, Targan S, Borneman J, McGovern DPB, **Braun J**. Crohn's disease, obesity, and high Crohn's disease genetic risk are associated with parallel changes in the microbiome of the cecal and sigmoid mucosal-luminal interface. DDW, Chicago IL May 2017
203. Li D, Jacobs J, Liu Z, **Braun J**, Targan SR, McGovern DPB. Shared gut microbiome dysbiosis in CD and obesity. DDW, Chicago IL May 2017
204. Ni J, Ting-Chin DS, Chen EZ, Bailey A, Roggiani M, Sirota-Madi A, Friedman ES, Wang L, Lin A, Alberberg LA, Baldassano RN, Braun J, Xavier RM, Clish CB, Yudkoff M, Li H, Goullian M, Bushman FD, Lewis JD, Wu GD. A Role for Bacterial Urease in Crohn's Disease and Gut Dysbiosis. DDW, Chicago IL May 2017.
205. Sen HN, Chaigne-Delalande B, Li Z, Jacobs J, **Braun J**. Gut Microbiome in Uveitis. ARVO, Baltimore MD May 2017
206. Volkmann ER, Hoffmann-Vold AM, Chang YL, Jacobs J, Tillisch K, Mayer E, Clements PJ, Hov J, Kummén M, Midtvedt Ø, Lagishetty V, Molberg Ø, **Braun J**. Longitudinal analysis of the gastrointestinal microbiota in systemic sclerosis. EULAR, Madrid, June 2017
207. Karstens L, Asquith M, Davin S, Fair D, Gregory WT, Wolfe A, Braun J, McWeeney S. Controlling contaminant sequences in low microbial biomass microbiome studies. GLBIO 2019 (Great Lakes Bioinformatics Conference), Madison WI May 2019. GLBIO 2019
208. Lagishetty V, Clemente J, Braun J, Jacobs J. Effects of an IBD-associated microbial community state on intestinal inflammation in humanized gnotobiotic mice. Crohns and Colitis Congress, Austin, TX, Feb 2020.
209. Shih T, Yusung S, Li D, Gonsky R, Botwin G, Casero D, Ziring D, Rabizadeh S, Denson LA, Kugathasan S, McGovern DM, Braun J. Environmental interaction of resolved human CMV infection and NK receptor genetics in pediatric Crohn's disease susceptibility and phenotype. DDW, Chicago, IL, May 2020
210. Li D, Potdar A, Haritunians T, Botwin G, Braun J, Dube S, McGovern D. Predict IBD with integration of DeepLearning and Omics BigData in diverse populations. DDW, Chicago, IL, May 2020
211. Lagishetty V, Arias N, Dong TS, Hauer M, Katzka W, Dubinsky MC, Braun J, Jacobs J. Effects of an IBD-associated microbial community state on intestinal inflammation in humanized gnotobiotic mice. DDW, Chicago, IL, May 2020

212. Naito T, Haritunians T, Khrom M, Li D, Braun J, Botwin GJ, Yang S, Abbou L, Mengesha E Stevens C, Masamune A, Daly M, McGovern DPB. Prevalence and Effect of Genetic Risk of Thrombo-embolic Disease in Inflammatory Bowel Disease. DDW, Chicago, IL, May 2020
213. Dubinsky M, Targan S, Braun J, Princen F, Lasch K, Dervieux T, McGovern, Candela N, Siegel CA. A Clinical Laboratory Evaluation of Performance Characteristics of a Clinical Decision Support Tool for Disease Complications in Crohn's Disease. ACG, Nashville, TN, Oct 2020
214. Botwin G, Li D, Figueiredo J, Cheng S, Braun J, McGovern DB, Melmed G. Adverse events following SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease. DDW, Virtual, May 2021.
215. Jonathan P. Jacobs, Elizabeth Spencer, Kyle Gettler, Judy Cho, Jean-Frederic Colombel, Drew Helmus, Pamela Reyes Mercedes, Amy Hart, Esi Lamouse-Smith, Jan Wehkamp, Carole Landers, Phillip Debbas, Gerold Bongers, Jeremiah Faith, Jonathan Braun, Marla C. Dubinsky. Risk profiling of unaffected members of families with a history of IBD using serology score, dysbiosis score, polygenic risk score, and fecal calprotectin. DDW, Virtual, May 2021.
216. Kevin Jiang, Yu-Ling Chang, Gregory Botwin, Dalin Li, Jason Lloyd-Price, Dermot P McGovern, David Casero, Jonathan Braun. Relating individual human intestinal microbial community states by ecologic succession. DDW, Virtual, May 2021.
217. Jonathan P. Jacobs, Julianne Yang, Elizabeth Spencer, Kyle Gettler, Judy Cho, Jean-Frederic Colombel, Drew Helmus, Pamela Reyes Mercedes, Amy Hart, Esi Lamouse-Smith, Jan Wehkamp, Carole Landers, Phillip Debbas, Gerold Bongers, Marla C. Dubinsky, Jeremiah Faith, Jonathan Braun. IBD-associated dysbiosis in unaffected relatives of IBD patients emerges in late adolescence and increases with age. DDW, Virtual, May 2021.
218. Pozdnyakova V, Botwin GJ, Appel KL, Bonthala N, Hwang C, Ziring D, Hampton M, Mengesha E, Zamudio CD, White S, Debbas P, Benliyan D, Makaryan A, Li Y, Ibrahim J, Hanna M, Mujukian A, Lee SK, Banty A, Wu M, Joung S, Sternbach S, Ebinger J, Sobhani K, Cheng S, McGovern D, Braun J, Melmed G. Humoral Response to Ad26.COV2.S and SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease. ACG, Oct 2021 Las Vegas, NV.
219. Cohen ER, Botwin GJ, Melmed G, McGovern D, Braun J, Boland B, Chiorean M, Fudman D, Hou J, Hwang C, Lazarev M, Lum DF, Mattar MC, McConnell R, Ostrov A, Wolf DC, Younis Z, Morganstern B, Horizon A, Appel KL, Venuturupalli S, Wallace DJ, Glover S, Ha C, Syal G, Banty A, Rabizadeh S, Feldman EJ, Lee SK, Stein T, Cheng S, Kuman R, Parekh N. Psychological Distress During a Global Pandemic: Prevalence and Risk Factors in a National Cohort of Inflammatory Bowel Disease (IBD) Patients. ACG, Oct 2021 Las Vegas, NV.
220. Kumar R, Botwin GJ, Horizon A, Appel KL, Mujukian A, Boland B, Chiorean M, Cohen ER, Fudman D, Hou J, Hwang C, Lazarev M, Lum DF, Mattar MC, McConnell R, Ostrov A, Parekh N, Wolf DC, Younis Z, Morganstern B, Venuturupalli S, Wallace D, Ebinger J, Glover

- S, Ha C, Syal G, Banty A, Pozdnyakova V, Rabizadeh S, Feldman E, Lee S, Stein T, Cheng S, Braun J, Melmed G, McGovern D, Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease After SARS-CoV-2 mRNA Vaccination. ACG, Oct 2021 Las Vegas, NV
221. Cohen ER, Botwin GJ, Boland B, Chiorean M, Fudman D, Hou J, Hwang C, Lazarev M, Lum DF, Mattar MC, McConnell R, Ostrov A, Wolf DC, Younis Z, Morganstern B, Horizon A, Appel KL, Kumar R, Venuturupalli S, Wallace DJ, Glover S, Ha C, Syal G, Banty A, Rabizadeh S, Feldman EJ, Lee SK, Stein T, Cheng S, Melmed G, McGovern D, Braun J, Parekh N. A National Cohort of IBD Patients Exhibit Strong COVID-19 Safety Practice Beliefs. ACG, Oct 2021, Las Vegas, NV
 222. Mujukian A, Botwin GJ, Kuman R, Boland B, Chiorean M, Cohen ER, Fudman D, Hou J, Hwang C, Lazarev M, Lum DF, Mattar MC, McConnell R, Ostrov A, Parekh N, Wolf DC, Ziad Y, Morganstern B, Horizon A, Appel KL, Venuturupalli S, Wallace DJ, Glover S, Ha C, Syal G, Banty A, Rabizadeh S, Feldman EJ, Lee SK, Stein T, Sun N, Wu M, Ebinger J, Cheng S, Melmed G, McGovern D, Braun J. Symptomology following SARS-CoV-2 mRNA Vaccination Among Patients with Inflammatory Bowel Disease Relative to Healthcare Workers. ACG, Oct 2021 Las Vegas, NV
 223. Dalin Li, PhD¹, Alexander Xu, PhD³, Joseph Ebinger², Philip Debbas¹, Andrea Banty¹, Edward Feldman¹, Christina Ha¹, Susie Lee¹, Shervin Rabizadeh¹, Theodore Stein¹, Theodore Solomon¹, Gaurav Syal¹, Stephan Targan¹, Eric Vasilias¹, David Ziring¹, Nirupama Bonthala¹, Melissa Hampton¹, Angela Mujukian¹ MD, Valeriya Pozdnyakova¹, Phillip Gu¹, Sandy Joung², Keren Appel⁴, Rashmi Kumar⁵, Brigid Boland⁶, Aline Charabaty⁷, Michael Chiorean⁸, Erica Cohen⁹, Oriana Damas, Ann Flynn, John Valentine¹⁰, Adam C. Ehrlich¹¹, David Fudman¹², Sarah Glover²⁹, Arash Horizon¹³, Dmitry Karayev¹³, Benjamin Kretzmann¹³, Jason Hou¹⁴, Caroline Hwang¹⁵, Mark Lazarev¹⁶, Donald Lum¹⁷, Rebecca Fausel¹⁷, Swapna Reddy¹⁷, Ryan McConnell¹⁸, Mark C. Mattar¹⁹, Mark Metwally²⁰, Arthur Ostrov²¹, Nimisha Parekh²², Laura Raffals²³, David T. Rubin²⁴, Sarah Sheibani²⁵, Corey A. Siegel²⁶, Douglas Wolf²⁷, Ziad Younes²⁸, Ian M. Kaplan, PhD³⁰ John C. Protko, MS,³¹ Kimia Sobhani, PhD³², Akil Merchant³, Susan Cheng² MD MPH, Jonathan Braun¹ MD PhD, Dermot P.B. McGovern¹ MD, PhD, Gil Y. Melmed¹ MD MS. Patients with Inflammatory Bowel Disease Have Impaired Humoral but Preserved Cellular Responses to SARS-CoV-2 mRNA Vaccination. DDW, May 2022, Control ID: 3695220
 224. Angela Mujukian, et al. POST-VACCINATION SYMPTOMS AFTER A THIRD DOSE OF SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE DDW, May 2022, Control ID: 3691105.
 225. Yoichi Kakuta¹, Tsuyoshi Shirai², Soshi Okazaki², Yusuke Shimoyama¹, Rintaro Moroi¹, Masatake Kuroha¹, Hisashi Shiga¹, Yoshitaka Kinouchi², Dalin Li³, Jonathan Braun³, Dermot P B McGovern³, Hiroshi Fujii², and Atsushi Masamune. ASSOCIATION ANALYSIS OF NOVEL DIAGNOSTIC AUTOANTIBODIES AGAINST ENDOTHELIAL PROTEIN C RECEPTOR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DDW, May 2022.

226. Dalin Li, PhD¹, Alexander Xu, PhD³, Joseph Ebinger², Philip Debbas¹, Andrea Bantyl¹, Edward Feldman¹, Christina Ha¹, Susie Lee¹, Shervin Rabizadeh¹, Theodore Stein¹, Theodore Solomon¹, Gaurav Syal¹, Stephan Targan¹, Eric Vasilias¹, David Ziring¹, Niru Bonthala¹, Gregory S. Botwin¹, Melissa Hampton¹, Emebet Mengesha¹, Angela Mujukian¹ MD, Valeriya Pozdnyakova¹, Phillip Gu¹, Sandy Joung², Keren Appel⁴, Rashmi Kumar⁵, Brigid Boland⁶, Aline Charabaty⁷, Michael Chiorean⁸, Erica Cohen⁹, Ann Flynn¹⁰, John Valentine¹⁰, Adam C. Ehrlich¹¹, David Fudman¹², Sarah Glover²⁹, Arash Horizon¹³, Dmitry Karayev¹³, Benjamin Kretzmann¹³, Jason Hou¹⁴, Caroline Hwang¹⁵, Mark Lazarev¹⁶, Donald Lum¹⁷, Rebecca Fausell¹⁷, Swapna Reddy¹⁷, Ryan McConnell¹⁸, Mark C. Mattar¹⁹, Mark Metwally²⁰, Arthur Ostrov²¹, Nimisha Parekh²², Laura Raffals²³, David T. Rubin²⁴, Sarah Sheibani²⁵, Corey A. Siegel²⁶, Douglas Wolf²⁷, Ziad Younes²⁸, Ian M. Kaplan, PhD³⁰ John C. Proskot, MS,³¹ Kimia Sobhani, PhD³², Akil Merchant³, Susan Cheng² MD MPH, Jonathan Braun¹ MD PhD, Dermot P.B. McGovern¹ MD, PhD, Gil Y. Melmed¹ MD MS. Patients with Inflammatory Bowel Disease Have Impaired Humoral but Preserved Cellular Responses to SARS-CoV-2 mRNA Vaccination. DDW, May 2022
227. Clonal T-Cell Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease is Often Deficient in Antibody-Responders, and Augmented by Anti-TNF Therapy, NCI SeroNet annual meeting, Mar 2022 (virtual)
228. Khan A, Li D, Anand R, Mujukian A, Mengesha E, Debbas P, Shin B, Chai NN, Jia C, Chiorian M, Jordan S, Cheng S, Ebinger J, Braun J, Melmed GY, McGovern DPB, FUNCTIONAL T-CELL RESPONSES TO ANCESTRAL AND OMICRON SARS-COV-2 STRAINS ARE AUGMENTED WITH ANTI-TNF EXPOSURE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD). DDW, May 2023, Washington D.C.
229. Li D, Fu Q, Debbas P, Vegesna M, Mengesha E, Ahmad T, Sundararaman N, Melmed GY, Braun J, Van Eyk J, McGovern DPB, INTEGRATION OF HIGH THROUGHPUT PROTEOMICS PROFILING, CLINICAL CHARACTERISTICS AND TNF-RESPONSE HIGHLIGHT THE ROLE OF PLATELETS IN INFLAMMATORY BOWEL DISEASES (IBD). DDW, May 2023, Washington D.C.
230. Cedillo-Castelan V, Li D, Sobhani K, Anand R, Chiorean M, Mengesha E, Hampton M, Mujukian A, Khan A, Joung S, Cheng S, Ebinger J, Braun J, McGovern D, Melmed GY. INFLUENCE OF HISPANIC ETHNICITY ON SARS-COV-2 VACCINE RESPONSE AND BREAKTHROUGH INFECTION IN INFLAMMATORY BOWEL AND AUTOIMMUNE DISEASES, AND HEALTHY CONTROLS. DDW, May 2023, Washington D.C.
231. Dube S, Li D, Hartitunians T, Yang S, Braun J, Debbas P, Dutra-Clarke R, Targan S, Venkateswaran S, Beecham AH, Gomez L, Quintero MA, Leavitt JS, Deshpande AR, Kerman DH, Proksell S, McCauley JL, Damas OM, Yang SK, Song K, Hwang SW, Park SH, Lee HS, Abreu MT, Ahmad T, Kugathasan S, Torres EA, Ye BD, McGovern DPB. Novel clinical associations with serology in a trans-ancestry Crohn's Disease (CD) cohort highlighting population homogeneity and heterogeneity. DDW, May 2024, Washington, DC.

232. Gonsky R, Fleshner P, Botwin G, Biener-Ramanujan E, Braun J, McGovern DPB, Targan SR. A PERIPHERAL MONOCYTE AGGREGATION-RELATED TRANSCRIPTOMIC PROFILE STRATIFIES TREATMENT RESISTANT CROHN'S DISEASE PATIENTS: DIMINISHED SELECTIN P AND CD226 EXPRESSION IS ASSOCIATED WITH PERIANAL FISTULA. DDW, May 2024, Washington, DC.
233. Fu Q, Vegesna M, Sundararaman N, Xuan Y, Eyk JE. Paradigm shift in biomarker translation: an innovative and automated pipeline to generate and select clinical-grade signature peptides during DIA discovery. ASMS, June 2024, Anaheim CA.
234. Fu Q, Vegesna M, Sundararaman N, Damoc E, Arrey TN, Pashkova A, Li D, Braun J, McGovern DPB, Murray C, Xuan Y, Van Eyk JE. TEAQ software: automating the targeted extraction, evaluation and assessment of the DIA data for selection of signature peptides for biomarker validation. ASMS, June 2024, Anaheim CA.